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Abstract 
A brain affected by Alzheimer’s disease (AD) causes many detrimental 
neurological deficits.  The two main neurological deficits of AD are neurofibrillary 
tangles (NFT) and amyloid plaques, which cause stress on the cell by preventing 
membrane transport, reducing mitochondrial function and interfering with signal 
transduction.  Specific to this PhD project, the production of amyloid plaques are an 
inĚŝƌĞĐƚƌĞƐƉŽŶƐĞƚŽĐůĞĂǀĂŐĞŽĨƚŚĞĂŵǇůŽŝĚƉƌĞĐƵƌƐŽƌƉƌŽƚĞŝŶ;WWͿĂƚƚŚĞɴ-site, 
ŝŶƐƚĞĂĚ ŽĨ ƚŚĞɲ-site.  The substitution of ĞŶǌǇŵĞ ĨƌŽŵɲ-ƐĞĐƌĞƚĂƐĞ ƚŽ ɴ-site APP 
ĐůĞĂǀŝŶŐĞŶǌǇŵĞϭ;ϭͿ͕ƉƌŽĚƵĐĞƐĂůŽŶŐĞƌ͕ϯϴƚŽϰϯĂŵŝŶŽĂĐŝĚ͕ɴĨƌĂgment that 
can aggregate to form a plaque.  ŶŝŶĐƌĞĂƐĞŝŶWWĐůĞĂǀĂŐĞďǇϭŝŶĐƌĞĂƐĞƐɴ
production, which in turn, causes the plaque burden to increase which cannot be 
controlled by regular immune responses.    
 
Hindering the cleavage of APP, by inhibiting BACE1 enzymatic activity, will 
ƌĞĚƵĐĞƚŚĞƉƌŽĚƵĐƚŝŽŶŽĨɴĂŶĚƉƌĞǀĞŶƚƉůĂƋƵĞĚĞƉŽƐŝƚŝŽŶ͘dŚĞƌĞĨŽƌĞ͕ƚŚĞĨŽĐƵƐŽĨ
this PhD project aims to define a binding candidate to BACE1 that can inhibit the 
cleavage of APP in a cell model.  Chapter 2 aimed to define a dodecapeptide binder 
to BACE1 by using the affinity selection technique, phage display.  The 
dodecapeptides were expressed as variable sequences on the pIII protein of a M13 
bacteriophage.  The BACE1 selecting peptides were amplified by infecting an ER2738 
E. coli host cell line with the binding phage.  The amplified binders were then retested 
with a higher stringency, using the biopanning technique.  The result was five rounds 
of biopanning that identified one peptide sequence motif.  This peptide candidate 
xiv 
 
was synthetically reproduced and tested successfully for specific binding to BACE1.    
Using a fluorescent assay to test enzymatic activity, the candidate also exhibited 
inhibitory properties when recombinant BACE1 was in the solution with a substrate.  
The candidate identified was able to bind to recombinant BACE1 and significantly 
inhibit enzymatic activity.  
 
The peptide candidate could inhibit substrate cleavage by recombinant BACE1 
in a one-on-one, controlled environment.  Chapter 3 aimed to further test the 
ĐĂŶĚŝĚĂƚĞĨŽƌƚŚĞĂďŝůŝƚǇƚŽƉƌĞǀĞŶƚƚŚĞƉƌŽĚƵĐƚŝŽŶŽĨɴŝŶĂŚƵŵĂŶŶĞƵƌŽďůĂƐƚŽŵĂ
cell line.  The SY5Y cell line naturally produces APP, which can then be cleaved by 
ϭ͕ƚŚƵƐƉƌŽĚƵĐŝŶŐɴ͘ hŶĚĞr oxidative stress conditions, using treatments of 
hydrogen peroxide (H2O2Ϳ͕ƚŚĞ^zϱzĐĞůůƐƉƌŽĚƵĐĞŵŽƌĞɴϰϬĂŶĚ ɴϰϮ͘dŽƚĞƐƚƚŚĞ
peptide candidate, SY5Y cells were treated in normal and stressed condition to 
ŵĞĂƐƵƌĞƚŚĞŽƵƚƉƵƚŽĨɴϰϬĂŶĚɴϰϮ͘ƐĂƌepresentation of BACE1 activity, SY5Y 
ĐĞůůƐ ĚŝĚ ŶŽƚ ƉƌŽĚƵĐĞ ĂƐ ŵƵĐŚ ɴϰϬ ĂŶĚ ɴϰϮ ǁŚĞŶ ƚƌĞĂƚĞĚ ǁŝƚŚ ƚŚĞ ƉĞƉƚŝĚĞ
candidate.  By inhibiting BACE1, the peptide candidate could reduce the loading of 
ďŽƚŚɴ40 and ɴϰϮŝŶƚŚĞ^zϱzĐĞůůůŝŶĞ͘ 
 
Testing possible BACE1 and APP feedback responses, as a reaction to the 
peptide candidate (now BACE1 inhibitor) treatments, was completed by investigating 
the changes of both BACE1 and APP protein levels in SY5Y cells.  These results were 
then analysed against mRNA levels to determine consistency with gene expression 
and protein production.  The aim of Chapter 4 was to determine whether the BACE1 
inhibitor could influence protein and gene expression of BACE1 and APP as a response 
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to the reduction in enzymatic activity.  The Western blot analysis showed consistent 
BACE1 protein levels across all treatment samples, but the amount of APP was 
increasing.  This was consistent with the qPCR results which showed no significant 
increases in either BACE1 or APP mRNA levels.  The inhibition of enzyme activity did 
not have any effect on BACE1 protein levels however, the amount APP increased as 
a response.  When compared with the qPCR results, the APP protein increase was 
more likely a response to the reduction in BACE1 activity as opposed to a 
compensation reaction, as mRNA production did not change. 
 
Analysis of BACE1 and APP fluctuations, caused by BACE1 inhibitor treatment, 
showed no detrimental feedback compensation.  The aim of Chapter 5 was to expand 
this result to test the whole proteome for possible BACE1 inhibitor side effects.  NT2 
human neuronal cells were treated and tested using the 2-dimensional gel 
electrophoresis technique to identify potential protein changes.  The gel spots with 
varying colour intensity were picked and analysed using mass spectrometry to 
identify the protein candidates.  A pattern emerged, showing the increasing 
treatments of BACE1 inhibitor were causing a gain in the glycolysis specific enzyme 
concentration.  These potential changes were confirmed by Western blot analysis, as 
an increase in triosephosphate isomerase, pyruvate kinase and aldolase A was a 
result.  The BACE1 inhibitor treatment on NT2 cells was influencing glycolysis output.  
In a brain effected by AD, where there is a reduction in glycolytic output, the BACE1 
inhibitor may be able to increase energy production along with reducing the amount 
ŽĨŝŶƚƌĂĐĞůůƵůĂƌɴŵŽŶŽŵĞƌƐ͘ 
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In summary, a BACE1 specific candidate was identified using the phage display 
and biopanning techniques.  The candidate exhibited the capability to bind 
specifically to BACE1 and inhibit substrate cleavage in an activity assay.  When in a 
human neuron cell line environment the peptide treatments were able to reduce the 
ĂŵŽƵŶƚ ŽĨ ɴ ƉƌŽĚƵĐĞĚ ŝŶ ^zϱz ĐĞůůƐ͘  Ɛ a response by the cells, no feedback 
compensation, to produce more BACE1 and APP, occurred due to the BACE1 inhibitor 
treatment.  When testing the proteome wide effects of BACE1 inhibitor treatment, 
an increase in the amount of glycolysis specific enzymes occurred.  This could be 
beneficial to the cells, considering the changes to glycolysis in a brain effected by AD, 
ĂůŽŶŐǁŝƚŚƚŚĞƌĞĚƵĐƚŝŽŶŝŶŝŶƚƌĂĐĞůůƵůĂƌɴŵŽŶŽŵĞƌƐ͘ 
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1.1  Neurodegenerative Disorders 
Neurodegenerative disorders cover a wide range of brain conditions relating 
to the damage or death of neuronal cells.1 Clinical analysis of patient symptoms 
identify a regression in structure and function of the brain and central nervous system 
(CNS), which denotes the final stage of a preceding neuronal dysfunction.2 The 
neurodegenerative diseases of dementia are of particular significance because of the 
devastating influence plaguing an aging population.  Life expectancy of the general 
public is increasing and with the influence of dementia on this demographic, disease 
rates are estimated to escalate. 
 
The predominant form of dementia, Alzheimer’s disease (AD), has a burden 
on disease that affected 26.6 million people worldwide in 2006.3 This direct influence 
of AD implicates 34% of the population over the age of 65 and 45% over the age of 
85.  The World Health Organization revised this figure in 2010 to incorporate 
dementia as a whole because of the difficulty to diagnose the different varieties of 
neurodegenerative disorders.4 The worldwide incidence of dementia was projected 
to reach 35.6 million in 2012 with an estimated 7.7 million new cases annually. This 
number is of particular significance to AD as it comprises an estimated 60-70% of 
dementia cases.4 These figures could be inflated further as cases go undiagnosed due 
to the requirement of a post-mortem autopsy, which is not often performed on the 
elderly. 
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The ripple effect and influence of dementia extends far from those primarily 
affected and into patient support networks.  The worldwide costs of AD are currently 
estimated to be US$604 billion annually and will only rise as the number of affected 
increase as a result of an aging population without an effective prevention strategy.4 
The chronic onset of the disease leads to an eventual requirement for long term 
palliative care.  The mental  and financial burdens for carers become increased as AD 
sufferers inevitably require long term formal care when disease evolves and 
symptoms increase with severity.5 AD patients in particular, require increased 
supervision after diagnosis due to an increased risk of developing associated diseases 
such as cardiovascular disease, depression,  diabetes, and bone weakening.6 
 
The symptoms defining AD are a direct response to the progressive neuronal 
and synaptic apoptosis in the cerebral cortex and subcortical regions of the brain.2 
The direct consequence is cellular atrophy, which includes degeneration in the 
temporal and parietal lobes, parts of the frontal cortex and cingulate gyrus.7,8 Areas 
of severe cellular atrophy in well-defined brain structures, result in debilitating 
symptoms including delusions, hallucinations, agitation, depression, anxiety, elation, 
apathy, disinhibition, irritability, aberrant motor behaviour and sleep disorders.9 As 
the chronic nature of the disease intensifies, the number of symptoms increase, 
becoming severely debilitating.  Death eventually results after long-term stress 
caused by reduction of brain structure and function.7  
 
Currently, there are a variety of different intervention strategies being 
investigated to alleviate these debilitating symptoms, and focus to reduce the cause 
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of neuronal cell death. Upwards of 100 irregular protein modifications occur in a brain 
with AD, including hyperexpression, fragmentation and phosphorylation.10  A number 
of these protein modifications could be a result of degenerating neurons triggering 
further damage to associated structures of the CNS.10 The overall damage from AD 
however is not restricted to the dysfunction of one mechanism, rather a number of 
significant molecular changes.  The initial trigger commencing disease pathology 
cannot be tracked by the symptoms as the molecular changes manifest as a result of 
the numerous sporadic cellular events stimulating brain atrophy and not sequentially 
as a response to a single stimulus. 
 
Histopathological review of AD patients highlighted amyloid plaques and 
neurofibrillary tangles (NFT) as the two significant molecular events resulting in the 
aforementioned cerebral atrophy and necrosis.2,11 Damage caused as a result of the 
amyloid plaques and NFTs makes them both the focus of intervention strategies to 
preventing neuronal cell death in AD.  Investigation into the onset of NFTs implicate 
the tau protein, which causes a destabilization of intracellular microtubules.12 Tau is 
a phosphoprotein that assists with thĞƉŽůǇŵĞƌŝƐĂƚŝŽŶŽĨɲ- ĂŶĚɴ-tubulin to form a 
functional microtubule, providing the scaffolding required to maintain cellular 
structural integrity.  In order for the effective transport and transfer of 
neurotransmitters, neuron structural integrity is vital.  Pathophysiology of NFT 
formation commences with the hyperphosphorylation of tau, subsequently 
disassembling the tubules and creating the tangles.  Blockages in both axons and 
dendrites due to tangle formation cause a loss of structure and function, decreasing 
the ability of neurons to transmit action potentials and transport neurotransmitters 
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across the synapse.13 Alleviation from this facet of the disease is yet to be elucidated.  
 
Formation of an amyloid plaque begins with the accumulation of amyloid-ɴ
;ɴͿƐƵď-units on the cell membrane, which cause dysfunction to the neuron.14 The 
increasing damage of amyloid plaques cause neuronal apoptosis by activating the 
complement cascade and stimulating the membrane attack complex.15 In severe 
cases of AD, where the concentration of amyloid-ɴŝƐŚŝŐŚĞƌ͕ƐŝŐŶŝĨŝĐĂŶƚĚĂŵĂŐĞƚŽ
the physical structure of the brain is a direct result of the immune response under 
stress. The activation of the complement cascade involves microglia and astrocytes, 
which have both protective and destructive attributes. The eventual outcome is 
apoptosis as the immune response becomes overwhelmed and cannot degrade the 
ŝŶĐƌĞĂƐŝŶŐ ĂŵŽƵŶƚ ŽĨ ɴ͘  ,ŝŶĚƌĂŶĐĞ ŽĨ ĂƉŽƉƚŽƐŝƐ ďǇ ŵĞĚŝĐĂƚŝŶŐ ǁŝƚŚ ĂŶƚŝ-
ŝŶĨůĂŵŵĂƚŽƌǇĚƌƵŐƐŚĂƐůŝƚƚůĞĞĨĨĞĐƚďĞĐĂƵƐĞɴŝƐŶĞƵƌŽƚŽǆŝĐ͕ŝŶƐŽůƵďůĞĂŶĚďĞĐŽŵĞƐ
vastly distributed around the brain when number become increased.16,17 By the time 
amyloid plaques have formed and begin to manipulate regular brain functioning, 
irreversible damage has already occurred and viable strategies to intervene have not 
been determined.  
 
Closer investigation of the AD brain exposes a plethora of associated failures 
to imperative neuronal cell functions causing synaptic dysfunction18, depletion of  
neurotransmitters19, mitochondrial dysfunction20, decreased cholesterol 
metabolism21, reduction of neurotrophin22 and axonal transport deficiencies.23 
Disease symptoms become apparent before the discovery of plaque establishment 
and NFT accumulation.24 The repercussions of tau hyperphosphorylation cause 
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symptoms similar to frontotemporal dementia (FTD) and Parkinson’s like defects 
unlike archetypal AD.25  The focus of this PhD project is to circumvent plaque 
ĨŽƌŵĂƚŝŽŶďǇƉƌŽĂĐƚŝǀĞůǇƉƌĞǀĞŶƚŝŶŐɴĚĞƉŽƐŝƚŝŽŶ͘ 
 
1.2  Amyloid Plaque Formation 
Amyloid plaques were originally purified in the early 80’s and examined to 
contain peptides of approximately 40 amino acids that aggregated as oligomers, later 
to be generically named amyloid-beta.26,27 Gene cloning and cDNA analysis of these 
ŵŽŶŽŵĞƌƐůĞĂĚƚŽƚŚĞĚĞƚĞƌŵŝŶĂƚŝŽŶƚŚĂƚɴŽƌŝŐŝŶĂƚĞĚĂƐƉĂƌƚŽĨĂůĂƌŐĞƌƉƌĞĐƵƌƐŽƌ
protein.28,29 This protein was later identified as the amyloid precursor protein (APP), 
ĂϲϵϱĂŵŝŶŽĂĐŝĚ͕ŵĞŵďƌĂŶĞďŽƵŶĚĐĞůůƌĞĐĞƉƚŽƌƚŚĂƚĐŽŶƚĂŝŶĞĚƚŚĞɴƐĞƋƵĞŶĐĞŝŶ
the extracellular domain.29 It is the proteolytic cleavage of APP by multiple secretases 
ƚŚĂƚƌĞůĞĂƐĞƐƚŚĞɴƉƌŽĚƵĐƚ͘ 
 
Proteolytic processing of APP occurs by one of two pathways, the 
amyloidogenic (pathogenic) or the non-amyloidogenic (non-pathogenic).  Transport 
to the cell membrane via endosomes is chaperoned by the intracellular adaptor 
protein, sorting nexin 17 (SNX17), where it becomes available for processing by the 
secretases.30 The development of amyloidogenesis is a consequence of APP 
ƉƌŽƚĞŽůǇƐŝƐ ďǇ ĞŝƚŚĞƌ ɲ-ƐĞĐƌĞƚĂƐĞ Žƌ ɴ-secretase.  A soluble, non-amyloidogenic 
ĨƌĂŐŵĞŶƚ ŝƐ ƉƌŽĚƵĐĞĚ ďǇ ɲ-secretĂƐĞ ďƵƚ ĐůĞĂǀĂŐĞ ďǇ ɴ-secretase produces an 
insoluble, amyloidogenic polypeptide.17 ůĞĂǀĂŐĞŽĨWWďǇƚŚĞɲ-secretase, a protein 
also being investigated as part of the disintegrin and metalloprotease (ADAM) family, 
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ĐůĞĂǀĞƐWWĂƚƚŚĞɲ-site releasing a soluble fragment sWWɲ ŝŶƚŽƚŚĞĞǆƚƌĂĐĞůůƵůĂƌ
space.31 This catabolism leaves the C-terminal fragment of 83 amino acid residues (C-
ϴϯͿ͕ ǁŚŝĐŚ ŝƐ ĂďƌƵƉƚůǇ ĐůĞĂǀĞĚ ďǇ ɶ-secretase in the intramembrane space.  Two 
subsequent fragments are produced from C-83, the APP intracellular domain (AICD), 
which is released in the cytosol, and the p3, which is released into the extracellular 
space (Figure 1.1).   
 
The amyloidogenic pathway also utilises APP as the substrate, however the 
ĞŶǌǇŵĞŝŶǀŽůǀĞĚŝƐɴ-secretase or beta site APP converting enzyme 1 (BACE1), which 
is the focus of this PhD project.  This enzyme also cleaves APP in the extracellular 
ƐƉĂĐĞďƵƚĂƚƚŚĞɴ-site, which is 16 amino acids towards the N-terminal releasing a 
shorter soluble APP-ɴ ;ƐWWɴͿ ĨƌĂŐŵĞŶƚ ĂƐ Ă ĐŽŶƐĞƋƵence.32,33 The remaining C-
terminal fragment of 99 amino acid residues (C-99) remains membrane bound until 
ĐůĞĂǀĞĚďǇɶ-secretase.  This sequential cleavage releases two fragments of AICD and 
ɴ;&ŝŐƵƌĞϭ.1Ϳ͘dŚĞƐĞɴŵŽŶŽŵĞƌƐĨŽƌŵƚŚĞŵĂŝŶĐŽŶƐƚŝƚƵĞŶƚŽĨĂmyloid plaques.    
 
The non-ĂŵǇůŽŝĚŽŐĞŶŝĐƉĂƚŚǁĂǇŚĂƐ ƚŚĞĂďŝůŝƚǇ ƚŽŶƵůůŝĨǇɴƉƌŽĚƵĐƚŝŽŶďǇƐŝŵƉůǇ
ƉƌĞĨĞƌĞŶƚŝĂůůǇĐůĞĂǀŝŶŐWWǁŝƚŚɲ-ƐĞĐƌĞƚĂƐĞƉƌŝŽƌƚŽƚŚĂƚŽĨϭ͘dŚĞɲ-site of APP 
ŝƐƐŝƚƵĂƚĞĚďĞƚǁĞĞŶƚŚĂƚŽĨɴ- ĂŶĚɶ-, producing the shorter p3 fragment instead of 
ɴ͘hŶĚĞƌƐƚĂŶĚŝŶŐƚŚĞĐŽŵƉĞƚŝƚŝŽŶĨŽƌĐůĞĂǀĂŐĞŽĨWWŝƐƐƚŝůůĚĞďĂƚĞĚďƵƚǁŚĞŶɲ-
secretase activity is inhibited or nullified in-vitro, activity of BACE1 does not 
increase.34 dŚĞĨƌĂŐŵĞŶƚƐŽĨƐWWɲĂŶĚ/ĨƌŽŵ the non-amyloidogenic pathway  
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suŐŐĞƐƚ Ă ƉƵƌƉŽƐĞ ƌĞƐƵůƚŝŶŐ ĨƌŽŵ ƚŚĞ ĐůĞĂǀĂŐĞ ŽĨ WW͘  dŚĞ ƐWWɲ ĐĂŶ ƉƌŽǀŝĚĞ
neurotrophic and neuroprotective properties as well as promoting neurite 
expansion, synapse production and cell adhesion, while AICD has a role in p53 
expression and caspase 3 activation, both associated with cell death and maintaining 
cellular actin dynamics.35-37 This difference in enzyme activity can change from a 
homeostatic mechanism promoting neuronal maintenance and growth to that of 
neurotoxicity and dysfunction.   
 
 
Figure 1.1.  The cleavage of APP follows either the amyloidogenic pathway via 
BACE1 or the non-ĂŵǇůŽŝĚŽŐĞŶŝĐƉĂƚŚǁĂǇǀŝĂɲ-secretase.  The non-amyloidogenic 
pathway (non-ƉĂƚŚŽŐĞŶŝĐͿďĞŐŝŶƐǁŝƚŚɲ-ƐĞĐƌĞƚĂƐĞ͕ǁŚŝĐŚƌĞůĞĂƐĞƐƐWWɲĞǆƚĞƌŶĂůůǇ
ĨƌŽŵƚŚĞĞŶĚŽƐŽŵĞŽƌĐĞůůŵĞŵďƌĂŶĞ͘dŚĞƌĞƐƵůƚŝŶŐϴϯĨƌĂŐŵĞŶƚŝƐĐůĞĂǀĞĚďǇɶ-
secretase in the intermembrane space releasing both the AICD and p3 fragments. 
The release of p3 into the extracellular space is not associated with plaque formation. 
Alternatively, the amyloidogenic (pathogenic) pathway begins with BACE1, instead of 
ɲ-secrĞƚĂƐĞ͕ ĂŶĚ ĐůĞĂǀĞƐ WW ŝŶ Ă ůŝƉŝĚ ƌĂĨƚ ƌĞŐŝŽŶ ŽĨ ƚŚĞŵĞŵďƌĂŶĞ͘  dŚĞ ƐWWɴ
ƌĞůĞĂƐĞĚŝƐƐŚŽƌƚĞƌƚŚĂŶƐWWɲĂŶĚŝƐƐƚŝůůƌĞůĞĂƐĞĚĞǆƚĞƌŶĂůůǇ͘dŚĞɶ-secretase cleaves 
C99, the same as in the non-amyloidogenic pathway, but releases the 38-42 amino 
ĂĐŝĚɴ͕ĂŶĚ /͘dŚĞĞǆƚĞƌŶĂůůǇƌĞůĞĂƐĞĚĨƌĂŐŵĞŶƚ͕ɴ͕ŚĂƐƚŚĞĐĂƉĂďŝůŝƚǇƚŽĨŽƌŵ
an amyloid plaque by aggregation. 
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The dŝǀĞƌŐĞŶĐĞŽĨƚǁŽƉĂƚŚǁĂǇƐĚĞƚĞƌŵŝŶĞƐƚŚĞƌĞůĞĂƐĞŽĨĞŝƚŚĞƌĂŶɴŽƌƉϯ
fragment. The p3 fragment is the shorter by-product of APP cleavage and has little 
known function.  However, the p3 fragment does not have the same ability to form 
stable oligomeric intĞƌŵĞĚŝĂƚĞƐ͕ ĂƐ ƚŚĂƚ ŽĨ ɴ͕ ĂŶĚ ƚŚĞƌĞĨŽƌĞ ƉŽƐĞƐ ŶŽ ƚŚƌĞĂƚ ƚŽ
synaptic function.  The p3 fragment does not have any involvement in the 
construction of amyloid plaques nor does it play any part in the non-amyloidogenic 
pathway.38,39 dŚŝƐ ŝŶĚŝĐĂƚĞƐ ƚŚĂƚ ƚŚĞ ɴ ƉĞƉƚŝĚĞ ŝƐ ƚŚĞŵĂŝŶ ŶĞƵƌŽƚŽǆŝĐ ĨƌĂŐŵĞŶƚ
ĞƐƚĂďůŝƐŚĞĚĨƌŽŵƚŚĞWWĨƌĂŐŵĞŶƚ͘dŚĞĐůĞĂǀĞĚƉƌŽĚƵĐƚŽĨɴŝƐŶĂƚƵƌĂůůǇĂƉĞƉƚŝĚĞ
of 40 amino acid residues but can be varied between 38 and 42, depending on where 
ɶ-secretase cleaves APP-CTF. 
 
1.2.1  Amyloid-ɴ 
dŚĞ ɶ-secretase complex influences both the amyloidogenic and non-
amyloidogenic pathway as it is responsible for the secondary cleavage of APP, 
dividing the remaining intracellular and extracellular fragments.  The enzyme 
complex has the definitive influence over the formation of a plaque by the fragment 
length that it cleaves.  Four main proteins form the complex with either one of 
presenilin 1 (PS1) or presenilin 2 (PS2), nicastrin (NCT), anterior pharynx-defective 
phenotype 1 (APH1) and presenilin enhancer 2 (PEN2).40 The cleavage process begins 
with a sub complex forming between NCT and Aph-1, which binds to one of the PS 
proteins.41 Pen-2 is used to activate the complex by selective binding.42 Either PS can 
be used in this process, with a 67% amino acid homology and two essential and 
separate aspartate residues, asp257 and asp385, essential to catalytic 
proficiency.43,44 ŽŶƐĞƋƵĞŶƚůǇ͕ Ă ĚĞĐƌĞĂƐĞ ŽĨ ɶ-secretase components results in a 
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reduction of overall functionality and can be a target for inhibiton.45 However, 
mutation or inhibition of either of the presenilins, whether it be PS1 or PS2, can be 
seen as target for preventing the production of ɴϰ0-42 but one can compensate for 
the other as they both maintain the ability to cleave APP.   
 
  dŚĞɶ-secretase, the consistent piece of the APP processing pathway, has a 
significant influence over the diseased state in which plaques are formed.  Upwards 
of 100 missense mutations identified in the presenilins create a difference in cleaved 
fragments of APP.46 dŚĞɴƉĞƉƚŝĚĞƉƌŽĚƵĐĞĚĐŚĂŶŐĞƐǁŝƚŚĂǀĂƌǇŝŶŐŽǀĞƌĂůůůĞŶŐƚŚ
of between 38-42 amino acids.17 The majority of these mutations influence a higher 
number of ɴϰϮ peptides that are more amyloidogenic and neurotoxic as they exhibit 
a higher binding affinity within the developing plaque.47,48 The wild-type presenilin 
ƚŚĂƚŐĞŶĞƌĂƚĞƐɴ40, is considered to be less neurotoxic, despite its abundance in 
ĂŵǇůŽŝĚƉůĂƋƵĞƐ͘ dŚĞɴ42 is less abundant but its high binding properties to the 
ŽƚŚĞƌɴĨƌĂŐŵĞŶƚƐƉƌŽĚƵĐĞƐĂƉůĂƋƵĞŝŶĂƐŚŽƌƚĞƌƚŝŵĞĨƌĂŵĞ͘dŚĞƉƌĞƐĞŶŝůŝŶƐĐƵƚ
downstream from the transmembranĞ ĚŽŵĂŝŶ ŝŶƚŽ ƚŚĞ ɸ-site of APP slightly 
shortening the AICD cleaving domain creating this longer fragment.49  With an 
ŝŶĐƌĞĂƐĞ ŝŶĂŐĞ͕ƚŚĞɴ42ͬɴ40 ƌĂƚŝŽĐŚĂŶŐĞƐ ŝŶ ĨĂǀŽƵƌŽĨɴϰϮ͕ĐƌĞĂƚŝŶŐŵŽƌĞŽĨ
these fragments which promotes oligomerisation, fibrillation and plaque generation.  
,ŽǁĞǀĞƌ͕ ǁŝƚŚ Ă ďŝŶĚŝŶŐ ĂĨĨŝŶŝƚǇ ƚŽ ɴ40, polymers can, as a consequence, bind 
together, meaning there does not need to be a high concentration to be effective.50 
dŚŝƐ ĐƌĞĂƚĞƐ ƚŚĞ ĐĂƐĐĂĚĞ ŽĨ ƉůĂƋƵĞ ŐĞŶĞƌĂƚŝŽŶ ǁŚĞƌĞ ŵŽƌĞ ɴ ŵŽŶŽŵĞƌƐ ĂƌĞ
produced and the degree of amyloidogenesis becomes increasingly detrimental.  
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  dŚĞƉƌŽĚƵĐƚŝŽŶŽĨɴŵŽŶŽŵĞƌƐŽĨƚĞŶŽƌŝŐŝŶĂƚĞƐǁŝƚŚŝŶƚŚĞĐĞůůĚƵƌŝŶŐǀĞƐŝĐůĞ
transport to the membrane and extracellular space.  The monomers can form the 
shape of ɲ-ŚĞůŝĐĞƐ͕ƌĂŶĚŽŵĐŽŝůƐŽƌɴ-sheets in a neutral pH, hindering regulation and 
providing a progression towards neurotoxicity and cell death.51-54 These individual 
fragments then block synaptic neurotransmitter transfer and trigger an apoptotic 
response via activation of the p53 promoter.55 ŽŶƐĞƋƵĞŶƚůǇ͕ƐŽůƵďůĞɴŽligomers 
ĐĂŶƚŚĞŶďĞƌĞĨĞƌƌĞĚƚŽĂƐɴ-derived diffusible ligands (ADDLs) with the ability to 
aggregate into protofibrils, spherical structures of 7-10nm wide, that can interrupt 
nerve signal transduction and decrease intracellular communication.56 dŚĞƐĞ ɴ
fibrils exhibit a toxic response to the neurons to which they are attached.57  
 
 /ŶĂŶĂƚƚĞŵƉƚƚŽŝŶƚĞƌĐĞƉƚƚŚĞĚĞǀĞůŽƉŝŶŐɴĨŝďƌŝůƐ͕ŐĞŶĞŬŶŽĐŬŽut studies of 
PS1 have found adverse reactions effecting the formation of the axial skeleton, 
neurogenesis and neuronal survival, which caused death to mice late in 
embryogenesis.58 These reactions could be a response of dysfunction via the Notch 
signalling pathway due to its involvement with cell proliferation, apoptosis, myelin 
ĨŽƌŵĂƚŝŽŶĂŶĚ ƚŚĞɶ-secretase complex.59 To inhibit the PS1 with the intention of 
ƉƌĞǀĞŶƚŝŶŐɴƉƌŽůŝĨĞƌĂƚŝŽŶ͕ǁŽƵůĚŽŶůǇĐƌĞĂƚĞĂŶƵŵďĞƌĂƐƐŽĐŝĂƚĞĚƌŝƐŬƐĂƐŶƵůůŝĨǇŝŶŐ
ɶ-secretase effects two regulatory pathways. 
 
1.2.2  Neuroinflammation 
  The increase of intra- ĂŶĚ ĞǆƚƌĂĐĞůůƵůĂƌ ɴ ŚĂƐ Ă ĚŝƌĞĐƚ ĞĨĨĞĐƚ ŽŶ ƚŚĞ
complement system and the recruitment of microglia, prompting the activation of 
inflammatory mechanisms.60 The microglia, derived from the mesenchyme and 
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transferred to the CNS where proliferation occurs, are classified as the macrophages 
of the brain and regulate apoptotic cell abundance.61 Stress incurred, mainly by 
amyloid plaque formation, triggers an immune response leading to activation of 
astrocǇƚĞƐĂŶĚŵŝĐƌŽŐůŝĂƚŽĚĞĐŽŶƐƚƌƵĐƚƚŚĞĚŝƐƚƌĞƐƐĞĚĐĞůůƐ͘ dŚĞɴĨƌĂŐŵĞŶƚĐĂŶ
activate this process via the receptor for advanced glycation end products (RAGE), a 
multi-ligand member of the immunoglobulin family that has increased production in 
an AD brain, and by CD40, an inflammatory signalling receptor.62-64 The general 
ŝŵŵƵŶĞƌĞƐƉŽŶƐĞŝƐĂŝŵĞĚĂƚĞůŝŵŝŶĂƚŝŶŐɴ͕ƌĞŵŽǀŝŶŐĚŝƐĞĂƐĞĚĐĞůůƐĂŶĚƌĞƐƚŽƌŝŶŐ
tissue integrity, but eventually causes damage as it becomes chronic in nature.  The 
activation of reactive oxygen species (ROS), prostaglandins, and pro-inflammatory 
cytokines are a characteristic of the chronic inflammation and neuronal dysfunction 
in AD.65  
 
  The onset of AD encourages the migration of microglia to plaque affected 
areas.  Cultured microglia from elderly human patients showed this migration as they 
ĐŽƵƉůĞĚǁŝƚŚɴĨŽƌƚŚĞƉƵƌƉŽƐĞŽĨĐĂƚĂďŽůŝƐŵ͘66 Similar findings were discovered in 
sections of cortex tested in vitro for microglia migration however, growing evidence 
ƐƵŐŐĞƐƚƐ ƚŚĂƚ ŽŶĐĞ ƉůĂƋƵĞ ĂĨĨĞĐƚĞĚ ĐĞůůƐ ĂƌĞ ĞŶĚŽĐǇƚŽƐĞĚ͕ ƚŚĞ ɴ ĨŝďƌŝůƐ ĂƌĞ ŶŽƚ
effectively degraded and eventually cause stress on surrounding cells.66-68 
Additionally, APP mRNA translation is upregulated in the event of trauma, nerve 
damage and brain ischemia, which can be beneficial for the release of more AICD, but 
ĂůƐŽƌĞƐƵůƚƐŝŶƚŚĞƉƌŽĚƵĐƚŝŽŶŽĨŵŽƌĞɴƐƉĞĐŝĞƐĐƌĞĂƚŝŶŐĂĨĞĞĚďĂĐŬƐǇƐƚĞŵƚŚĂƚŝƐ
actually more detrimental.69-71 BACE1 has also been found to be regulated by ɴϰϮ 
via the c-Jun N-terminal kinase (JNK) pathway, otherwise known as the stress-
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activated signalling pathway, which is important for the mediation of pro-
inflammatory cytokines.72,73 Once ɴƉƌŽĚƵĐƚŝŽŶŽƵƚǁĞŝŐŚƐƉůĂƋƵĞĐůĞĂƌĂŶĐĞĚƵĞƚŽ
the production of ɴϰϮ and a decreased inflammatory response, the disease 
accelerates causing the symptoms from irreversible cellular damage to appear. 
 
  All aspects of amyloid plaque progression relate back to the enzymatic activity 
of BACE1.  The amyloidogenic cleavage of APP can be regulated with an inhibitor to 
BACE1 without interfering with the non-ĂŵǇůŽŝĚŽŐĞŶŝĐƉĂƚŚǁĂǇƵƐŝŶŐɲ-secretase, 
which forms the overall aim of this PhD project.  The catabolic activity toward other 
BACE1 substrates can be regulated with a passive inhibitor rather than blocking the 
enzyme all together.  
 
1.3  BACE1 
1.3.1  BACE1 Production and Natural Degradation 
dŚĞϭĞŶǌǇŵĞ;ĂůƐŽĐĂůůĞĚɴ-secretase, Asp2 or memapsin2) is developed 
in the endoplasmic reticulum from a 501 amino acid, 60kDa, immature precursor 
protein.  Transfer from the endoplasmic reticulum to the Golgi is dependent on the 
prodomain, which is removed by the proprotein convertase, furin.74 At this stage, the 
immature BACE1 can already cleave APP so is not a true zymogen but the removal of 
the prodomain can double the proteolytic effectiveness whilst increasing structural 
stability.75,76 The immature BACE1 is deacetylated and transformed in the Golgi by 
post-translational modification into a type 1 transmembrane protein.77 A bi-lobal 
structure is formed with two aspartate motifs (D93TG and D289SG in a D-T/S-G-T/S 
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configuration), forming the active site that stimulates water molecules to hydrolyse 
peptide bonds, a defining characteristic of aspartic proteases.78,79 The proteolytic 
ability of this motif is only limited by site-directed mutagenesis of the aspartate 
residues.79 The active site remains an important structure of this enzyme because of 
its proposed vulnerability.  Although it has been the focus of inhibition studies since 
its discovery in 1999, no effective, pharmaceutically viable options have been 
identified.33,80-83 The distinctiveness surrounding BACE1 is highlighted when 
comparing it to other aspartic proteases and the contrasting characteristics of a C-
terminal cytosolic tail and a transmembrane domain. 
 
The transfer of BACE1 from the Golgi to the cell membrane is mediated by 
endosome where it remains membrane bound.  The serine and di-leucine residues of 
BACE1 act as a signal for the Golgi-ůŽĐĂůŝǌĞĚɶ-ear-containing ARF binding protein 1 
(GGA1), a sorting protein that aids the link between the transporting endosome and 
the cell membrane.84 The endosome provides an optimal transport vesicle because 
of its internal acidic nature (approximately pH 4.5), fundamental pH required for the 
conformational shape and functionality of BACE1, and it is a more stable environment 
for transporting proteins.85,86 Decreases in acidity below pH4.0 can have a negative 
effect on Wat1, a molecule considered to be the nucleophile that attacks the carbonyl 
carbon of a peptide bond in the active site resulting in BACE1 loss of functionality. 
Shifts in pH to a more alkaline environment above pH7.0, render the enzyme inactive 
and unable to cleave a substrate (Figure 1.2A, B, C).85  
  
The BACE1 active site placement renders it vulnerable as it becomes exposed 
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to the extracellular space during the transition from the Golgi to the lipid bi-layer of 
the membrane where it concludes its intracellular transport. This region confers 
BACE1 susceptible to post-translational modification, protein to protein interactions 
or even inhibitor attachment because of the increased availability to the extracellular 
space.  It is here within the more stable, cholesterol rich regions of the membrane 
where BACE1 comes into contact with membrane bound APP.87 The high cholesterol 
regions create lipid rafts, which form as an essential membrane stabilizer of the 
intermediate space, and also provides improved signal transduction and intracellular 
trafficking of proteins within the cell.88 What is considered a liability for the enzyme 
actually allows for the foundation of a specific environment, stable enough for 
cleavage to occur and where APP is available.   
 
BACE1 is found in a number of tissues throughout the body however, the 
majority of expression is found in the brain.89 The levels of expression have been 
debated due to conflicting tissue preparation techniques, sample locations, varying 
in vivo models and the inconsistent use of controls; however,  the overall deposition 
of plaques within an AD sufferer suggests a localised mutation.90 The rise in BACE1 
ĞǆƉƌĞƐƐŝŽŶĐŽƵůĚĞǆƉůĂŝŶ ƚŚĞƌĞĂƐŽŶ ĨŽƌƵŶĐŽŶƚƌŽůůĂďůĞĂŐŐƌĞŐĂƚŝŽŶŽĨɴ͕ďƵƚ ƚŚĞ
marginal increases reported suggest another factor is involved.91 Alternatively, the 
increase in cellular BACE1 could be a result of inefficient degradation and recycling of 
the enzyme. The natural degradation of BACE1 is mediated by the ubiquitin 
proteasome pathway, which tags BACE1 as it is transported from endosomes to 
lysosomes.  The ubiquitination of BACE1 occurs with the sorting proteins, ADP 
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 ribosylation factor 6  ARF6) and GGA3 (another member of the GGA family), which 
if inhibited reduces intercellular sorting.92-95 Degradation by lysosomes is ambiguous 
but with an increase in BACE1 availability within an AD brain, there are little to no 
increases in mRNA levels.  The failed or impaired lysosome could be a contributing 
factor to the increase in cellular BACE1 where it could be getting recycled back into 
endosomes (Figure 1.2D).91   
 
 
Figure 1.2. BACE1 trafficking. BACE1 is constructed in the ER and processed, with the 
removal of the proBACE1 domain, in the Golgi.  A)  BACE1 is a membrane bound 
protease and so is either exocytosed from the Golgi or transported to an endosome 
with the help of the sorting protein GGA1.  From here, the cleavage of APP to produce 
ĞǆƚƌĂĐĞůůƵůĂƌɴƚĂŬĞƐƉůĂĐĞŝŶƚŚĞůŝƉŝĚƌĂĨƚƌĞŐŝŽŶŽĨƚŚĞŵĞŵďƌĂŶĞ͘dŚĞƐǇŶƚŚĞƐŝƐ
ŽĨɴŽĐĐƵƌƐƚŚƌŽƵŐŚƚŚĞĂŵǇůŽŝĚŽŐenic (pathogenic) pathway. B) Processing of APP 
ĐĂŶŽƚŚĞƌǁŝƐĞŽĐĐƵƌǁŚŝůƐƚƉƌĞƐĞŶƚŝŶƚŚĞĞŶĚŽƐŽŵĞĂŶĚƐŽĐĂŶƌĞůĞĂƐĞɴŝŶƚŽƚŚĞ
ĐǇƚŽƉůĂƐŵ͘ Ϳ dŚĞ ɴ ĐĂŶ ƚŚĞŶ ĞŝƚŚĞƌ ĂŐŐƌĞŐĂƚĞ ƚŽŐĞƚŚĞƌ Žƌ ďĞ ĞŶĚŽĐǇƚŽƐĞĚ ďǇ
lysosomes and degraded. D) Once APP proteolysis has occurred, BACE1 is either 
internalized to endosomes via GGA1 and ARF6 or labelled with ubiquitin and 
endocytosed.  With assistance from the sorting protein, GGA3, the lysosomes will 
either recycle or degrade BACE1. 
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Recently, Ă ŶĂƚƵƌĂů ŝŶŚŝďŝƚŝŽŶ ŽĨ ϭ ŚĂƐ ďĞĞŶ ĨŽƵŶĚ ǀŝĂ ƚŚĞ ƐWWɲ
fragment, produced from the non-amyloidogenic pathway.96 dŚĞ ƐWWɲƉƌŽĚƵĐĞĚ
ĨƌŽŵWW͕ŚĂƐďĞĞŶĨŽƵŶĚƚŽŝŶĨůƵĞŶĐĞŝƚƐŽǁŶĐůĞĂǀĂŐĞ͘ƐWWɲŵĂŝŶƚĂŝŶƐƚŚĞĂďŝůŝƚǇ
to bind to BACE1 and interfere with the APP cleavage in a mouse model, resulting in 
an overall reduction in Aɴ ĨŽƌŵĂƚŝŽŶ ƵŶĚĞƌ ƉŚǇƐŝŽůŽŐŝĐĂů ĐŽŶĚŝƚŝŽŶƐ͘96 The 
consequence of this pathway being impaired in any way could result in an increase in 
BACE1 production thus increasing the cleavage of further units of APP.  Production 
ĂŶĚŚŽŵĞŽƐƚĂƐŝƐ ŽĨ ƐWWɲ ĐŽƵůĚƉƌŽǀŝĚĞĂŵŽƌĞŶĂƚƵƌĂů ŝŶƚĞƌǀĞŶƚŝŽŶ ƐƚƌĂƚĞŐǇ ĨŽr 
future research.  
 
1.3.2  BACE2 and Closely Related Proteins 
ϮŝƐĂĐůŽƐĞůǇĂƐƐŽĐŝĂƚĞĚɴ-secretase to BACE1; sequence analysis show 
amino acid residue similarities of 45% and structural comparisons of 75% homology.97 
ϮŝƐĂůƐŽĐůĂƐƐŝĨŝĞĚĂƐĂŶĂƐƉĂƌƚŝĐƉƌŽƚĞĂƐĞǁŝƚŚƚŚĞĂďŝůŝƚǇƚŽĐůĞĂǀĞWWĂƚƚŚĞɴ-
site.98 In vitro studies have also indicated BACE2 could be a possible competitor of 
BACE1 for the cleavage of the APP protein but it is not formally expressed in excess 
in the brain, and does not compensate for the loss of BACE1 in murine gene knockout 
models.87,99 KǀĞƌĞǆƉƌĞƐƐŝŽŶŽĨϮŚĂƐďĞĞŶ ĨŽƵŶĚ ƚŽ ƌĞĚƵĐĞɴƉƌŽĚƵĐƚŝŽŶ ŝŶ
primary neuronal cultures derived from APP transgenic mice.  This could be caused 
by the ability of BACE2 to cleave APP before BACE1 or because BACE2 cleaves a longer 
ɴĨƌĂŐŵĞŶƚ;ϳϵƌĞƐŝĚƵĞƐͿĨƌŽŵWW͕ǁŚŝĐŚŝƐĂƉƉƌŽĂĐŚŝŶŐƚŚĞĐůĞĂǀĞĚĨƌĂŐŵĞŶƚŽĨ
ɲ-secretase than that of BACE1.87,97    
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ϮŝƐŶŽƚƉƌŝŵĂƌŝůǇĞǆƉƌĞƐƐĞĚŝŶƚŚĞďƌĂŝŶǁŚĞƌĞɴŝƐƉƌŽĚƵĐĞĚ͘ϮŝƐ
commonly expressed in the colon, kidney and pancreas, showing that whilst 
theoretically still having the ability to increase the pathogenesis of AD it is not 
ĐŽŶƐŝĚĞƌĞĚĂƚŚƌĞĂƚƚŽɴŐĞŶĞƌĂƚŝŽŶ͘98,100 BACE1 is the main amyloidogenic enzyme, 
and remains the major contributor to amyloid plaque formation.  BACE1 shows 
sequence homology with a number aspartic proteases other than BACE2, including 
Renin and Cathepsin D.  These homologs are generally used for selectivity testing with 
in vitro assays to confirm unwanted binding does not occur. 
 
1.3.3  Substrates of BACE1 
The BACE1 protein is not solely defined by the cleavage of APP and has the 
ability to cleave other proteins; namely the amyloid-like precursor proteins 1 and 2, 
WWɸ;ǁŚŝĐŚŝƐĂŶŽƚŚĞƌĐůŽƐĞůǇƌĞůĂƚĞĚN-terminal product of APP), neuregulin-1 and 
-ϯ ;ŝŶǀŽůǀĞĚ ŝŶ ĂǆŽŶ ŵǇĞůŝŶĂƚŝŽŶͿ͕ ɴ-subunits of voltage-gated sodium channels 
(required for neuronal action potentials), P-selectin glycoprotein ligand-1 (PSGL1) 
(which regulates leukocyte adhesion in the inflammatory process), the interleukin 1 
receptor type-II  (IL1-R2) and the low density lipoprotein receptor-related protein 1 
(LLRP1) (a multifunctional endocytic and signalling receptor).101-106 With the use of an 
unbiased, quantitative proteomics method, the identification of 64 new potential 
substrates were uncovered.  The majority of these were type I transmembrane 
proteins and an additional three glycophosphatidylinositol anchors, as well as one 
type II transmembrane protein, all of which are membrane bound.107 The actions of 
these substrates range from signal transmission to inflammation, which are 
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fundamental dysfunctions associated with AD and may exacerbate the symptoms.    
 
ŵǇůŽŝĚŽŐĞŶŝĐ ƉĂƚŚǁĂǇ ĐƌĞĂƚŝŶŐ ĞŶǌǇŵĞƐ ϭ ĂŶĚ ɶ-secretase have a 
broader effect on other substrates created from the processing of unrelated proteins.  
Murine models with a BACE1 -/- deletion produced symptoms of hyperactivity, 
premature death and seizure like behaviours, whilst presenilin -/- mice displayed 
ĞĂƌůǇ ŶĞƵƌŽĚĞŐĞŶĞƌĂƚŝǀĞ ďĞŚĂǀŝŽƵƌƐ ĂŶĚ ŝŶĐƌĞĂƐĞĚ ɴ ůŽĂĚŝŶŐ͕ Ă ĐŽŶƐĞƋƵĞŶĐĞ ŽĨ
unprocessed substrates.108-111 dŚĞ ɶ-secretase complex is essential for the Notch 
signalling pathway and if inhibited completely could hinder development of the 
nervous system.112 dŚĞ ɶ-secretase complex is also required for the non-
amyloidogenic pathway and complete inhibition or deletion of the cleavage pathway 
will be detrimental to the homeostatic processing relating to neuronal development 
and function.   
 
1.4 Challenges 
 1.4.1  Past BACE1 Inhibitors 
BACE1 has been a focal point for AD intervention since it was discovered due 
to the integral and ŽďǀŝŽƵƐ ŝŶĨůƵĞŶĐĞ ŽǀĞƌ ɴ production.  From a therapeutic 
ƉĞƌƐƉĞĐƚŝǀĞ͕ ƚŚĞ ƉƌŽĂĐƚŝǀĞ ŝŶŚŝďŝƚŝŽŶ ŽĨ ϭ ƌĞŵĂŝŶƐ Ă ĨĞĂƐŝďůĞ ŽƉƚŝŽŶ ĂƐ ɴ is 
produced by a relatively basic protein/enzyme interaction.  The extracellular 
positioning exposes the enzymatic active site allowing the inhibitor to access mature 
ϭ͘ϭŶƵůůŵƵƌŝŶĞŵŽĚĞůƐŚĂǀĞƐŚŽǁŶƚŚĂƚɴŝƐŶŽůŽŶŐĞƌƉƌŽĚƵĐĞĚǁŚĞŶ
WWŝƐŶŽƚĐůĞĂǀĞĚĂƚƚŚĞɴ-site, encouraging the persistent search for a therapeutic 
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intervention.109 BACE1 maintains the ability to bind to a wide variety of peptidic 
structures, while specific binding is a desirable attribute there is still access to the 
active site for therapeutic targeting.113 Closely related members of the aspartic 
protease family, namely Renin and HIV protease-1 (HIV-1), have successfully been 
inhibited providing confidence that BACE1 is a viable option for inhibition.114  
 
Drug intervention of AD to date is limited between therapeutic relief of 
symptoms and prevention of the underlying etiology of the disease.115 The available 
treatments can only minimise symptoms but are the only viable option for sufferers 
of AD.  This method effectively slows the decline of cognition, function and behaviour 
but masks the underlying neurodegeneration occurring via plaque deposition.116 The 
drugs currently available to treat AD are divided into two categories; cholinesterase 
inhibitors and receptor antagonists.115   
 
 Cholinesterase inhibitors attempt to prevent the metabolism of acetylcholine, 
allowing neurons to maintain an excited state.117 Cholinesterase inhibiting drugs like 
donepezil, galantamine and revastigmine are only effective in the early stages of AD 
by allowing the retention of acetylcholine.115 Inhibiting the hydrolysis of acetylcholine 
by cholinesterase, once the neurotransmitter has crossed the synapse, allows the 
cholinergic neuron to remain active.117 This action becomes redundant when 
progression of NFTs interferes with the normal signal transmission of the axon.13 
Cholinesterase inhibitors have been shown to increase the amount of 
phosphorylated tau which can further the progression of AD, minimising the 
effectiveness of the drug.118,119 
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The other pharmaceutical option is memantine, an uncompetitive N-methyl-
D-aspartate (NMDA) receptor antagonist that prevents binding of the primary 
excitatory neurotransmitter in the brain, glutamate.120,121 As a result, glutamatergic 
overstimulation can occur causing neuronal cell damage by increased localized 
calcium stores and excitotoxicity.122 Both cholinesterase inhibitors and NMDA 
receptor antagonists have damaging side effects and can only offer therapeutic relief 
of symptoms and thus, are not useful for a long-term intervention strategy.   
 
Therapeutic relief by donepezil, galantamine and memantine, are necessary 
to optimize the productivity of the brain whilst the disease progresses. However, all 
current pharmaceutical interventions are unable to translate to a definite cure.  The 
ƉƌŽĚƵĐƚŝŽŶ ŽĨ ɴ ƌĞŵĂŝŶƐ ƚŚĞ ďĂƐŝƐ ŽĨ ƐĞŶŝůĞ ƉůĂƋƵĞ ƉƌŽĚƵĐƚŝon and should be 
investigated as an important therapeutic target.  Theories propose that by inhibiting 
BACE1 before it cleaves APP, the formation of the beta amyloid residues will be 
reduced.123,124 To prevent plaque formation, inhibition of BACE1 would be most 
effective after translation and before binding to APP, so sAPPɴĚŽĞƐŶŽƚŐĞƚĐůĞĂǀĞĚ͘ 
 
Current drug discovery for pharmaceutical intervention aims to hinder the 
BACE1 enzymatic activity during transport to the cell surface.  Notable methods look 
at high-throughput screening (HTS), fragment-based drug discovery (FBDD) and 
substrate-based inhibitors.125 None of these methods have produced an inhibitor 
that been successful in therapeutic trials.  The more complex approach, generally 
taken by larger pharmaceutical companies, relate to either the HTS strategy or a 
FBDD approach.  Both processes use a large library of complex compounds in order 
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to find a suitable hit, followed by a long modification process to refine it into a 
suitable chemical.  Initial use of HTS sourced complex, high-molecular weight, 
compounds that were difficult to manipulate.  Potential therapeutic candidates 
showed strong oral availability and good brain permeability but could not provide the 
standards of potency and selectivity for therapeutic trials.125,126 
 
The HTS method has been substituted by the FBDD approach as it uses smaller 
and more specific compounds.127 The screening of a fragment library is more 
appealing because a higher hit ratio is produced, and the options produce more 
favourable drug properties.  The main problem with the compounds is the low 
potency and selectivity. Often, fragments that showed promise were too small to 
effectively bind to BACE1 and have not produced any inhibition with the effectiveness 
required for therapeutic trials. 
 
A large range of inhibitors are currently being researched including primary, 
secondary and tertiary amines, hydroethylamines (HEA) of many different 
conformations, statines, arylamino compounds and acyclic acylguanidines. Most of 
these compounds act as transition state mimics with a reduced peptidic form, that 
preclude them from the same scrutiny as peptide based structures. To their 
detriment, hydroxyethylamine derivatives display poor brain exposure, mainly due to 
p-glycoprotein (PgP) mediated efflux.128-130 Bristol-Myers Squibb produced a HEA-
derivative that contained an indol and a 7-azoindole carboxamide that showed a high 
potency in vitro that had an IC50 of 10nM and a low affinity for BACE2 and Cathepsin 
ďƵƚƐƚƌƵŐŐůĞĚƚŽŵĂŝŶƚĂŝŶďƌĂŝŶɴůĞǀĞůƐin vivo.131 
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Another study has looked to hybridize the HEA isotere and replace the 
sulfonate ester present in one molecule with the sulphonamide of another.132 The 
result was a compound that had high potency IC50 of 15nM to BACE1 that could bind 
to the hydrophobic space of the active site.  Unfortunately, this compound was able 
to bind to BACE2, minimising selectivity to BACE1.  Due to issues with HEA structures 
crossing the Blood Brain Barrier (BBB), Merck changed to a macrocyclic inhibitor 
produced by cross linking the P1 and P3 sidechains of an isophthalamide-based 
inhibitor. This process helped improve potency but a bolus of 100 mg/kg fed to APP-
zŵƵƌŝŶĞŵŽĚĞůĐŽƵůĚŽŶůǇŽďƚĂŝŶɴĚĞĐƌeases of 25% in the first hour, decreasing 
to 10% after the third.133  
 
  Additionally, BACE1 inhibitors have been manufactured from peptide 
sequences via a substrate-based method.  The initial peptide sequences showed 
promise with high potency and selectivity but did not progress as a viable 
pharmaceutical target because the large, unstable by-products it produced. Branded 
OM99-2, this peptide was originally used to determine many functions and shapes of 
BACE1 including the active site.  OM99-2 was able to maintain a high potency but 
unfortunately it was too bulky to cross the BBB.  Revision of this method looked 
specifically at the structure and function of BACE1 in order to manufacture a peptide 
sequence that would exploit its weaknesses.134,135 It was designed to competitively 
inhibit the binding regions and shut down the enzymatic properties.  The finished 
product was a long peptide (18 amino acid residues) which produced a high potency 
but was not stable enough for use in therapeutic trials. 
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These studies made it clear that peptidic structures could fulfil the desired 
properties required for an inhibitor, the only issue being BBB transport, motivating 
research to investigate smaller molecules that can freely penetrate the tight gap 
junctions. The potential inhibitor needs to be lipophilic to permeate the BBB by 
passive diffusion or passage through the membrane actively with the use of a 
transporter without being freely exported the same way.  Developing a polypeptide 
structure that maintains high potency with cell permeability would fulfil all inhibitory 
criteria.  Since amino acids, peptides and proteins are the building blocks of the 
human form and function, these inhibitors can maintain relative anonymity and can 
also minimise unwanted excretion and degradation.    
 
1.4.2  Crossing the Blood Brain Barrier 
The BBB is a network of brain capillaries that regulate the transfer of nutrients 
and co-factors important to the function and maintenance of the brain.  The BBB 
structure begins at the lumen, which is lined with a monolayer of capillary endothelial 
cells held together by tight gap junctions. This monolayer is complemented by 
pericytes for the purpose of BBB-specific gene expression and inducing polarisation 
of the astrocyte end-feet with the surrounding basal lamina.136 The tight junctions 
are specialised to prevent the paracellular diffusion of polar molecules from systemic 
circulation and brain parenchyma.137 Accompanying the endothelium are a number 
of compounds that defend against foreign transfer like cytochrome p450 and 
glutathione S-transferase in conjunction with transporters and the multidrug 
resistance associated proteins 1 and 2 (MRP1/2).138-140   
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The defence mechanisms protecting the brain from systemic circulation 
become a challenging interference when fabricating an inhibitor, particularly when it 
comes to testing localised drug effectiveness.  The molecular weight threshold, which 
is a relevant property of all membranes, is extremely stringent at less than <450Da.141 
This creates a challenge that goes beyond the production of protein specific 
intervention strategies.  In the case of BACE1, there are a number of different 
challenges, as previously mentioned, influencing the inhibition of APP cleavage.  With 
the influence of the BBB, the drug will be required to maintain an ability to inhibit 
BACE1 but also maintain solubility across the membrane or pass through the tight 
junctions of vessel epithelium.   
 
The natural functioning of the BBB is to maintain tight junctions to prevent 
unwanted contaminants but can be temporarily disrupted for the purpose of drug 
administration.  The relaxing of these junctions with hyperosmotic chemicals, for 
example, could be enough to encourage transport into the brain.  The only concern 
with this method is the unfavourable uptake of plasma proteins, such as albumin, 
which is toxic to astrocytes.142 Consequently, it could also affect drug retention and 
enhance unwanted migration of otherwise rejected contaminants.   
 
Another drastic, invasive technique involves drilling into the cranium and 
administering the treatment via intracerebroventricular injection, intracerebral 
implantation and convection enhanced diffusion.  These techniques are incredibly 
invasive and require drug effectiveness to more successful than the toxicity 
created.143 Intracerebroventricular injection has been found to cause haemorrhage 
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after needle removal but has otherwise has shown favourable effectiveness.144 These 
invasive techniques are questionable and should be considered with extreme caution 
but should not be disregarded if effective. 
 
  Lipid carriers have the most potential for BBB transport. Water soluble 
inhibitors, that cannot penetrate a cell membrane, are bound to the lipid carriers for 
the purpose of BBB transport.145 This facilitates entry into the brain, but once across 
the BBB the inhibitor either needs to be effective while immobilised or the carrier 
needs to be removed. The naturally occurring, 60 amino acid, galanin-like peptide 
(GALP) has the ability to cross the BBB where needed with the use of a saturable 
transport system.146 The GLUT1 glucose transporter is another natural carrier system 
that is used frequently as glucose is the main energy source of the brain.147 If this 
method can be transformed for BACE1 inhibitors, the transfer of larger, more potent 
molecules with an increased selectivity could be achieved.  
 
1.4.3  Transporters 
The ability to transport potential inhibitors across the BBB can determine the 
success or failure of potential therapeutic treatment. The BBB has manipulated the 
inhibitor composition to accommodate for small (<450 Da) molecules with the 
potential to pass the barrier without triggering an immune response.  The 
repercussions of this style have been low potency and selectivity in vivo with a 
requirement for greater effectiveness that is achieved using larger inhibitors.  The 
potential for transporters could revolutionize the future of drug administration by 
providing a medium where the larger, more effective inhibitors can cross this barrier.  
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Earlier transporters aimed to cross the BBB by utilising the native channels 
and receptors. The idea was to couple an inhibitor with the specific ligand of a surface 
receptor like that of the H1 histone, insulin, insulin-like growth factors or 
transferrin.148-151 These systems can also work by binding the inhibitor to antibodies 
that identify surface epitopes already present in the BBB.  The coupling of an 18mer 
peptide to transferrin receptor specific antibodies were used to penetrate the BBB 
via the transferrin receptor for the inhibition of the rev gene of HIV-1.152 This study 
demonstrated a 15-fold increase in transfer across the BBB. This system can be 
modified to display a number of different biotinylated peptides, and may potentially 
be manipulated for other compounds. 
 
An advanced method of targeted liposomes progresses from the inhibitor-
ligand structure to a colloidal carrier system.  The concept utilises BBB receptors and 
channels, and has improved the process with an overall increase in the concentration 
of transported inhibitor.  The liposomal system has the ability to hold >10,000 drug 
molecules which reduces the need for extremely high potency.153 The main 
vulnerability of this system is the need to avoid opsonins (members of the 
complement system) and immunoglobulins that cover the colloidal particle to 
activate phagocytosis. This method has already been used to transfer daunomycin, 
an anti-cancer treatment, across the BBB.153 The negative of this system however, is 
the vulnerability to macrophages via opsonisation and the lack of selectivity that 
liposomes have in regards to the brain and BBB.  The targeted liposome system has 
already been used successfully to transfer sodium borocaptate in defence against 
malignant glioma, encouraging the expansion of this research to include the 
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treatment of neurodegenerative diseases.154 
 
A new approach of facilitated molecular treatment uses fullerenes as a 
mediator, stabilising and potentiating drug delivery.  Fullerenes are an allotropic form 
of carbon that can be arranged into a 60 atom hollow sphere, 1 nanometre in 
diameter, that is coupled with an inhibitor.155 These fullerene systems has already 
shown promise for the treatment of chronic multiple sclerosis.156 Whilst still in the 
early stages of research, the clinical recovery was attributed to a reduction in axon 
loss and demyelination in the spinal region of the CNS in a murine model.  Another 
study has shown a reduction of infarct size in gerbils and rats with the use of a 
hexasulfinonated C60 that was administered intravenously.157,158 Further research is 
required for application in human treatments, however the potential for preventing 
amyloid plaque formation is highly anticipated. 
 
1.5  Future Perspectives 
There are a number of exciting directions that future research will take to 
determine a safe and effective treatment for AD. The regulation of internal pathways 
for the natural management of BACE1 activity is of key interest as it involves the 
crossroad from compound based, active site mimics.  The recent study identifying the 
ƐWWɲ ĂƐ Ă ϭ ŵŽĚƵůĂƚŽƌ ĐŽƵůĚ ŵŽƚŝǀĂƚĞ ƚŚĞ ŝŶǀĞƐƚŝŐĂƚŝŽŶ ŽĨ ƚŚĞ ďƌŽĂĚĞƌ
pathway rather than focussing on the enzyme itself.96 Pathway regulation may 
reduce side effects and associated pathologies due to the broad spectrum enzymes 
that envelope amyloidogenesis. 
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The implicatiŽŶŽĨɴƐŝŐŶĂůůŝŶŐ ŝŶƉůĂƋƵĞ ĨŽƌŵĂƚŝŽŶ ŝƐĂŶŽƚŚĞƌĐŽŶĐĞƉƚĨŽƌ
investigation into the possibility of a feedback system.  An increase in production of 
ɴŵŽŶŽŵĞƌƐĞŶĐŽƵƌĂŐĞƐƉůĂƋƵĞĨŽƌŵĂƚŝŽŶĂŶĚŵŝŐƌĂƚŝŽŶ͖ĂĚĞƚĂŝůĞĚƵŶĚĞƌƐƚĂŶĚŝŶŐ
of this process would benefit deconstruction methods.  The application of a potential 
BACE1 inhibitor is rudimentary to the prevention of amyloid plaques because the 
amyloidogenic pathway would become bypassed completely͘  tŝƚŚ ŵŝŶŝŵĂů ɴ
production, the pressure released on the natural inflammatory defences would allow 
for the metabolism of impeding plaques. 
 
DĂŶǇɶ-secretase inhibitors have progressed to phase III clinical trials with the 
ĂŝŵƚŽƉƌĞǀĞŶƚɴƉƌŽĚƵĐƚŝŽŶďƵƚƚŚĞĐŽŶƐĞƋƵĞŶĐĞŽĨƵŶƌĞůĂƚĞĚƐŝĚĞĞĨĨĞĐƚƐĚĞĞŵ
them a liabilty.159 The detrimental effect on the unrelated Notch signalling pathway, 
important in axon myelination and apoptosis, could be more detrimental than plaque 
formation because of the regulatory purpose in which it serves.112   
 
The past and present BACE1 inhibitors have yet to pass phase III clinical trials 
and there is currently no commercially available treatment.  Merck have developed 
the MK-8931 inhibitor that is currently undergoing phase II/III clinical trials with 
results due in 2018.160 /ƚŵĂŝŶƚĂŝŶƐĂŶĂďŝůŝƚǇƚŽƌĞĚƵĐĞɴ40͕ɴ42 ĂŶĚƐWWɴůĞǀĞůƐ
while being well tolerated in vivo and shows minimal adverse reactions.  The MK-
8913 inhibitor exhibits an affinity for BACE1 which has previously been problematic 
for small compounds (<450 Da).  Eli Lilly and AstraZeneca have collaborated for the 
AMARANTH project, which is investigating the AZD3293/LY3314814 BACE1 inhibitor.  
The large phase II/III trial testing the orally administered BACE1 inhibitor involves 
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ŵŽƌĞƚŚĂŶϭ͕ϱϬϬƉĂƚŝĞŶƚƐĂĐƌŽƐƐϭϱĐŽƵŶƚƌŝĞƐŵĞĂƐƵƌŝŶŐɴůĞǀĞůƐŝŶĐĞƌĞďƌŽƐƉŝŶĂů
fluid.161 Preclinical data for this trial has not yet been published as the study is due 
for completion in 2019.  Both trials involve at small compound (<450 Da) that nullifies 
the restrictive BBB but face alternative hurdles of selectivity and bioavailability.     
 
A nƵŵďĞƌŽĨɴƐƉĞĐŝĨŝĐĂŶƚŝďŽĚǇƚƌĞĂƚŵĞŶƚƐŚĂǀĞďĞĞŶƚƌŝĂůůĞĚ͕ĂƚƚĞŵƉƚŝŶŐ
to assist plague clearance after APP cleavage by encouraging microglia recruitment.  
Gantenerumab, recently produced by Roche, was hypothesised to bind preferentially 
ƚŽ ďƌĂŝŶ ɴ ďƵƚǁas discontinued during phase III trials.162 The antibody showed 
promising results in vitro but decreased effectiveness in vivo.  Solanezumab 
(LY2062430), another monoclonal antibody candidate currently in phase III trials, is 
concentrating on safety monitoring of prolonged treatment but is reported to have 
reduced cognitive decline.163 Most of these specific antibodies source monomeƌŝĐɴ
as it is being produced, which could potentially restrict effectiveness with already 
developed plaques as they aim to reactively intervene during amyloidogenic 
ƉĂƚŚǁĂǇ͘  Ŷ ĂŶƚŝďŽĚǇ ƚŚĂƚ ůĂďĞůƐ ɴ ĨƌĂŐŵĞŶƚƐ ƉƌŝŽƌ ƚŽ ƉůĂƋƵĞ ĨŽƌŵĂƚŝŽŶ ĐŽƵůĚ
complement a BACE1 inhibitor, proactively diverting plaque formation for patients 
that have recently been diagnosed.   
 
Once a viable candidate has been identified, research can be directed to 
promote plaque clearance and neurogenesis to aid regeneration of a brain affected 
by AD.  Exploration into the use of stem cell therapy has looked to replace lost brain 
mass with multi-potent adult neural stem cells, which are found in the subgranular 
and subventricular zones. The CNS has the ability to regenerate a number of neuronal 
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cell lines with astrocytes, oligodendrocytes, and functional neurons, however the 
challenge is to develop a system that can repopulate the subregions of the brain.164 
By utilizing these cell lines, the brain would need to be “rebuilt” to regenerate the 
structures affected by the plaque formation without the involvement of invasive 
procedures.  However, this would be implicated by numerous ethical challenges. 
 
1.6  Conclusions 
The initial cellular changes leading to the development of AD are still debated. 
However, early stages of the disease are known to be initiated by the accumulation 
of amyloid plaques.  The amyloidogenic pathway, mediated by the proteolytic 
cleavage of APP, is the major focus for the alleviation of AD.  BACE1, the defining 
enzyme of this process, is responsible for the cleavage of APP which results in 
production of ƚŚĞŶĞƵƌŽƚŽǆŝĐɴĨƌĂŐŵĞŶƚ͘dŚĞĚŝĨĨĞƌŝŶŐĨƌĂŐŵĞŶƚůĞŶŐƚŚƐ͕ďĞƚǁĞĞŶ
38-42 amino acids, influences the acute generation of amyloid plaques and is 
cooƌĚŝŶĂƚĞĚďǇƚŚĞɶ-ƐĞĐƌĞƚĂƐĞĐŽŵƉůĞǆ͘dŚĞĨŽĐƵƐŝƐƉůĂĐĞĚŽŶĨƌĂŐŵĞŶƚƐɴ40 and 
ɴ42 for their abundance in total plaque loading, and as the active components in 
plaque construction.   
 
tŚŝůƐƚƚŚĞƌĞŝƐĂŶŝŶĚŝĐĂƚŝŽŶƚŚĂƚɶ-secretase complex maintains the ability to 
determine the severity of ƉůĂƋƵĞĨŽƌŵĂƚŝŽŶďǇĂůƚĞƌŝŶŐɴůĞŶŐƚŚ͕ƚŚĞƌĞĂƌĞĂŶƵŵďĞƌ
of reasons to avoid inhibition.  The negative influence on the Notch signalling 
pathway can impair axon myelination and prevent cell maturation leading to cell 
death, which rules it out as a target.  This is a hallmark of the obscurity influencing 
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intervention strategies, as plaque formation is created by the basic cleavage of a 
protein by two enzymes, but a broader number of associated substrates and 
pathways create adverse reactions. This motivates the notion of regulation as 
opposed to complete inhibition, to alleviate majority of the proteolysis.   
 
The BACE1 cleavage of APP could be a response, or trigger, to AD progression 
ĂƐŝƚŝƐĨƵŶĚĂŵĞŶƚĂůŝŶƚŚĞƉƌŽĚƵĐƚŝŽŶŽĨɴďƵƚŝƚŝƐĂŶĂƚƵƌĂůƉƌŽĐĞƐƐǁŚŝĐŚŝŶĐƌĞĂƐĞƐ
in the diseased state.  In order to regulate this process, a third party inhibitor is 
required.  The development of a viable inhibitor is influenced by a number of 
obstacles including the ability to maintain the pharmaceutical properties between in 
vitro and in vivo testing and the BBB.  The transfer between the tight junction of brain 
endothelium and the neuronal cells has defined the way BACE1 inhibitors are 
engaged.   The change from basic peptidic structures to that of small <450Da 
chemicals has solved one hurdle by creating another.  The original in vitro studies of 
peptidic inhibitors maintained positive selectivity for BACE1 but were too bulky for 
transport.  Further investigation analysing smaller more manageable peptidic 
structures could provide another angle to maintaining those positive pharmaceutical 
properties.  
 
The overall aim of this PhD project is to define an inhibitor that prevents the 
ĞŶǌǇŵĂƚŝĐĂĐƚŝǀŝƚǇŽĨϭ͘ǇŝŶŚŝďŝƚŝŶŐƚŚĞĐůĞĂǀĂŐĞŽĨWWĂƚƚŚĞɴ-site, the 
amyloidogenic pathway will cease to produce the plaque proĚƵĐŝŶŐ͕ɴ͘hƐŝŶŐƚŚĞ
affinity selection technique of biopanning by phage display, the initial aim of this 
project is to identify a dodecapeptide that binds specifically to BACE1.  This 
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candidate will be required to bind to BACE1 and reduce the enzymatic ability in a 
human neuronal cell model, while causing minimal side effects.  This peptide 
antagonist will provide a candidate for the possible future treatment of amyloid 
plaques.
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Chapter 2 
 
Identification of a Peptide Inhibitor Candidate to BACE1 
 
 
 
 
 
 
 
 
 
 
Summary 
Aims 
An increase in APP cleavage by BACE1 releases peptide fragments that can 
aggregate, forming amyloid plaques.  Prevention of this process, by inhibiting BACE1, 
is key to avoiding plaque formation. The aim of this chapter is to utilise the phage 
display and biopanning methods to identify a 12-mer peptide with a high binding 
affinity to BACE1 and to interrupt the pathway to plaque formation in vitro. 
 
Methods 
The phage display and biopanning techniques were used to identify a 
dodecapeptide candidate with high binding affinity to a biologically active, 
recombinant BACE1.  A large library of peptide candidates, expressed on a phage 
capsid, were reduced by affinity selection over five rounds of biopanning.  The bound 
BACE1 specific candidates were amplified by transducing an ER2738 E. coli host cell 
line in preparation for the subsequent round of biopanning.  After five rounds of 
biopanning, the pooled phage were divided to identify the range of BACE1 specific 
peptide candidates.  DNA from the phage was precipitated and sequenced to 
determine a motif from the binding candidates.  The deduced sequence was used to 
synthetically replicate the peptide isolated from the phage display and tested for 
binding ability and specificity with a BACE1 direct binding assay.  The peptide was also 
tested in vitro for BACE1 inhibition using a fluorescent assay.   
 
Results 
The biopanning technique, extended to five rounds to further refine the 
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phage candidate pool, increased in titre from round one, increasing the net amount 
of BACE1 binders with each round.  Blue plaques, denoting M13 specific transduced 
cells, were lysed and the ssDNA purified, amplified and sequenced.  Of the 12 plaques 
sequenced, a single motif was recognised across six of the samples and was 
synthetically reproduced.  The peptide was biotinylated and used to detect direct 
binding to the recombinant BACE1 protein used in the phage display.  The peptide 
showed a strong binding affinity to BACE1 with a significant colorimetric increase at 
nanomolar concentrations.  The BACE1 activity assay resulted in the successive 
reduction of APP substrate cleavage as more peptide was introduced to the reaction.  
The activity assay showed a significant reduction in BACE1 activity by adding 
concentrations of peptide in the nanomolar range.  
 
Conclusion 
The phage display and biopanning technique was able to identify a peptide 
with a high binding affinity to BACE1.  The increasing titre of phage from biopanning 
rounds indicated a BACE1 specific pool of binders which was confirmed by the 
sequencing and direct assay. When synthetically produced, the peptide maintained a 
high binding affinity to BACE1 as the increase in concentration created a significant 
gain in experimental response.  The high binding affinity of the peptide was causing 
an inhibitory effect on the activity of BACE1 as the ability to cleave the APP substrate 
in the in vitro assay was reduced.  The peptide candidate was added to the assay at 
increasing concentrations and caused a subsequent reduction in substrate cleavage 
denoting a reduction in BACE1 activity.  
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2.1  Introduction 
2.1.1  Phage Display and Biopanning 
The phage display technique is a high throughput method used to identify a 
binding candidate to a target molecule.165  Phage display was established in 1985 by 
using a M13 bacteriophage to express a peptide on the capsid, moving the affinity 
selection techniques away from antibodies.165 The bacteriophage externally displays 
a peptide fused to an attachment protein on the tail end of the capsid, allowing it to 
come into contact with a target and bind with a natural affinity.  Variation of the 
displayed peptide sequence allows the formation of a combinatorial library, 
increasing the likelihood of discovering a target binder.  The pool of peptide 
candidates bind by affinity capture, selecting the appropriate molecule in a natural 
environment without the need for initial modification.  The non-binding candidates 
are discarded, minimising the pool.   
 
Reintroducing the bound phage by biopanning to the same target can reduce 
the number of candidates by increasing stringency.  Increasing the number of 
biopanning rounds and amplifying the bound phage using a bacterial host strain, 
reduces the number poor binders and develops the potential candidates.  Using the 
M13 bacteriophage, DNA can be extracted and sequenced to characterise the 
peptide binder.  
 
2.1.2  Types of Phage Display 
Many different molecule display methods have been established with the 
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intention of identifying a ligand with high binding affinity to a target including 
ribosomal display166,167, mRNA display167, bacterial168 and eukaryotic display169,170 
and viral display.170,171 All display techniques are similar in principal but phage display 
specifically selects for peptide-protein and peptide-chemical binding. The benefit of 
selecting peptides is the high binding affinity and specificity they exhibit to a 
macromolecule like a protein or enzyme and effect normal functionality. Successful 
use of the phage display technique has selected peptide binders to a broad spectrum 
of enzymes, including: alkaline phosphatase172, hepsin173, tissue 
metalloproteinases174 and tyrosinase.175 The simplicity of peptidic structures allows 
for easy modification by the addition, subtraction or substitution of residues for 
binding optimisation.  
 
2.1.3  Construction of the Library 
The high-throughput of short peptide sequences is paramount to defining a 
candidate.  Random oligonucleotides are inserted into the gene III region of the 
phage cloning vector between the coding sequence and N-terminal end of the PIII 
surface protein projecting the peptide from the tail end of the phage.165 The 
oligonucleotides can be translated into peptides of between 5 and 40 amino acid 
residues.176,177 A library of peptides of up to seven residues in length can test for up 
to 1.1x109 candidates in one round phage display. 
 
2.1.4  M13 Bacteriophage  
The M13 bacteriophage is the most commonly used for phage display as it is 
non-lytic, is a flexible filamentous shape, has five different types of surface protein 
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and can allow for the display of peptides at both the C- and N-terminus.178 The M13 
phage has five different types of surface proteins, PIII (product of gene 3), PVI, PVII, 
PVIII and PIX that are used for bacterial adhesion.  The minor coat proteins PIII and 
PVI display five copies each at one end of the phage while PVII and PIX are at the 
other end.179 The PIII surface protein is fundamental for F-pilus binding the host 
bacterial cell however, modification of the PIII gene can allow for the display of a 
peptide that is incorporated into an already permanent structure without any loss of 
function.180  
 
2.1.5  ER2738 E. coli Host Strain Transduction  
The M13KE vector inserted into the M13 bacteriophage differs from the wild-
ƚǇƉĞĂƐƚŚĞ>ĂĐɲŐĞŶĞŚĂƐďĞĞŶŝŶƐĞƌƚĞĚŶĞĂƌƚŚĞŽƌŝŐŝŶŽĨƌĞƉůŝĐĂƚŝŽŶ͘dŚĞ>ĂĐɲ
ŐĞŶĞƉƌŽĚƵĐĞƐɴ-galactosidase which metabolises X-gal producing a blue plaque.181  
Usually this gene is used for genetic engineering as it represents plasmid transfection 
ďǇ ŝŶƐĞƌƚŝŶŐ ĨŽƌĞŝŐŶ E ŝŶƚŽ ƚŚĞ ɴ-galactosidase site. Successful transfection is 
ŝŶĚŝĐĂƚĞĚ ďǇ Ă ǁŚŝƚĞ ĐŽůŽƵƌĞĚ ƉůĂƋƵĞ ĂƐ ƚŚĞ ƉƌŽĚƵĐƚŝŽŶ ŽĨ ɴ-galactosidase is 
interrupted and the X-gal does not get metabolised.  The transduction occurring as a 
result of phage gene transfer to the E. coli ŚŽƐƚƐƚƌĂŝŶƚƌĂŶƐůĂƚĞƐƚŚĞɴ-galactosidase 
enzyme which results in a blue coloured plaque.  As the phage display peptides are 
ŝŶĐŽƌƉŽƌĂƚĞĚŝŶƚŽW///ƐƵƌĨĂĐĞƉƌŽƚĞŝŶƐĂŶĚŶŽƚŝŶƚŽƚŚĞŽƌŝŐŝŶŽĨƌĞƉůŝĐĂƚŝŽŶ͕ƚŚĞɴ-
galactosidase enzyme is produced normally as opposed to being interrupted.182  The 
plaques being produced from the phage display titre will appear blue indicating 
successful transduction has occurred. These plaques can be amplified to isolate the 
phage to determine the sequence that bound the target in the phage display.  
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 The current attempts at treating AD by inhibition of BACE1 have not been able 
ƚŽƉƌĞǀĞŶƚɴƉƌŽĚƵĐƚŝŽŶŝŶŚƵŵĂŶƚƌŝĂůƐ͘dŚĞĐŽŵŵŽŶŝƐƐƵĞǁŝƚŚŝŶŚŝďŝƚŽƌƐƌĞůĂƚĞ
to binding selectivity and affinity which can be achieved by using a short peptide.  This 
chapter is aimed at using the constructed 12-mer phage library to identify a peptide 
sequence that could not only bind to BACE1 but to inhibit it in vitro. 
 
2.2  Materials and Methods 
2.2.1  E. coli Stock Plates 
E.coli stock plates were prepared by inoculating 10ml of Luria-Bertani (LB) 
broth media, 10g bacto-tryptone, 5g yeast extract, 5g sodium chloride (NaCl), with 
10μl of ER2738 E. coli stock included in the phage display kit (New England Biolabs, 
USA).  The inoculated media was incubated overnight at 37°C with shaking.  10Ɋl of 
the culture was added to 10ml LB and grown to early log phase (0.01-0.05 OD600).  
The cells were diluted to single colonies by streak technique on LB agar plates with 
tetracycline, LB media with 15g/l agar and 20mg/l tetracycline, and grown for 24hrs 
at 37°C.  Stock plates were stored at 4°C for a maximum of two weeks. 
 
2.2.2  Phage Display and Biopanning of BACE1 
Immobilization of BACE1 Target Enzyme 
Recombinant human BACE1 (Sigma-Aldrich, USA) was diluted in 150μl 
blocking buffer, 0.1M sodium bicarbonate (NaHCO3) (pH 8.6), 5mg/ml bovine serum 
albumin (BSA), 0.02% NaN3, to 50μg/ml and added to a single well of a 96 well 
microtitre plate.  The plate was covered and with Parafilm and incubated with gentle 
rocking at 4°C overnight in a humidified container.   The solution was discarded and 
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replaced with 170μl blocking buffer and incubated at 4°C for a further 60 minutes.  
The blocking buffer was removed and the well washed six times with 170μl 0.1% TBS-
T (50mM Tris-HCl (pH 7.5), 150mM NaCl with 0.1% (v/v) Tween-20).  
 
Phage Display of Complete 12-mer Library 
A 100-fold representation of the phage display peptide library (New England 
ŝŽůĂďƐ͕h^ͿǁĂƐ ƐƵƐƉĞŶĚĞĚ ŝŶϭϬϬʅůŽĨ Ϭ͘ϭйd^-T and added to the plate well 
containing the immobilized target and incubated for 60 minutes at room temperature 
with gentle rocking.  The solution was discarded and the well washed 10 times with 
0.1% TBS-T.  The unbound phage in solution were discarded and the bound phage 
eluted by adding 100μl of glycine buffer, 0.2M glycine-HCl (pH 2.2) with 1mg/ml BSA, 
to the microtitre plate well and gently rocked for 7 minutes.  The solution was 
transferred to a microcentrifuge tube and neutralised with 150μl of a 1M Tris-HCl (pH 
9.1) solution, which formed the Unamplified Eluate. 
 
Amplification of Eluate 
In a 50ml centrifuge tube, 10ml of LB was inoculated with a single ER2738 E. 
coli colony picked from the stock plate and incubated at 37°C to early-log phase 
(OD600 0.01-0.05).   1ml of the culture was transferred to a 250ml conical flask 
containing 20ml of LB and 100μl of unamplified phage and incubated with vigorous 
shaking at 37°C for 4.5 hours.  The cell culture was transferred to a sterile 50ml 
Beckman Coulter centrifuge tube and pelleted by centrifugation at 12,000xg for 10 
minutes at 4°C.  The supernatant was transferred to a new sterile tube and the 
centrifugation repeated.  The upper 80% of the supernatant was transferred to 
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ĂŶŽƚŚĞƌƐƚĞƌŝůĞĐĞŶƚƌŝĨƵŐĞƚƵďĞĂůŽŶŐǁŝƚŚϯϬϬʅůW'ͬNaCl, 20% (w/v) polyethylene 
glycol–8000 with 2.5M NaCl, vortexed and allowed to precipitate overnight at 4°C.  
The phage were pelleted by centrifugation at 12,000xg for 15 minutes at 4°C.  The 
supernatant was discarded and the pellet re-suspended in 1ml TBS, 50mM Tris-HCl 
(pH 7.5) with 150mM NaCl, and transferred to a microcentrifuge tube.  The 
suspension was pelleted at 17,000xg for 10 minutes. The supernatant was transferred 
to a new microcentrifuge tube along with 1/6 volume PEG/NaCl and allowed to 
precipitate on ice for 60 minutes. The phage was pelleted at 17,000xg for 10 minutes 
with the supernatant being discarded and the pellet re-suspended in 200μl TBS.  This 
formed the Amplified Eluate. 
 
Determination of Amplified Phage Titre 
In a 50ml centrifuge tube, 10ml of LB was inoculated with 10μl of the 
overnight ER2738 culture and incubated at 37°C with shaking to mid-log phase (OD600 
~0.5).   Unamplified phage were diluted to 10-4 in LB media and plated in 10-fold 
increments from 10-1 while amplified phage were diluted to 10-11 in LB media and 
plated in 10-fold increments from 10-8͘ϭϬʅůŽĨƚŚĞĚŝůƵƚŝŽŶƐǁĞƌĞƉƌĞ-incubated with 
ϮϬϬʅů ŽĨ ƚŚĞŵŝĚ-log phase E. coli host strain for 10 minutes.  Pour plates were 
constructed using 4ml of molten top agar, 10g/l bacto-tryptone, 5g/l yeast extract, 
85mM sodium chloride and 7g/l agar, mixed with the phage/E. coli suspension and 
added to the already prepared IPTG/X-gal plates.  Once set, the plated were 
incubated for 18 hours at 37°C and plaque forming units per millilitre (pfu/ml) 
calculated.  All biopanning preparations were maintained in the sterile environments 
of a Thermo Scientific KS18 Class II safety cabinet to minimise contamination. 
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Biopanning 
 Biopanning second round steps are a continuation of the original phage 
display protocol but the addition of the library to the immobilised target is 
substituted for the amplified phage from the previous round.  The pfu/ml of amplified 
eluate is used to maintain the input of ~1x1011 phage virions into the subsequent 
rounds.  The Tween-20 concentration for the wash steps prior to the phage 
incubation was increased by increments of 0.1% (v/v) for every subsequent round. 
 
DNA Precipitation 
The fifth round of biopanning was not amplified and the unamplified eluate 
was titred as previous.  Within the 18 hour incubation time, twelve plaques were 
picked individually and transferred to individual 1ml ER2738 broth cultures grown to 
early-log phase (OD600 0.01-0.05) where they were incubated for 4.5 hours at 37°C 
with vigorous shaking.  The cultures were transferred to microcentrifuge tubes and 
pelleted by centrifugation at 14,000xg for 30 seconds. The supernatant was 
transferred to a fresh tube and re-ƐƉƵŶ͘ϱϬϬʅůŽĨƐƵƉĞƌŶĂƚĂŶƚǁĂƐƚƌĂŶƐĨĞƌƌĞĚƚŽĂ
ĨƌĞƐŚ ƚƵďĞ ĐŽŶƚĂŝŶŝŶŐ ϮϬϬʅů ŽĨ WEG/NaCl and incubated for 20 minutes at room 
temperature.  The PEG precipitation was pelleted by centrifugation at 14,000xg for 
ϭϬŵŝŶƵƚĞƐĂƚϰΣ͘dŚĞƉĞůůĞƚǁĂƐƐƵƐƉĞŶĚĞĚŝŶϭϬϬʅůŽĨŝŽĚŝŶĞďƵĨĨĞƌ͕ϭϬŵDdƌŝƐ-
HCl (pH 8.0), 1mM EDTA and 4M sodium iodide (Na/Ϳ͘ϮϱϬʅůŽĨϳϬй;ǀͬǀͿĞƚŚĂŶŽůǁĂƐ
added to the tube and incubated for 15 minutes at room temperature. The 
precipitate was centrifuged at 14,000xg for 10 minutes at 4°C and the supernatant 
ĚŝƐĐĂƌĚĞĚ͘dŚĞƌĞŵĂŝŶŝŶŐƉĞůůĞƚǁĂƐƐƵƐƉĞŶĚĞĚŝŶϯϬʅůŽĨdďƵĨĨĞƌ, 1M Tris (pH 8.0) 
with 0.5M EDTA.  The precipitated DNA concentration was quantified using a ND-
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1000 NanoDrop spectrophotometer (Thermo Fisher Scientific, USA). 
 
Amplification and Purification of Phage DNA for Sequencing  
The purified DNA samples were individually amplified using the BigDye® 
Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific, USA).  The kit was 
assembled for templates, adding 2μl of the terminator ready reaction mix, 3.5μl of 
the big dye sequencing buffer and 6.5μl of the primer along with 10ng of template 
and dH2KƚŽϮϬʅů͘dŚĞƚƵďĞƐǁĞƌĞĂĚĚĞĚƚŽĂŶD:ZĞƐĞĂƌĐŚWd-100 thermocycler 
(Bio-Rad, USA) and run for 25 cycles of 96°C for 10 seconds, 50°C for five seconds and 
60°C for four minutes.  The PCR products were transferred to microcentrifuge tubes 
and centrifuged for one minute at 2500xg then 2μl of 125mM EDTA, 2μl of 3M sodium 
acetate and 50μl of 100% ethanol, was added.  The tubes were vortexed briefly then 
incubated at room temperature for 15 minutes.  The tubes were re-spun at 2500xg 
for 30 minutes. The supernatant discarded and 70μl of 70% ethanol added to the 
pellet and centrifuged at 1650xg for 15 minutes. The bulk of the supernatant was 
removed with remaining left to evaporate in the class II safety cabinet allowing the 
pellet dry on the base of tube ready for sequencing.  The nucleic acids resulting from 
the sequencing were viewed electronically using Finch TV software (Geospiza Inc., 
USA).  The synthetic peptide was produced with and without a biotin label by Auspep 
Pty. Ltd. (Australia). 
 
2.2.3  Direct Assay Determining Binding of Biopanning Candidate to BACE1 
Recombinant BACE1, as used in the phage display, was immobilised on wells 
ŽĨ ĂŵŝĐƌŽƚŝƚƌĞ ƉůĂƚĞ Ăƚ ǀĂƌǇŝŶŐ ŶĂŶŽŵŽůĂƌ ĐŽŶĐĞŶƚƌĂƚŝŽŶƐ ƚŽ ϭϬϬʅů ǁŝƚŚ ďůŽĐŬŝŶŐ
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buffer and incubated overnight in a humidified container at 4°C with rocking. The 
solution was discarded and replaced with blocking buffer and incubated for a further 
hour at 4°C.  The solution was discarded and the wells washed three times with 0.1% 
TBS-T.  The biotinylated peptide, as a result of the phage display and biopanning, was 
ĚŝůƵƚĞĚƚŽǀĂƌǇŝŶŐĐŽŶĐĞŶƚƌĂƚŝŽŶƐŝŶϭϬϬʅůŽĨĚ,2O and added to the corresponding 
plate wells for 60 minutes at room temperature with rocking.  Two negative controls 
were constructed, one of no peptide and the other of no BACE1 target.  The solution 
was then discarded and the wells washed 3 times with 0.3% TBS-T.  Then a 1:500 
dilution of streptavidin/horse radish peroxidase (HRP) conjugate (Amersham 
Biosciences Inc, USA) in 0.1% TBS-T was added to the wells and incubated for 60 
minutes at room temperature with rocking. The solution was then discarded and 
washed three times with 0.1% TBS-T.  For the detection, a 100ml solution was 
prepared by dissolving a tablet of phospho-citrate buffer with sodium perborate in 
dH2O.  7.5ml was used to dissolve one tablet of the HRP conjugate, o-
phenylenediamine dihydrochloride (OPD).  200μl of the OPD solution were then 
added to all wells and incubated for 60 minutes at room temperature in the dark.  
The reaction was stopped by adding 50μl of 4M sulfuric acid before reading the 
reaction on a HALO MPR-96 (Dynamica, Australia) at wavelength 492nm. 
 
2.2.4  Specificity Test of the Candidate to BACE1 
Solutions of recombinant BACE1, Renin, Cathepsin D and BACE2 were 
individually prepared in a 0.1M NaHCO3 ;Ɖ,ϴ͘ϲͿďƵĨĨĞƌĂƚĂĐŽŶĐĞŶƚƌĂƚŝŽŶϭʅD͘dŚĞ
plate was sealed an incubated overnight at 4°C with rocking.  The solution was 
ĚŝƐĐĂƌĚĞĚĂŶĚƌĞƉůĂĐĞĚǁŝƚŚϭϴϬʅůŽĨďůŽĐŬŝŶŐďƵĨĨĞƌĂŶĚŝŶĐƵďĂƚĞĚĨŽƌĂĨƵƌƚŚĞƌŚour 
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at 4°C.  The blocking buffer was discarded and the wells washed three times with 
200μl of 0.1% TBS-T.  Solutions containing various concentrations of biotinylated 
peptide were prepared in dH2KĂŶĚϭϬϬʅůĂĚĚĞĚƚŽƚŚĞĐŽƌƌĞƐƉŽŶĚŝŶŐǁĞůůƐ͘ dŚĞ
plate was incubated for 60 minutes at room temperature with rocking. The wells 
were washed again 3 times with 200μl of 0.3% TBS-T.  Then a 1:500 dilution of 
streptavidin/HRP conjugate (Amersham Biosciences Inc, USA) in 0.1% TBS-T was 
ĂĚĚĞĚƚŽƚŚĞǁĞůůƐĂƚϭϱϬʅůĂŶĚincubated for 60 minutes at room temperature with 
ƌŽĐŬŝŶŐ͘dŚĞƐŽůƵƚŝŽŶǁĂƐƚŚĞŶĚŝƐĐĂƌĚĞĚĂŶĚǁĂƐŚĞĚƚŚƌĞĞƚŝŵĞƐǁŝƚŚϮϬϬʅůŽĨϬ͘ϭй
TBS-T.  For the detection, a 100ml solution was prepared by dissolving a tablet of 
phospho-citrate buffer with sodium perborate in dH2O.  7.5ml was used to dissolve 
one tablet of OPD, which was then added to all wells and incubated for 60 minutes 
at room temperature in the dark.  The reaction was stopped by adding 50μl of 4M 
sulfuric acid before reading the reaction on a HALO MPR-96 (Dynamica, Australia) at 
wavelength 492nm. 
 
2.2.5  Competition Specificity Test to Confirm BACE1 Specificity 
 ϭʅD ƐŽůƵƚŝŽŶ ŽĨ ƌĞĐŽŵďŝŶĂŶƚ ϭǁĂƐ ŝŵŵŽďŝůŝƐĞĚ ŽŶ ƚŚĞǁĞůůƐ ŽĨ Ă
microtire plate immobilisation buffer at and incubated overnight at 4°C with rocking.  
The solution was discarded and the wells blocked for further hour at 4°C.  During this 
ƚŝŵĞ͕ϭʅDZĞŶŝŶ͕ĂƚŚĞƉƐŝŶ͕ϮĂŶĚĐŽŵďŝŶĂƚŝŽŶŽĨĂůůƚŚƌĞĞǁĞƌĞŝŶĐƵďĂƚĞĚ
in microcentrifuge tubes with 100nM of peptide in TBS-T for 30 minutes. The plate 
wells were washed three times with TBS-T and replaced with the pre-treatments and 
incubated for 60 minutes at room temperature with rocking.  The wells were washed 
again 3 times with 0.3% TBS-T.  Then, a 1:500 dilution of streptavidin/HRP conjugate 
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(Amersham Biosciences Inc, USA) in 0.1% TBS-T was added to all wells and incubated 
for 60 minutes at room temperature with rocking. The solution was then discarded 
and washed three times with TBS-T.  For the detection, an OPD solution was prepared 
and added to all wells.  The reaction was stopped after the colour had developed by 
adding 50μl of 4M sulfuric acid.  The plate wells were analysed on a HALO MPR-96 
(Dynamica, Australia) at wavelength 492nm. 
 
2.2.6  BACE1 Activity Assay with Direct Binding Method 
The BACE1 activity was tested with fluorescent activity assay kit (Sigma 
Aldrich, Australia).  The kit contained a 7-methoxycoumarin-4-acetyl-0.5mg [Asn670, 
Lue671]-amyloid b/A4 precursor protein 770 fragment 667-676-(2,4-
dinitrophenyl)lys-arg-arg amide trifluoroacetate salt fluorescent substrate that was 
ĚŝƐƐŽůǀĞĚŝŶD^KƚŽĂϱϬϬʅDƐƚŽĐŬ͘&ŽƌƚŚĞĐŽŶƐƚƌƵĐƚŝŽŶŽĨƚŚĞĂƐƐĂǇ͕ƚŚĞƐƵďƐƚƌĂƚĞ
ƐƚŽĐŬǁĂƐĚŝůƵƚĞĚƚŽϱϬʅDǁŝƚŚĂƐƵƉƉůŝĞĚĨůƵŽƌĞƐĐĞŶƚĂƐƐĂǇďƵĨĨĞƌ͘dŚĞsubstrate 
solution required dissolving of the 0.5mg APP in 0.05ml dimethyl sulfoxide which was 
divided into 1.2ml tubes in 50μl aliquots and stored as a stock solution at -20°C.  To 
begin the reactions, a 10-fold dilution of BACE1 from the kit to 40nM in FAB and the 
inhibitor was diluted down to concentrations of 1, 10 and 100 in Milli-Q water.  
Instead of placing all elements into a solution prior to incubation, as above, the 
inhibitor was immobilized on nitrocellulose and added to a 0.2ml tube containing the 
reagents, the inhibitor was compensated for in the total solution by adding more FAB.  
A grid, of 1cm x 1cm squares, was marked out on a nitrocellulose membrane 
according to the sample numbers and the respective inhibitor concentrations.  The 
squares used for the BACE1 inhibition had 10, 100 or 200nM of inhibitor solution 
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pipetted onto the centre of the respective square and allowed to dry, controls were 
left dry without inhibitor.  All squares were placed into 50ml tubes, according to 
inhibitor concentration, containing 25ml blocking buffer (5% (w/v) Diploma instant 
skim milk powder with Milli-Q water) and incubated for 30 minutes at room 
temperature on a Ratek rotary suspension mixer at medium speed.  The squares were 
removed and place in fresh 50ml tubes, according to inhibitor concentration, that 
contained 25ml Milli-Q water and washed on a rotary suspension mixer for five 
minutes.  After the initial wash, the water was removed and replaced twice more for 
a total of three washes.  The squares were then removed and placed in their 
respective 0.2ml tubes according to reaction number.  The tubes contained 78μl of 
fluorescent assay buffer (FAB) and 20μl of the substrate, diluted 10-folded from the 
stock.  2μl of BACE1 from the kit, diluted 10-fold to 40nM, was added to all tubes and 
incubated with agitation for 2 hours at 37°C.  After incubation, the nitrocellulose 
squares were removed and the remaining solution transferred to a Granier flat 
bottom, 96-well plate and read on a BMG Labtech Fluostar Omega fluorometer with 
excitation of 320nm and emission 405nm. 
 
2.3  Results 
2.3.1  Biopanning and Phage Display 
Identification of a peptide with strong binding affinity to BACE1 was 
determined using the phage display and biopanning techniques.  The biologically 
active BACE1 target was bound to a microtitre plate well and the peptide candidates’ 
expressed on a phage capsid were provided ample access to the large protein.  Using 
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the natural affinity, the binding phage remained while the unbound washed away.  
These high affinity binders were tested over five rounds of biopanning to refine the 
pool down to the best candidates.    
 
Phage titre was determined by dilution of the amplified eluate with infection 
of the ER2738 host strain.  The pooled phage were amplified and used in the 
subsequent round to test candidate binding affinity.  The biopanning was extended 
from three rounds to five as a stringency requirement to minimise the number of 
BACE1 binders as the candidates were being obstructed with an increase in wash 
buffer concentration.  This method was successful as the phage DNA sequencing 
revealed only one candidate across all 12 samples.  The increase in stringency 
represented by the Tween-20 concentration in the wash buffer did not influence the 
titre produced.  Across the five rounds of biopanning, the titre increased from 7x109 
plaque forming units per millilitre (pfu/ml) in the first round to 3x1011 by the fourth.  
The phage titre was not required for the final round as each plaque was amplified 
individually as opposed to the pool used previously. 
 
The phage titre of the fourth round of biopanning mimicked the initial input 
of phage.  The 1011 phage from the library, added to the experimental well for round 
one, was a 100-fold representation of the 109 varying sequences. If the phage titre 
did not increase back to the 1011 then the candidates would have been rejected due 
to non-specific binding.  To maintain this consistently across all biopanning rounds, 
the phage virion pool was calculated from the pfu/ml of previous round of phage 
display and adjusted accordingly. 
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The eluate from the fifth round of biopanning was plated with the unamplified 
eluate to pick the individual colonies for sequencing.  The phage eluate was serially 
diluted to 10-4 and plates the same as previous rounds.  Of the 53 plaques produced, 
12 were picked and amplified individually.  None of the plated phage dilutions 
contained any contamination with white, wild-type plaques denoting host 
transduction was successful and sterile techniques were maintained.   The 
transduction was confirmed with all 12 sequences containing the additional 
sequence representing the M13KE cloning vector of the phage.   
 
2.3.2  Phage DNA Sequencing 
All isolated DNA samples were quantified using an ND-1000 NanoDrop 
spectrophotometer, and analysed for purity.  The samples were analysed by 
comparing the 260/280nm wavelengths producing results between the expected 1.7 
and 2.1 levels.  The near pure DNA samples were complemented by the 
chromatograms which produced clearly identifiable nucleotide peaks.  The inserts 
were identified by the KpnI/Acc65 and EagI restriction enzyme sites where the DNA 
insert was ligated, then the triple glycine leader sequence added as a part of all 12-
residue peptides of the pIII surface proteins.  Of the 12 plaques that were picked from 
the fifth round of biopanning, six of these contained an insert and six did not (Figures 
2.1 and 2.2). Of the six chromatograms that showed an insert was present, the 
sequence was the same (Table 2.1).  The sequence was dissected using a BLAST 
search via the National Centre for Biotechnology Information (NCBI) database for 
possible crossover with other proteins, peptides and inhibitors. 
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Plaque 
Number DNA Sequence 
1 No insert 
2 TCT ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻ ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻGGT GGA GGT 
3 TCT ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻ ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻGGT GGA GGT 
4 TCT ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻ ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻGGT GGA GGT 
5 TCT ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻ ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻGGT GGA GGT 
6 No insert 
7 No insert 
8 No insert 
9 No insert 
10 No insert 
11 TCT ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻ ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻGGT GGA GGT 
12 TCT ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻ ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻGGT GGA GGT 
Table 2.1. Phage DNA sequences characterised from the fifth biopanning round.  
DNA was isolated from the round five unamplified eluate. Identification of the 
variable insert is determined by locating the three successive glycine residues that 
flank as a leader sequence, which is present across all fused peptides.  These inserts 
were sequenced to characterise the variable peptide that was expressed on the 
capsid and bound to the target. Twelve blue plaques were selected with six 
containing sequences that were identical.  The remaining six plaques did not contain 
an insert.   
x The sequence is blocked due to intellectual property restrictions.  
 
 
 
Figure 2.1.  M13 phage DNA chromatogram with insert sequence.  The phage DNA 
isolated from the phage display and biopanning round five was sequenced to 
determine the peptide that was binding to the target BACE1. The insert is pinpointed 
by a triple glycine leader sequence, which is included universally.  The 12-mer peptide 
is translated from the adjoining nucleotides from peaks of the chromatogram.  The 
target sequence is highlighted in blue. 
x The sequence is blocked due to intellectual property restrictions.
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Figure 2.2.  M13 phage DNA chromatogram without insert sequence.  The phage 
template was isolated from a single plaque grown from the biopanning round five.  
The KpnI/Acc65 and EagI restriction sites remain when the insert was to be ligated 
but no triple glycine leader is present.  The insert sequence location is highlighted in 
blue. 
 
 
2.3.3  Direct ELISA Determining Binding of Biopanning Candidate to BACE1 
The phage peptide identified from the sequencing was translated into a 
synthetic peptide reproduction and tested with a direct binding assay.  The assay 
followed the same technique to immobilise the BACE1 target as the phage display; 
recreating the same conditions encountered during the peptide isolation steps.  The 
synthetic peptide was biotinylated at the C-terminus allowing a streptavidin/HRP 
conjugate to bind, providing a visual representation of the target binding produced 
with the OPD substrate.  The same stringency was used in both the assay and 
biopanning round 5 to confirm the binding affinity between the peptide and target. 
 
The colorimetric response as a result of peptide binding to the BACE1 target 
increased significantly when compared with the no peptide control.  As the peptide 
concentration increased so did the response to binding.  In comparison to the 
negative control, which did not contain any peptide, the 1nM test sample showed a 
significant increase in the amount of response generated (Figure 2.3).  The peptide 
concentration was increased 10-fold, to 10nM and 100nM, which generated more 
binding with the BACE1 target.  All experimental variables from 1nM to 100nM 
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concentration, showed strong binding was occurring between the peptide and the 
immobilised BACE1 target. 
 
Figure 2.3. Direct binding assay between the BACE1 enzyme and peptide.  The 
immobilised BACE1 target was introduced to 1nM, 10nM and 100nM solutions 
containing the peptide generated from the phage display.  The negative control did 
not contain any peptide which did not generate any binding.  Total binding between 
the target and peptide is represented by a colorimetric response.  All values are 
reported as means + SEM (n=3). Statistical significance was determined by using the 
Student’s t-test (p < 0.05). 
*Denotes a significant difference between the 1nM and the negative control tests.  
**Denotes a significant difference between the 1nM and 10nM tests.  
***Denotes a significant difference between the 10nM and 100nM tests. 
 
2.3.4  Specificity Test of the Candidate to BACE1 
The BACE1 DNA sequence and translated protein show substantial homology 
with BACE2, Renin and Cathepsin D.  Using the same direct binding assay as above, a 
target specificity confirmation experiment was performed on BACE2, Renin and 
Cathepsin D.  All targets were immobilised on corresponding wells of a microtitre 
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plate and the test parameters determined by the results from the direct binding 
assay.    
 
The binding of the peptide to BACE1 maintained a similar level to that of the 
direct binding assay as previously shown.  The well containing immobilised Renin did 
not show any significant response as a result of binding.  However, there was a small 
colorimetric response to both Cathepsin D and BACE2.  The peptide gave a significant 
binding response to these two proteins when compared to the negative control, but 
were far less than to that of BACE1 (Figure 2.4).   The binding levels were much lower 
for these enzymes than for BACE2 and were investigated further for confirmation. 
 
 In confirmation of BACE1 specific binding, BACE2 and Cathepsin D were pre-
treated with the peptide prior to the reaction, allowing a possible reaction to occur.  
The pre-treatment was then transferred to wells containing immobilised BACE1 and 
the direct ELISA continued as previously described.  The test was designed to 
determine that the peptide would selectively bind to BACE1 over that of the other 
homologs.  The peptide was also pre-treated in solution with Renin, Cathepsin D and 
BACE2 individually and then as a combination for the one experiment.  The pre-
treatments were transferred to the test wells containing immobilised BACE1 and 
incubated in the same conditions as the direct binding assay for continuity.   
 
Pretreating the peptide with Cathepsin D had a minimal effect on subsequent 
binding to BACE1.  This was the same for Renin and BACE2 with the responses 
showing no significant difference to the BACE1 control.  The binding occurring 
54 
 
between immobilised BACE1 target and peptide was maintained across all 
experimental wells (Figure 2.5).  With all homologs added as a combination 
experiment, there was no significant difference created by the pre-treatment, and 
the binding between the peptide and BACE1 remained consistent.  Any of the binding 
to the homologs was minimised once the peptide came into contact with BACE1. 
 
 
Figure 2.4.  BACE1 specificity test in comparison with homologs.  BACE1, BACE2, 
Cathepsin D and Renin were immobilised onto a microtitre plate and introduced to a 
100nM solution containing the peptide.  The binding occurring between the target 
and peptide is represented by an increase in colorimetric response.  All values are 
reported as means + SEM (n=3). 
Statistical significance was determined by using the Student’s t-test (p < 0.05). 
*Denotes statistical significance between the 1nM test and the negative control. 
**Denotes statistical significance between BACE2 and the negative control. 
***Denotes statistical significance between the Cathepsin D and the negative 
control. 
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Figure 2.5.  BACE1 specificity test with competitive pre-treatment with homologs.  
BACE1 was immobilised onto microtitre plate wells and BACE2, Cathepsin D and 
Renin were used for peptide pre-treatment.  The pre-ƚƌĞĂƚŵĞŶƚƐĐŽŶƚĂŝŶĞĚϭʅDŽĨ
target and 100nM of the peptide inhibitor.  The combined sample contained the 
BACE2, Cathepsin D and Renin targets in the one pre-treatment.  The pre-treatments 
were then transferred to the wells containing immobilised BACE1.  The increase in 
binding to the immobilised BACE1 is represented by a colorimetric response.  All 
values are reported as means + SEM (n=3).  No significant difference was observed 
using the Student’s t-test (p < 0.05). 
 
2.3.5  BACE1 Activity Assay with Direct Binding Method 
The active BACE1 maintains an ability to cleave the APP substrate in vitro.  
Testing the BACE1 specific peptide for inhibitory properties in vitro, was determined 
by simulating the in vivo pathway.  An APP fragment substrate represented the full 
length protein and when cleaved by the recombinant BACE1, releases the 7-
methoxycoumarin fluorophore.  The peptide was immobilised on nitrocellulose 
before being introduced to the experimental solution containing BACE1 and APP to 
determine preferential binding.  The immobilised peptide was removed, along with 
any bound BACE1, before the fluorometric analysis was performed. 
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The addition of a BACE1 specific peptide to the reaction reduced the amount 
substrate cleavage maintaining the quenched fluorophore.  The 1nM concentration 
sample of immobilised peptide did not significantly reduce to the amount of 
substrate cleavage but a 10-fold increase was more effective.  The increase from 1nM 
to 10nM showed a significant reduction (23%) in the amount of substrate being 
cleaved.  The response was reduced further to 44% with a 10-fold increase in peptide 
concentration to 100nM (Figure 2.6).  The increase in peptide concentration was 
decreasing the amount of fluorescence observed as a response to the cleavage of the 
substrate.  
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Figure 2.6.  Percentage reduction of BACE1 activity with enzyme specific peptide 
treatment.  BACE1 activity assay after removal of immobilised peptide nitrocellulose.  
The effect on APP by BACE1, after the addition of the peptide in concentrations of 
1nM, 10nM and 100nM respectively, is represented by the reduction in substrate 
cleavage.  Percentage of APP cleavage reduction signifies the degree of BACE1 
cleavage of the APP substrate after incubation with the immobilised peptide. This 
data was compared with the negative control.  This data represents the percentage 
reduction of BACE1 activity + SD (n=2).  Percentage inhibition was calculated with 
comparison to the negative control, values are expressed above the respective 
treatment. 
*Denotes a significant difference between the 10nM and negative control. 
**Denotes a significant difference between the 100nM and negative control. 
 
2.4  Discussion 
2.4.1  BACE1 Specific Biopanning and Phage Display 
The identification of a peptide with natural binding affinity for BACE1 was 
sourced by using the phage display and biopanning techniques.  By using the phage 
display technique, 1.1x109 different peptide sequences were tested within the one 
reaction and allowed to selectively bind according to a natural affinity.  By retaining 
the amplified eluate and using the biopanning technique, the isolated BACE1 binders 
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were re-tested to reduce the number of candidates.  
 
The amplified eluates maintained an increasing titre as the biopanning rounds 
became more stringent.  The increased stringency did not affect the pooled phage of 
strong binders as the titre increased, represented by the number of blue plaques.  
The blue plaques were selected for sequencing in round five as transduction is 
represented by the metabolism of X-gal.  The transduction of phage DNA to the 
ER2738 E. coli host strain transferred the LacZ gene.  The metabolism of X-gal, 
included in the LB agar plates, was represented by the prodƵĐƚŝŽŶ ŽĨ ƚŚĞ ɴ-
galactosidase enzyme which caused plaques to develop a blue colour.  The wild-type 
phage do not carry this gene and do not metabolise the X-gal.  The fifth round eluate 
did not contain any white plaques to select a wild-type. 
 
The 12 blue plaques, from the biopanning round 5 unamplified eluate, 
produced six sequences containing an insert and six without.  The six without insert 
maintained the M13KE cloning vector but there was no insert present on the 
chromatogram, along with the triple glycine leader.  The possibility of picking the 
wild-type phage was rejected as the plaques picked were blue in colour and the up 
and downstream sequences were consistent with the M13KE cloning vector.  The 
insert sequence was rejected at some stage during the amplification and purification 
steps.  The purification steps could have created stress on the insert causing it to be 
released and the strand ligated back to the original position.  The six plaques that 
maintained the insert contained the same sequence along with the triple glycine 
leader. With the sequence motif apparent, there was no need for conformational 
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phage binding and the synthetic peptide was produced to test for direct binding and 
inhibition of the BACE1 target.  
  
2.4.2  Direct Binding Assay 
Binding between the peptide and BACE1 target was tested by direct assay.  
BACE1 was immobilised on the microtitre well using the same protocol as in the 
phage display to maintain consistency.  The peptide was biotinylated and introduced 
in concentrations of 1nM, 10nM and 100nM.  The peptide was biotinylated to bind 
the streptavidin/HRP conjugate to determine binding by the OPD substrate.  The 
increase in peptide binding was represented by the increase in colorimetric response.  
The binding to BACE1 was confirmed with a significant increase in the response which 
correlated with the addition of extra peptide.  
 
The same stringency of wash buffer was used in the assay as the phage 
display, which was increased to 0.5% Tween-20 in the final round.  The higher 
stringency was used to test the binding affinity of the peptide because it was 
synthetically produced and no longer bound to the phage.  The peptide binding under 
these conditions confirms the binding characteristics shown in the phage display.    
 
2.4.3  Specificity Test 
The cross reactivity of a BACE1 inhibitor to the closely related BACE2, Renin 
and Cathepsin D can cause potentially harmful adverse reactions as part of a 
treatment.  The significant binding and inhibition of Renin could alter cardiac output 
and systemic blood flow while alteration of Cathepsin D activity can influence cell 
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signalling and apoptosis.183,184 The specificity assay was designed to test this cross 
reactivity by performing a direct assay with BACE1 substituted for one of the 
homologs.  The peptide did not show any affinity to Renin but Cathepsin D and BACE2 
produced a significant increase in the amount of binding when compared with the 
negative control.  However, when the peptide was pre-incubated in solution with the 
individual homologs then added to a plate well immobilised BACE1, the peptide no 
longer exhibited the cross reactive effects.  The binding to BACE1 was consistent 
across all experimental groups.  The peptide was also pre-incubated with all the 
homologs at once, which did not create any cross reactivity as there was no significant 
difference when compared with the no pre-treatment, BACE1 only control.   
 
2.4.4  BACE1 Activity Assay Utilising Direct Binding of the Peptide  
The peptide showed a binding affinity for BACE1 specifically, even in the 
presence of similar enzymes, but required the ability to inhibit the cleavage of APP 
which reůĞĂƐĞƐ ƚŚĞ ƉůĂƋƵĞ ĨŽƌŵŝŶŐ ɴ ƐƉĞĐŝĞƐ͘  dŚĞ ƉĞƉƚŝĚĞǁĂƐ ŝŵŵŽďŝůŝƐĞĚ ŽŶ
nitrocellulose before the BACE1 activity reaction could take place to prevent 
unwanted background responses.  The BACE1, substrate and nitrocellulose bound 
peptide were incubated together to determine the amount of cleavage which was 
represented as a fluorometric response.  The APP fragment, maintained between the 
7-methoxycoumarin-4-acetyl fluorophore and the 2,4-dinitrophenyl quencher, was 
cleaved by the active BACE1, which triggered the fluorometric response.  The 
negative control did not contain any BACE1 specific peptide and produced the highest 
amount of substrate cleavage.  The amount of inhibition increased significantly with 
the 10-fold addition of peptide.  The peptide was able to bind to BACE1 and, as a 
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consequence, APP cleavage was reduced, highlighting the usefulness of the peptide 
inhibitor as a potential therapeutic for further study.  
 
2.5  Conclusion 
Using the phage display and biopanning techniques, a peptide was 
successfully identified, which bound to the BACE1 target.  The phage DNA was 
sequenced to determine the peptide that was expressed on capsid.  The peptide was 
synthetically produced and tested successfully for a binding affinity to BACE1.  A 
potential cross reactivity with the closely related Cathepsin D and BACE2 was 
thwarted by a competition assay with BACE1.  The pre-treatment with Cathepsin D 
and BACE2 did not reduce the amount of binding to BACE1 when compared with the 
control. The BACE1 specific peptide was able to indirectly reduce the enzymatic 
cleavage of APP resulting in a decrease in substrate production.
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Chapter 3 
 
/ĚĞŶƚŝĨŝĐĂƚŝŽŶ ŽĨ Ă WĞƉƚŝĚĞ ŝŶĚŝŶŐ ĂŶĚŝĚĂƚĞ ĨŽƌ ɴ ĂŶĚ
Investigation into the Inhibition Created by the Upstream 
BACE1 Inhibitor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
Aims 
The complex variety in amyloid plaque structures, caused as a result of 
ĐŽŵƉůĞǆ ƚŚƌĞĞ ĚŝŵĞŶƐŝŽŶĂů ĂŐŐƌĞŐĂƚŝŽŶ ŽĨ ɴ subunits, can be influenced by 
preventing oligomerisation.  By inhibiting BACE1 activity͕ƚŚĞůĞǀĞůƐŽĨɴƉƌŽĚƵĐƚŝŽŶ
could be reduced, thus its oligomerisation and deposition as plaque could be 
hindered.  The aim of this chapter is to define BACE1 inhibitor effectiveness by 
ĚĞƚĞƌŵŝŶŝŶŐɴƉƌŽĚƵĐƚŝŽŶŝŶŚƵŵĂŶŶĞƵƌŽŶĂůĐĞůůƐ͘ǇƵƐŝŶŐƚŚĞƉŚĂŐĞĚŝƐƉůĂǇĂŶĚ
biopanning techniques, the aim of this chapter is to identify a peptide binder 
ƵŶŝǀĞƌƐĂůĨŽƌďŽƚŚɴϰϬĂŶĚɴϰϮƚŚĂƚĐĂŶďĞƵƐĞĚĂƐĂĐĂƉƚƵƌĞŵŽůĞĐƵůĞĨŽƌ an ELISA.  
Treatment of SY5Y cells with H2O2 to induce oxidative stress will increase the 
ƉƌŽĚƵĐƚŝŽŶŽĨɴϰϬĂŶĚɴϰϮ͘dŚĞĂŝŵŝƐƚŽŝŶĚƵĐĞŽǆŝĚĂƚŝǀĞƐƚƌĞƐƐŽŶ^zϱzĐĞůůƐĂŶĚ
ƋƵĂŶƚŝĨǇ ďŽƚŚ ɴϰϬ ĂŶĚ ɴϰϮ ƉƌŽĚƵĐĞĚ͘ /ŶƚƌŽĚƵĐƚŝŽŶ ŽĨ ϭ ŝŶŚŝďŝƚŽƌ ƚŽ ƚŚĞ
neuronal cell culture treatment will test for effectiveness in an environment like that 
of AD.   
 
Methods 
  dŚĞƌĞĐŽŵďŝŶĂŶƚɴϰϬĂŶĚɴϰϮǁĂƐŝŵŵŽďŝůŝƐĞĚŽŶƚŽǁĞůůƐŽĨĂŵŝĐƌŽƚŝƚƌĞ
plate for the phage display and biopanning.  The targets were panned to 3 rounds to 
obtain a variety of binders.  The phage DNA was sequenced and the candidates tested 
ĨŽƌƚĂƌŐĞƚďŝŶĚŝŶŐǁŝƚŚĂDϭϯ>/^͘ƐĂŶĂůƚĞƌŶĂƚŝǀĞ͕ƌĞĐŽŵďŝŶĂŶƚɴϰϬĂŶĚɴϰϮ
were biotinylated and bound to streptavidin coated magnetic beads for the 
preparation of solution phase panning. The targets were incubated with the Ph.D.-
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C7C phage library and the binders isolated by magnetic capture of the beads.  The 
ƚĂƌŐĞƚďŝŶĚĞƌƐǁĞƌĞƐĞƋƵĞŶĐĞĚĂŶĚƚĞƐƚĞĚŝŶĚŝǀŝĚƵĂůůǇǁŝƚŚĂŶDϭϯ>/^͘ɴϰϬĂŶĚ
ɴϰϮ>/^ƐǁĞƌĞƐet up to test for BACE1 inhibitor effectiveness in SY5Y cell culture.  
The cells were treated with BACE1 inhibitor for 24 hours then the lysates recovered 
for the use in the ELISA.  The cells were also treated with H2O2, to increase the amount 
ŽĨɴ͕ĂŶĚĐounter treated with the BACE1 inhibitor. The treatment effect on the SY5Y 
cells was determined by a viability test.   
 
Results 
 dŚĞƉŚĂŐĞĚŝƐƉůĂǇ͕ǁŝƚŚƚŚĞɴϰϮƚĂƌŐĞƚ͕ƉƌŽĚƵĐĞĚĂŶŝŶĐƌĞĂƐŝŶŐƚŝƚƌĞĂĐƌŽƐƐ
the three rounds and the DNA was sequenced to obtain the construction of the 
ƉĞƉƚŝĚĞ ŝŶƐĞƌƚ͘  dŚĞ ɴϰϬ ƚĂƌŐĞƚ ĚŝĚ ŶŽƚ ƉƌŽĚƵĐĞ ĂŶ ŝŶĐƌĞĂƐŝŶŐ ƚŝƚƌĞ ĂŶĚ ǁĂƐ
ĚŝƐĐŽŶƚŝŶƵĞĚ͘  dŚĞ ƉůĂƋƵĞƐ ŝƐŽůĂƚĞĚ ĨƌŽŵ ƚŚĞ ɴϰϮ ƌŽƵŶĚ ƚŚƌĞĞ ďŝŽƉĂŶŶŝŶŐǁĞƌĞ
ƐĞƋƵĞŶĐĞĚƉƌŽĚƵĐŝŶŐĂƵŶŝǀĞƌƐĂůɴĐĂŶĚŝĚĂƚĞ͘dŚĞĐĂŶĚŝĚĂƚĞǁĂƐƚĞƐƚĞĚĨŽƌ binding 
ƚŽďŽƚŚɴƚĂƌŐĞƚƐǁŝƚŚĂŶDϭϯƉŚĂŐĞ>/^ďƵƚĞǆŚŝďŝƚĞĚďŝŶĚŝŶŐƚŽƚŚĞĐŽŶƚƌŽůǁĞůů
that contained only blocking buffer.  As an alternative, the targets were immobilised 
ƚŽ ŵĂŐŶĞƚŝĐ ďĞĂĚƐ ĂŶĚ ƉĂŶŶĞĚ ŝŶ ƐŽůƵƚŝŽŶ͘  ŽƚŚ ƚŚĞ ɴϰϬ ĂŶĚ ɴϰϮ ĞůƵĂƚĞƐ
increased titre across the three rounds.  The plaques were sequenced and produced 
three different candidates each.  The phage corresponding to the targets were tested 
for cross reactivity using the M13 phage ELISA.  Given the consistent results to both 
targets, all candidates were tested with the negative control which contained only 
blocking buffer.  All samples produced similar binding responses to both the targets 
and the negative controls.  The candidates were also tested by using an alternate 
M13 ELISA protocol which contained a different blocking buffer but similar binding 
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responses occurred.  The SY5Y cells, treated with BACE1 inhibitor, maintained 
viability across all treatment groups.  SY5Y cells were also treated with H2O2 and 
BACE1 inhibitor and also maintained viability across all the treatments.  The treated 
ĐĞůůƐǁĞƌĞ ůǇƐĞĚĂŶĚƚĞƐƚĞĚ ĨŽƌɴϰϬĂŶĚɴϰϮƉƌŽĚƵĐƚŝŽŶ͘  dŚĞ ĐĞůůƐǁŝƚŚϭ
inhibitor exhibited a reduction in the amount colorimetric response which 
ƌĞƉƌĞƐĞŶƚĞĚɴϰϬĂŶĚɴϰϮůŽĂĚŝŶŐ͘ůƐo, the SY5Y cells with induced with oxidative 
ƐƚƌĞƐƐĞǆŚŝďŝƚĞĚĂƌĞĚƵĐƚŝŽŶŝŶƚŚĞĂŵŽƵŶƚŽĨɴϰϬĂŶĚɴϰϮƉƌŽĚƵĐĞĚǁŚĞŶƚƌĞĂƚĞĚ
with the BACE1 inhibitor. 
 
Conclusions 
The phage display and biopanning techniques were performed to identify 
ƉĞƉƚŝĚĞďŝŶĚĞƌƐĨŽƌɴϰϬĂŶĚɴϰϮ͘dŚĞɴϰϮĞůƵĂƚĞƐƉƌŽĚƵĐĞĚĂǀŝĂďůĞ͕ŝŶĐƌĞĂƐŝŶŐ
ƚŝƚƌĞĂĐƌŽƐƐƚŚĞĨŝƌƐƚƚǁŽƌŽƵŶĚƐĂŶĚƐŽƚŚĞEǁĂƐƐĞƋƵĞŶĐĞĚ͘dŚĞɴϰϬĞůƵĂƚĞĚŝĚ
not increased and ŶŽǀŝĂďůĞĐĂŶĚŝĚĂƚĞǁĂƐŝƐŽůĂƚĞĚ͘dŚĞƉŚĂŐĞƐƉĞĐŝĨŝĐĨŽƌɴϰϮǁĞƌĞ
sequenced and produced one single, universal candidate.  This candidate was tested 
for binding confirmation and cross reactivity in an M13 ELISA but the negative 
ĐŽŶƚƌŽů͕ǁŝƚŚŽƵƚɴϰϮ͕Ɖƌoduced a response that was not significantly different to the 
wells immobilised with target.  This binding was considered nonspecific and was 
discontinued.  The protocol was changed to a solution phase bead capture approach 
ǁŚŝĐŚŵĂĚĞƚŚĞɴϰϬĂŶĚɴϰϮƚĂƌgets more accessible to the displayed peptides on 
the phage.  Both targets generated three varied sequences each and cross reacted 
well but again, the candidates all bound, non-specifically, to the negative control that 
ĚŝĚŶŽƚĐŽŶƚĂŝŶĂƚĂƌŐĞƚ͘ɴϰϬĂŶĚɴϰϮ>/^ƐŬŝƚƐǁĞƌĞƚŚĞŶƵƐĞĚƚŽƚĞƐƚĨŽƌɴ
ůŽĂĚŝŶŐĂƐŶŽĐĂƉƚƵƌĞƉĞƉƚŝĚĞǁĂƐŐĞŶĞƌĂƚĞĚĨƌŽŵƚŚĞďŝŽƉĂŶŶŝŶŐ͘dŚĞ^zϱzĐĞůůƐɴ
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load was reduced as a result of BACE1 inhibition created by the peptide isolated in 
Chapter 2. H2O2 was used to stimulate oxidated stress on the SY5Y cells which lead to 
ƚŚĞŝŶĐƌĞĂƐĞŝŶɴůŽĂĚŝŶŐ͘dŚĞϭŝŶŚŝďŝƚŽƌǁĂƐƐƵĐĐĞƐƐĨƵůůǇĂďůĞƚŽƌĞĚƵĐĞɴ
load created by the oxidative stress.  
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3.1  Introduction 
ϯ͘ϭ͘ϭdŽǆŝĐŝƚǇƌĞĂƚĞĚďǇŝĨĨĞƌŝŶŐɴŐŐƌĞŐĂƚĞƐ 
Alzheimer’s disease is characterised by the deposition of amyloid plaques 
ŐĞŶĞƌĂƚĞĚĨƌŽŵƚŚĞĂŐŐƌĞŐĂƚŝŽŶŽĨɴĨƌĂŐŵĞŶƚƐ͘11  The BACE1 enzyme cleaves APP, 
ƌĞůĞĂƐŝŶŐƚŚĞɴĨƌĂŐŵĞŶƚƐ ŝŶƚŽďŽƚŚƚŚĞŝŶƚƌĂ- and extracellular spaces.  Primarily 
ƚŚĞɴŵŽŶŽŵĞƌƐĨŽƌŵĚŝŵĞƌƐ͕ƚƌŝŵĞƌƐĂŶĚŽůŝŐŽŵĞƌƐďƵƚƚŚĞŶĨŽƌŵĂŶƵŶŬŶŽǁŶ
amount of three dimensional structures.  The soluble oligomers can then form more 
complex structures of protofibrils, spherical structures of 2.7-ϰ͘ϮŶŵ ĚŝĂŵĞƚĞƌ͕ ɴ
diffusible ligands (ADDLs) and micelles.56,185,186 dŚĞ ƐŽůƵďůĞ ɴ͕ ĂƐ ŽůŝŐŽŵĞƌŝĐ
structures, cause the toxicity associated with AD, as opposed to the more complex 
fibrils.  AD pathophysiology has been identified as the correlation between disease 
severity and monomer number not necessarily plaque deposition as originally 
hypothesised.187,188   
 
Oligomers become amorphous aggregates and do not form any one specific 
structure during aggregation.  Likewise, plaques do not necessarily keep increasing 
over the course of the disease like a tumour would.189 The oligomers continue to be 
produced and plaques increase in number but no uncontrollable development of one 
individual growth occurs.189  The cause of this migration is not completely understood 
ďĞĐĂƵƐĞŽĨƚŚĞǀĂƌŝŽƵƐĨŽƌŵƐŝŶǁŚŝĐŚɴƵŶŝƚƐĂŐŐƌĞŐĂƚĞ͘ 
 
Amyloid plaques migrate as oligomers to localised regions according to pre-
existing areas containing plaques then proliferate further.190 All cases of AD do not 
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follow a consistent plaque migration pattern, hence why it is important to nullify 
them as monomers, dimers and trimers before they develop into a less soluble 
structure.189 Murine modelling showed that plaque progression develops over time 
by building up a stock of these oligomers before the debilitating symptoms become 
more apparent.191 The more complex forms of aggregated ɴmake AD difficult to 
prevent because the potential treatment cannot focus on just one plaque type, it 
needs to be multifaceted and adaptive.  
 
dŚĞɴϰϬĂŶĚɴϰϮĨƌĂŐŵĞŶƚƐ͕ƉƌŽĚƵĐĞĚĂƚĞĂƌůǇƐƚĂŐĞƐŽĨƚŚĞĚŝƐĞĂƐĞ͕ĐĂŶ
be more accessible to inhibitor binding as monomers, dimers and trimers.  The 
ĨŽƌŵĂƚŝŽŶŽĨƉƌŽƚŽĨŝďƌŝůƐ͕ƉůĂƋƵĞƐĂŶĚ>ƐƌĞƐƚƌŝĐƚĂĐĐĞƐƐƚŽɴŵŽŶŽŵĞƌƐ͕ǁŚŝĐŚ
limits the time required for them to be metabolised.  Oligomers can be exposed 
before the formation of these more complex structures, creating a window of 
opportunity for an inhibitor to bind and promote excretion.   
 
3.1.2  Oxidative Stress and AɴWƌŽĚƵĐƚŝŽŶ 
There is a strong correlation between reactive oxygen species (ROS), like H2O2, 
ĂŶĚɴƚŽǆŝĐŝƚǇ͘192 The brain is more vulnerable to ROS than other organs as it has a 
high rate of oxygen consumption with a requirement for unsaturated fatty acids while 
producing only a small amount of antioxidant enzymes for catabolism.193-195 ɴ
ƐƉĞĐŝĞƐ͕ ŶĂŵĞůǇ ɴϰϮ͕ ĐĂŶ ƉƌŽĚƵĐĞ ŵŽƌĞ ZK^ ĂƐ ǁĂƐ ĚĞŵŽŶƐƚƌĂƚĞĚ ǁŝƚŚ ƚhe 
activation of NADPH oxidase in microglial cells of a murine model.196,197 The oxidative 
ƐƚƌĞƐƐ ĐĂŶĂůƐŽ ƚƌŝŐŐĞƌƉƌŽůŝĨĞƌĂƚŝŽŶŽĨɴǁŚŝĐŚ ĐĂŶďĞ ƌĞƉůŝĐĂƚĞĚ in vitro using a 
neuronal cell model.198-200 dŚĞ ƉƌŽĚƵĐƚŝŽŶ ŽĨ ɴŵŽŶŽŵĞƌƐ ĚƵĞ ƚŽ ZK^ ĂŶĚ ǀŝĐĞ
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versa, is a continual feedback system detrimental to the neuronal cells.  
 
The SY5Y neuroblastoma cell line is an in vitro ŵŽĚĞůĨŽƌĂƐɴŵŽŶŽŵĞƌƐ
are naturally produced from the cleavage of APP by BACE1.201-203 With a treatment 
of H2O2͕ƚŚĞůĞǀĞůƐŽĨɴĐĂŶďĞŝŶĐƌĞĂƐĞĚĨŽƌĂŶĂůǇƐŝƐŚŽǁĞǀĞƌ͕ĐĞůůǀŝĂďŝůŝƚǇĐĂŶďĞ
ĐŽŵƉƌŽŵŝƐĞĚ ĂƐ Ă ĐŽŶƐĞƋƵĞŶĐĞ͘  dŚĞ ƌĂŝƐĞĚ ůĞǀĞůƐ ŽĨ ɴ͕ ƉƌŽĚƵĐĞĚ ďǇ ƚŚĞ ,2O2 
treatment, could be reduced by administering a BACE1 inhibitor to the cells 
promoting viability and reducing the negative effects of ROS.200,201 This chapter 
primarily aims to define BACE1 inhibitor effectiveness by quantifying the amount of 
ɴƉƌŽĚƵĐĞĚǁŝƚŚƚŚĞŝŶĚƵĐĞĚŽǆŝĚĂƚŝǀĞƐƚƌĞƐƐ͘ǇĚĞǀĞůŽƉŝŶŐĂŶɴƐƉĞĐŝĨŝĐ>/^͕
inhibitor effectiveness can be measured with treatment of whole human cells in vitro.  
Using the phage display and biopanning techniques, a peptide binder universal to 
ďŽƚŚɴϰϬĂŶĚɴϰϮǁŽƵůĚďĞƵƐĞĚĂƐĂĐĂƉƚƵƌĞŵŽůĞĐƵůĞĨŽƌƚŚĞ>/^ďƵƚĐŽƵůĚ
also be developed to intercept monomers before aggregation into more complex 
structures.   
 
3.2 Materials and Methods 
3.2.1  Direct Phase Panning for ɴϰϬĂŶĚɴϰϮBinding Candidates   
/ŵŵŽďŝůŝǌĂƚŝŽŶŽĨƚŚĞɴϰϬĂŶĚɴϰϮdĂƌŐĞƚ 
ɴϰϬ ĂŶĚ ɴϰϮ ;^ŝŐŵĂ-Aldrich, USA) were diluted to 100nM in a 0.1M 
NaHCO3 (pH 8.6) immobilisation buffer and added to individual wells of a microtitre 
plate.  The plate was incubated overnight at 4°C in a humidified container with gentle 
rocking.  170μl of blocking buffer was added to empty wells and incubated at 4°C for 
60 minutes.  The solution was removed and wells washed six times with 0.1% TBS-T.  
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Phage Display of Constrained 7-mer Library 
A 100-fold representation of the Ph.D.-C7C phage display peptide library (New 
England Biolabs, USA) was diluted in 0.1% TBS-T and added to the corresponding 
wells.  The plate was incubated for 60 minutes at room temperature with gentle 
rocking.  The solution was discarded and the wells washed 10 times with 0.1% TBS-T.  
The bound phage were removed with a glycine buffer and neutralised with 1M Tris-
HCl (pH 9.1), which formed the Unamplified Eluate. 
 
Amplification of Eluate 
10ml of LB was inoculated with a single ER2738 E. coli colony picked from a 
stock plate and incubated at 37°C to early-log phase (OD600 0.01-0.05).   1ml of the 
culture was transferred to corresponding 250ml conical flasks containing 20ml of LB 
and 100μl of unamplified phage then incubated with vigorous shaking at 37°C for 4.5 
hours.  The cultures were pelleted by centrifugation at 12,000xg for 10 minutes at 
4°C.  The supernatant was transferred to a new sterile tube and the centrifugation 
repeated.  The phage were precipitated with a 1/6 volume of 20% (m/v) PEG/NaCl, 
vortexed briefly and allowed to precipitate overnight at 4°C.  Phage were pelleted by 
centrifugation at 12,000xg for 15 minutes at 4°C.  The supernatant was discarded and 
the pellets re-suspended in 1ml TBS and transferred to a microcentrifuge tube.  The 
suspension was centrifuged at 17,000xg for 10 minutes. The supernatant was 
transferred to a new microcentrifuge tube along with 1/6 volume PEG/NaCl and 
allowed to precipitate on ice for 60 minutes. The phage pelleted at 17,000xg for 10 
minutes with the supernatant being discarded and the pellet re-suspended in 200μl 
TBS, which formed the Amplified Eluate. 
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Determination of Amplified Phage Titre 
In a 50ml centrifuge tube, 10ml of LB was inoculated with 10μl of the 
overnight ER2738 culture and incubated at 37°C with shaking to mid-log phase (OD600 
~0.5).   Unamplified phage were diluted to 10-4 in LB media and plated in 10-fold 
increments from 10-1 while amplified phage were diluted to 10-11 in LB media and 
plated in 10-fold increments from 10-8͘ϭϬʅůŽĨƚŚĞĚŝůƵƚŝŽŶƐǁĞƌĞƉƌĞ-incubated with 
ϮϬϬʅů ŽĨ ƚŚĞŵŝĚ-log phase E. coli host strain for 10 minutes.  Pour plates were 
constructed using 4ml of molten top agar mixed with the phage/E. coli suspension 
and added to the already prepared IPTG/X-gal plates.  Once set, the plates were 
incubated for 18 hours at 37°C and plaque forming units per millilitre (pfu/ml) 
calculated.  All biopanning preparations were maintained in the sterile environments 
of a Thermo Scientific KS18 Class II safety cabinet to minimise contamination. 
 
Biopanning 
 Biopanning second round steps are a continuation of the original phage 
display protocol but the phage library is substituted for the amplified phage from the 
previous round.  The cfu/ml of amplified eluate is used to maintain the input of 
~1x1010 phage virions into the subsequent rounds.  The Tween-20 concentration for 
the wash steps prior to the phage incubation was increased by increments of 0.1% 
(v/v) for every subsequent round. 
 
DNA Precipitation 
The third round of biopanning was not amplified and the unamplified eluates 
were titred as previous described.  Within an 18 hour incubation time, twelve plaques 
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were picked individually and transferred to individual 1ml ER2738 broth cultures 
grown to early-log phase (OD600 0.01-0.05), where they were incubated for 4.5 hours 
at 37°C with vigorous shaking.  The cultures were transferred to microcentrifuge 
tubes and pelleted by centrifugation at 14,000xg for 30 seconds. The supernatant was 
transferred to a fresh tube and re-ƐƉƵŶ͘ϱϬϬʅůŽĨƐƵƉĞƌŶĂƚĂŶƚǁĂƐƚƌĂŶƐĨĞƌƌĞĚƚŽĂ
ĨƌĞƐŚ ƚƵďĞ ĐŽŶƚĂŝŶŝŶŐ ϮϬϬʅů ŽĨ W'ͬEĂů and incubated for 20 minutes at room 
temperature.  The PEG precipitation was pelleted by centrifugation at 14,000xg for 
ϭϬŵŝŶƵƚĞƐĂƚϰΣ͘dŚĞƉĞůůĞƚǁĂƐƐƵƐƉĞŶĚĞĚŝŶϭϬϬʅůŽĨŝŽĚŝŶĞďƵĨĨĞƌĂŶĚϮϱϬʅůŽĨ
70% (v/v) ethanol was added to the tube and incubated for 15 minutes at room 
temperature. The precipitate was centrifuged at 14,000xg for 10 minutes at 4°C and 
ƚŚĞƐƵƉĞƌŶĂƚĂŶƚĚŝƐĐĂƌĚĞĚ͘dŚĞƌĞŵĂŝŶŝŶŐƉĞůůĞƚǁĂƐƐƵƐƉĞŶĚĞĚŝŶϯϬʅůŽĨdďƵĨĨĞƌ͘
The precipitated DNA concentration was quantified using a ND-1000 NanoDrop 
spectrophotometer (Thermo Fisher Scientific, USA). 
 
Amplification, Purification and Sequencing of Phage DNA 
The purified DNA samples were individually amplified using the BigDye® 
Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific, USA).  The kit was 
assembled for templates, adding 2μl of the terminator ready reaction mix, 3.5μl of 
the big dye sequencing buffer and 6.5μl of the primer along with 10ng of template 
and dH2KƚŽϮϬʅů͘dŚĞƚƵďĞƐǁĞƌĞĂĚĚĞĚƚŽĂŶD:ZĞƐĞĂƌĐŚ͕Wd-100 thermocycler 
(Bio-Rad, USA) and run for 25 cycles of 96°C for 10 seconds, 50°C for five seconds and 
60°C for four minutes.  The PCR products were transferred to microcentrifuge tubes 
and centrifuged for one minute at 2500xg then 2μl of 125mM EDTA, 2μl of 3M sodium 
acetate and 50μl of 100% ethanol, was added.  The tubes were vortexed briefly then 
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incubated at room temperature for 15 minutes.  The tubes were re-spun at 2500xg 
for 30 minutes.  The supernatant discarded and 70μl of 70% ethanol added to the 
pellet and centrifuged at 1650xg for 15 minutes. The bulk of the supernatant was 
removed with remaining left to evaporate in a class II safety cabinet, allowing the 
pellet to dry on the base of tube ready for sequencing.  The nucleic acids resulting 
from the sequencing were viewed electronically using Finch TV software (Geospiza 
Inc., USA). 
 
3.2.2  Solution Phase Panning by Affinity Bead Capture fŽƌɴϰϬĂŶĚɴϰϮŝŶĚŝŶŐ
Candidates 
ŝŽƚŝŶǇůĂƚŝŽŶŽĨɴdĂƌŐĞƚƐ 
A working solution of 0.1M (2-N-morpholino) ethanesulfonic acid (MES) (pH 
ϱ͘ϱͿǁĂƐ ƉƌŽĚƵĐĞĚ ƚŽĚŝůƵƚĞ Ăůů ŽƚŚĞƌ ĐŽŵƉŽŶĞŶƚƐ͘ hƐŝŶŐ ƚŚĞD^ ďƵĨĨĞƌ͕ Ă ϱϬʅů
ďŝŽƚŝŶǇůĂƚŝŽŶ ƐŽůƵƚŝŽŶ ǁĂƐ ŵĂĚĞ ǁŝƚŚ ϲϲϱŶD ɴϰϬ ĂŶĚ ɴϰϮ ;^ŝŐŵĂ-Aldrich, 
ƵƐƚƌĂůŝĂͿ͕ ϲ͘ϲϱʅD ϭ-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
;Ϳ ;dŚĞƌŵŽ ^ĐŝĞŶƚŝĨŝĐ͕ ƵƐƚƌĂůŝĂͿ ĂŶĚ ϲϲ͘ϱʅD ĂŵŝŶĞ-PEGn-biotin (Thermo 
Scientific, Australia).  The solution was mixed well and left to incubate for 2 hours 
ǁŝƚŚƐŚĂŬŝŶŐ͘ϭϮʅůŽĨƚŚĞƐŽůƵƚŝŽŶǁĂƐƚƌĂŶƐĨĞƌƌĞĚƚŽĂĞďƌĂDŝĐƌŽ^ƉŝŶĞƐĂůƚŝŶŐ
Column and passed through at 1000xg for 2 minutes to remove the non-reacted 
biotinylation reagent and EDC by products.  
 
Solution Phase Panning by Affinity Bead Capture 
ϱϬʅůŽĨŵĂŐŶĞƚŝĐďĞĂĚƐǁĞƌĞǁĂƐŚĞĚŝŶϭŵůŽĨϬ͘ϭйd^-T with a brief, gentle 
vortex.  The beads were pelleted by magnetic capture and the remaining solution 
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discarded.  The beads were suspended in blocking buffer and incubated for 60 
minutes at 4°C, mixing occasionally.  During the incubation, a 100-fold representation 
of the NEB Ph.D.C7C phage liďƌĂƌǇǁĂƐŵŝǆĞĚǁŝƚŚϭϬŶDŽĨďŝŽƚŝŶǇůĂƚĞĚɴϰϬĂŶĚ
ɴϰϮŝŶϮϬϬʅ>ŽĨd^-T and incubated for 20 minutes.  The beads were then washed 
four times with 0.1% TBS-T, pelleting by magnetic capture every time.  The 
phage/target solution was transferred to the beads and incubated for 15minutes at 
room temperature, mixing occasionally.  The bead captured biotinylated target with 
binding phage were washed 10 times with 0.1% TBS-T, pelleting by magnet for every 
wash.  The binding phage were eluted by adding 1ml of glycine buffer, 0.2M glycine-
HCl (pH 2.2) and 1mg/ml BSA, and incubating for 10 minutes.  The remaining beads 
were captured by magnet and the supernatant transferred to a fresh tube.  The basic 
glycine solution containing phage was immediately neutralised with ϭϱϬʅůdƌŝƐ-HCl 
(pH 9.1).  This is the Unamplified Eluate. 
 
The eluate was amplified the same as described above and titred.  For 
subsequent rounds, the Tween concentration in the wash buffer was raised by 0.1% 
to increase stringency, removing poor binding phage.  After three successful rounds, 
the phage DNA was removed and prepared for sequencing as described above. 
 
3.2.3  M13 Phage ELISA of Solution Phase Panning Binding Candidates 
The phage were amplified individually prior to sequencing and retained for 
the M13 binding ELISA.  After the sequencing, the unanimous binders were used to 
test for binding between the peptide and target.   
 
75 
 
Phage Amplification 
The individually isolated phage were amplified again prior to the ELISA.  A 
1:100 dilution of an overnight ER2738 culture containing tetracycline in 20ml of LB 
ŵĞĚŝĂǁĂƐ ĂĚĚĞĚ ƚŽ Ă ϮϱϬŵů ƌůĞŶŵĞǇĞƌ ĨůĂƐŬǁŝƚŚ ϱʅů ŽĨ ƚŚĞ ƉŚĂŐĞ ƐƚŽĐŬ͘  dŚĞ
culture was incubated at 37°C for 4.5 hours with vigorous shaking.  The culture was 
transferred to a sterile 50ml centrifuge tube and the cells pelleted at 12,000xg for 10 
minutes at 4°C.  The supernatant was transferred to a fresh tube and the 
centrifugation step repeated.  The upper 80% of the supernatant was transferred to 
another fresh tube along with 3ml of PEG/NaCl and incubated overnight at 4°C to 
precipitate the phage.  The phage were pelleted by centrifugation at 12,000xg for 16 
minutes at 4°C and the supernatant discarded.  The phage pellet was suspended in 
TBS and transferred to a microcentrifuge tube.  The remaining cell fragments were 
pelleted by centrifugation at 17,000xg and the supernatant containing phage was 
transferred to a fresh tube.  The phage were re-ƉƌĞĐŝƉŝƚĂƚĞĚ ďǇ ĂĚĚŝŶŐ ϮϬϬʅů ŽĨ
PEG/NaCl and incubating at on ice for 60 minutes. The phage were pelleted by 
centrifugation at 17,000xg for 10 minutes with the supernatant being discarded.  The 
ƉĞůůĞƚǁĂƐƐƵƐƉĞŶĚĞĚŝŶϱϬʅůŽĨd^͘ 
 
NEB M13 Phage ELISA 
ŽƚŚ ƚŚĞ ɴϰϬ ĂŶĚ ɴϰϮ ǁĞƌĞ ĚŝůƵƚĞĚ ƚŽ ϭϬϬŶD ŝŶ ƐŽĚŝƵŵ ďŝĐĂƌďŽŶĂƚĞ
immobilisation buffer and immobilised onto the corresponding wells of a 96-well 
plate.  The plate was set up with all relevant templates to be tested in triplicate. The 
plate was sealed with Parafilm and placed in a humidified container and incubated 
overnight at 4°C with shaking.  The target solutions were discarded and replaced with 
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ϭϳϬʅů ŽĨ ďůŽĐŬŝŶŐ ďƵĨĨĞƌ ĂĚĚĞĚ͘  dŚĞ ƉůĂƚĞ ǁĂƐ ƉůĂĐĞĚ ďĂĐŬ ŝŶƚŽ ƚŚĞ ŚƵŵŝĚŝĨŝĞĚ
container and incubated at 4°C for one hour.  The buffer was discarded and the wells 
washed six times with 0.1% TBS-T.  The amplified phage templates were diluted in 
ϭϬϬʅůŽĨϬ͘ϭйd^-T and added to the corresponding wells.  Phage samples were 
incubated at room temperature for one hour with rocking.  The phage solutions were 
removed and the wells washed six times with 0.3% TBS-T.  A horseradish peroxidase 
(HRP) labelled anti-M13 monoclonal antibody (Abnova, USA) was diluted 1:500, 
added to all test and control wells and incubated for one hour at room temperature 
with rocking.  During this incubation period, the contents of one phosphate citrate 
buffer tablet (Sigma-Aldrich, Australia) was added to 100ml of di water.  7.5ml of this 
buffer was transferred to a 15ml tube which contained an OPD tablet (Life 
Technologies, Australia).  The remaining antibody solution was removed and the well 
washed with six times with 0.1% TBS-T.  The OPD substrate was added to all wells and 
incubated for 30 minutes at room temperature.  The reactions were analysed by plate 
reader set at a wavelength of 405nM.  
 
Alternate M13 ELISA 
&ŽƌĂůůƉŚĂŐĞƚĞŵƉůĂƚĞƐƚŽďĞƚĞƐƚĞĚ͕ϭϬϬŶDŽĨɴϰϬĂŶĚɴϰϮƚĂƌŐĞƚƐǁĞƌĞ
diluted in a 0.05M NaHCO3 (pH 9.5), immobilisation buffer added to a 96-well 
microtitre plate and incubated for two hours in a humidified container at room 
ƚĞŵƉĞƌĂƚƵƌĞǁŝƚŚƌŽĐŬŝŶŐ͘dŚĞǁĞůůƐǁĞƌĞƚŚĞŶďůŽĐŬĞĚǁŝƚŚϮϬϬʅůŽĨϮй;ǁͬǀͿŶŽŶ-
fat milk powder in phosphate buffered saline (PBS), 137mM NaCl, 2.7mM potassium 
chloride (KCl), 8.1mM disodium phosphate (Na2HPO4), 1.47mM monopotassium 
phosphate (KH2PO4), at 4°C.  Blocked wells were washed four times with 0.1% PBS-T.  
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For testing of phage binding, the individually amplified plaques produced in the 
biopanning rounds, was amplified again as described above.  The phage samples were 
diluted to 1x1013 ƉĨƵͬŵůŝŶϮϬϬʅůŽĨϬ͘ϭйW^-T and added to the corresponding wells 
and incubated for two hours in a humidified container at room temperature with 
rocking.  The remaining phage were removed and the wells washed five times with 
0.1% PBS-T.  A HRP labelled/anti-M13 monoclonal conjugate (GE, USA) was diluted 
ϭ͗ϱϬϬϬŝŶďůŽĐŬŝŶŐďƵĨĨĞƌĂŶĚϮϬϬʅůĂĚĚĞĚƚŽĂůůǁĞůůƐƚŽďŝŶĚǁŝƚŚƚŚĞƉŚĂŐĞƉƌĞƐĞŶƚ
in the wells. The plate was incubated for 60 minutes at room temperature with 
rocking. The remaining unbound antibodies in solution were removed and the wells 
washed five times with 0.1% PBS-T. An 0.4mM 2,2'-azino-bis(3-ethylbenzothiazoline-
6-sulphonic acid) (ABTS) substrate stock solution was prepared in 5ml of 0.05M citric 
acid bufĨĞƌ;Ϭ͘ϬϱDĐŝƚƌĂƚĞŵŽŶŽŚǇĚƌĂƚĞ;Ɖ,ϰ͘ϬͿͿ͘WƌŝŽƌƚŽƚŚĞƌĞĂĐƚŝŽŶ͕ϴϲʅůŽĨϯй
H2O2 ǁĂƐĂĚĚĞĚƚŽŵĂŬĞƚŚĞƐƵďƐƚƌĂƚĞƐŽůƵƚŝŽŶ͘ϮϬϬʅůŽĨƚŚĞƐƵďƐƚƌĂƚĞƐŽůƵƚŝŽŶǁĂƐ
added to all wells and incubated until a suitable green colour was produced.  The 
substrate cleavage was determined with a plate reader set at a wavelength of 405nM. 
 
3.2.4  SY5Y Cell Culture and Treatments with the BACE1 Inhibitor 
A vial containing cryopreserved SY5Y cells (Sigma-Aldrich, Australia) (ATCC 
CRL-2266) was removed from liquid nitrogen storage and thawed in a water bath at 
37°C.  The cells were transferred to a 75mm2 (Corning) untreated flask containing 
media, HamsF12:EMEM (1:1), 2mM glutamine, 1% non-essential amino acids and 
15% foetal bovine serum (FBS) (v/v).  The flask was placed in an incubator at 37°C 
with 5% CO2.  The media discarded and replaced after two days of incubation.   
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Passaging Cells 
The cells were seeded at 80% confluency by removing and discarding the 
media and washing the cell monolayer twice with PBS containing 137mM NaCl, 
2.7mM KCl, 8.1mMNa2HPO4 and 1.47mM KH2PO4.  Then, the cells were harvested by 
adding 3ml of 0.25% Trypsin-ethylenediaminetetraacetic acid (EDTA) in PBS.  The cells 
were removed from the flask after a 2 minute incubation time and gently agitated to 
remove.  The flask was checked for attached cells under an inverted microscope 
before quenching with 7ml of fresh media.  The cells were washed over the base of 
the flask three times then 1ml transferred to two new 75mm2 flasks.     
 
Storage of Cells 
Cells grown during passage three and four were developed on a 75mm2 flask 
to 90% confluency.  The media was discarded and the monolayer washed twice with 
PBS.  The cells were harvested with 3ml of 0.25% trypsin/EDTA/PBS and quenched 
with 7ml of media.  Cell viability and number were calculated using a TC10 Automated 
Cell Counter (Bio-Rad Laboratories, Inc., USA).  The cell solution was transferred to a 
15ml tube and pelleted at 1000xg for 5 minutes.  The media was removed and cells 
suspended in cryomedia, 40% (v/v) FB S, 10% (v/v) dimethyl sulfoxide (DMSO) and 
50% (v/v) media, to 1x106 cell/ml and 1ml transferred into cryovials.  The vials were 
added to a Mr. Frosty (Nalgene, USA) container and placed in the -80°C freezer for 24 
hours.  The vials were then transferred to the liquid nitrogen storage dewar. 
 
Cell Viability and Number Calculation 
ϮϬϬʅů ŽĨ ĐĞůůƐ͕ ĂĨƚĞƌ ƚƌǇƉƐŝŶŝƐĂƚŝŽŶ ĂŶĚ ƋƵĞŶĐŚŝŶŐ͕ ǁĞƌĞ ƚƌĂŶƐĨĞƌƌĞĚ ƚŽ Ă
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microcentrifuge tube and pelleted at 1,000xg for 5 minutes to remove any traces of 
the remaining serƵŵ͘dŚĞŵĞĚŝĂǁĂƐƌĞŵŽǀĞĚĂŶĚƚŚĞƉĞůůĞƚǁĂƐŚĞĚǁŝƚŚϮϬϬʅůŽĨ
W^͘dŚĞĐĞůůƐǁĞƌĞƚŚĞŶƐƵƐƉĞŶĚĞĚŝŶϮϬϬʅůŽĨ,ĂŵƐ&ϭϮ͗DDĂŶĚϮϬʅůƚƌĂŶƐĨĞƌƌĞĚ
ƚŽĂĨƌĞƐŚŵŝĐƌŽĐĞŶƚƌŝĨƵŐĞƚƵďĞ͘ϮϬʅůŽĨƚƌǇƉĂŶďůƵĞĚǇĞƐŽůƵƚŝŽŶǁĂƐĂĚĚĞĚƚŽƚŚĞ
ϮϬʅůŽĨĐĞůůƐĂŶĚůŽĂĚĞĚŝŶto the TC10 sample chambers on the counting slide.  The 
slide was added to the TC10 Automated Cell Counter and the cell viability and counts 
analysed. 
 
Cell Treatments 
SY5Y cells were grown to 80% confluency and harvested using 3ml of 0.25% 
trypsin/EDTA/PBS and quenched with 7ml of media.  The cells were transferred to a 
six-well plate and allowed to adhere overnight.  Media was pre-treated for 24 hours 
with the BACE1 peptide inhibitor (as characterised in Chapter 2) to 1, 10 and 100nM 
in media.  The old media was replaced with the treatment media and the cells 
incubated for 24 hours.  The media was removed and the monolayer washed with 
PBS.  The cells were lysed in the wells with CelLytic MT (Sigma-Aldrich, Australia) and 
protein concentration determined with a Qubit fluorometer (Life Technologies, 
ƵƐƚƌĂůŝĂͿ͘dŚĞůǇƐĂƚĞƐǁĞƌĞƵƐĞĚŝŵŵĞĚŝĂƚĞůǇŝŶƚŚĞɴϰϬĂŶĚɴϰϮ>/^Ɛ͘ 
 
SY5Y Hydrogen Peroxide Treatment 
SY5Y cells were grown to 80% confluency, trypsinised and transferred to 6-
well plates, as described above.  The media was pre-ƚƌĞĂƚĞĚǁŝƚŚϮϬϬʅDŚǇĚƌŽŐĞŶ
peroxide (H2O2) for 24 hours before adding to the cells.  Testing the BACE1 inhibitor, 
generated from Chapter 2, the H2O2 pre-treatments contained one of a 1, 10 and 
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100nM concentrations.  After the treated cells were incubated for 24 hours, the 
monolayer was washed once with PBS and lysed on the plate with CelLytic MT (Sigma-
Aldrich, Australia). 
 
3.2.5  ,ƵŵĂŶɴϰϬĂŶĚɴϰϮ>/^ with Treated SY5Y Cell Lysates  
The human ɴϰϬĂŶĚɴϰϮ>/^Ɛ;/ŶǀŝƚƌŽŐĞŶ͕h^ͿǁĞƌĞƉƵƌĐŚĂƐĞĚĂƐŬŝƚƐ
from Life Technologies (Australia). 
 
ELISA 
dŚĞŚƵŵĂŶɴϰϬĂŶĚɴϰϮ>/^Ɛ;/ŶǀŝƚƌŽŐĞŶ͕h^ͿǁĞƌĞƉƵƌĐŚĂƐĞĚŝŶĂϵϲ-
well format with the capture antibody immobilised on the well surface. The plates 
were divided into 12 rows of 8 and used as required.  The corresponding wells were 
ƚŚĂǁĞĚĂƚƌŽŽŵƚĞŵƉĞƌĂƚƵƌĞ͘Ğůů ůǇƐĂƚĞƐǁĞƌĞƚŚĂǁĞĚĂŶĚƐƚĂŶĚĂƌĚŝƐĞĚƚŽϱϬʅŐ
ƉƌŽƚĞŝŶͬǁĞůů ŝŶ ƚŚĞ ƐƚĂŶĚĂƌĚ ĚŝůƵĞŶƚ ďƵĨĨĞƌ ƚŽ ϱϬʅů͘   ϰ-(2-aminoethyl) 
benzenesulfonyl fluoride hydrochloride (AEBSF) protease inhibitor was added to a 
ϭŵDĨŝŶĂůĐŽŶĐĞŶƚƌĂƚŝŽŶƚŽƉƌĞǀĞŶƚƚŚĞƉƌŽƚĞŽůǇƐŝƐŽĨɴƉĞƉƚŝĚĞƐ͘dŽƚŚĞůǇƐĂƚĞƐ͕
ϱϬʅů ŽĨɴĚĞƚĞĐƚŝŽŶĂŶƚŝďŽĚǇǁĂƐ ĂĚĚĞĚĂŶĚ ƚŚĞǁĞůůƐ ƐĞĂůĞĚĂŶĚ ŝŶĐƵďĂƚĞĚ ĨŽƌ
three hours at room temperature with rocking.  The solution was decanted and the 
ǁĞůůƐǁĂƐŚĞĚĨŽƵƌƚŝŵĞƐǁŝƚŚƚŚĞƉƌŽǀŝĚĞĚǁĂƐŚďƵĨĨĞƌ͘dŚĞŶϭϬϬʅůŽĨ,ZWůĂďĞůůĞĚ
secondary antibody (anti-rabbit) was added to all wells and incubated for 30 minutes 
with rocking. The wells were washed fŽƵƌ ƚŝŵĞƐďĞĨŽƌĞĂĚĚŝŶŐϭϬϬʅůŽĨ ƐƚĂďŝůŝǌĞĚ
chromogen (tetramethylbenzidine) to each well.  The wells were covered and placed 
ŝŶƚŚĞĚĂƌŬƵŶƚŝůďůƵĞĐŽůŽƵƌĐŚĂŶŐĞŚĂĚŽĐĐƵƌƌĞĚƚŚĞŶϭϬϬʅůŽĨƐƚŽƉƐŽůƵƚŝŽŶǁĂƐ
added before analysing the reaction in a plate reader (absorbance 450nm). 
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3.3 Results 
3.3.1  ŝƌĞĐƚWŚĂƐĞWĂŶŶŝŶŐĨŽƌɴϰϬĂŶĚɴϰϮŝŶĚŝŶŐĂŶĚŝĚĂƚĞƐ 
/ĚĞŶƚŝĨǇŝŶŐƉĞƉƚŝĚĞďŝŶĚĞƌƐ͕ƐƉĞĐŝĨŝĐĨŽƌƚŚĞɴϰϬĂŶĚɴϰϮďǇ-products of the 
amyloidogenic cleavage of APP, was investigated by using the same phage display 
protocol as applied previously to select a 12-ŵĞƌƉĞƉƚŝĚĞĨŽƌϭ͘dŚĞɴϰϬĂŶĚ
ɴϰϮƚĂƌŐĞƚƐǁĞƌĞŝŵŵŽďŝůŝƐĞĚƐĞƉĂƌĂƚĞůǇŽŶĂŵŝĐƌŽƚŝƚƌĞƉůĂƚĞĂŶĚĂůůŽǁĞĚƚŽďŝŶĚ
with the constrained C7C 7-mer peptide, phage display kit.    
 
As a representation of peptide-ɴϰϮƚĂƌŐĞƚďŝŶĚŝŶŐ͕ƚŚĞƉŚĂŐĞƚŝƚƌĞŝŶĐƌĞĂƐĞĚ
over the first two rounds of biopanning from 2x109 to 5x1010cfu/ml so plaques were 
picked from the round three unamplified eluate and sequenced.  The phage 
generated from these plaques were used in binding confirmation ELISAs.  The 
ĂŵƉůŝĨŝĞĚ ĞůƵĂƚĞ ŐĞŶĞƌĂƚĞĚ ĨƌŽŵ ƚŚĞ ɴϰϬ ƚĂƌŐĞƚ͕ ĚŝĚ ŶŽƚ ŝŶĐƌĞĂƐĞ ŝŶ ƚŝƚƌĞ͕ ŐŽŝŶŐ
below 1x108cfu/ml in the second round and as a result was discontinued.    
 
Sequencing 
dŚĞ ƉŚĂŐĞ ƚŝƚƌĞ ĨŽƌ ƚŚĞɴϰϮ ƚĂƌŐĞƚ ŝŶĐƌĞĂƐĞĚ accordingly and six plaques 
were selected for phage sequencing.  These plaques were then amplified individually 
and the phage precipitated.  The DNA was extracted and amplified with PCR before 
sequencing.  Of the six plaques picked, four produced identical sequences (Table 3.1).  
Identification of the insert was determined by identification of the triple glycine 
leader and the two cysteine residues, GTC TGT XXX7 TGC GGT GGA GGT, that become 
oxidised during the phage construction, giving the loop appearance.   
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Plaque 
Number DNA Sequence 
1 No insert 
2 TGT ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻTGC 
3 TGT ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻTGC 
4 TGT ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻTGC 
5 No insert 
6 TGT ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻ TGC 
 
Table 3.1. Biopanning third round ƐĞƋƵĞŶĐŝŶŐĨŽƌƚŚĞɴϰϮƐƉĞĐŝĨŝĐƉŚĂŐĞďŝŶĚĞƌƐ͘ 
Blue plaques, isolated from the unamplified eluate of biopanning round three, were 
sequenced to determine the DNA sequence. These phage contained the expressed 
ƉĞƉƚŝĚĞ ƚŚĂƚ ďŽƵŶĚ ƚŽ ɴϰϮ͘  KĨ ƚŚĞ Ɛŝǆ ƉůĂƋƵĞƐ sequenced, four of them were 
identical and two did not produce an insert.  
x The sequence is blocked due to intellectual property restrictions.   
 
M13 Phage ELISAs of Biopanning Candidates 
After the individual plaque amplification for the round three eluate, half of 
the phage were kept for the ELISA.  Only one of the purified phage samples was 
ƉƌĞƉĂƌĞĚĨŽƌƚŚĞ>/^ďĞĐĂƵƐĞŽĨƚŚĞŵĂƚĐŚŝŶŐƐĞƋƵĞŶĐĞŵŽƚŝĨ͘dŚĞɴϰϬƚĂƌŐĞƚĚŝĚ
not bind a succĞƐƐĨƵůƉŚĂŐĞďƵƚǁĂƐ Ɛƚŝůů ƚĞƐƚĞĚ ĨŽƌ ĐƌŽƐƐ ƌĞĂĐƚŝǀŝƚǇǁŝƚŚ ƚŚĞɴϰϮ
specific peptide.  
 
dŚĞɴϰϬĂŶĚɴϰϮƚĂƌŐĞƚƐǁĞƌĞŝŵŵŽďŝůŝƐĞĚŽŶŵŝĐƌŽƚŝƚƌĞƉůĂƚĞƐĨŽůůŽǁŝŶŐ
the phage display protocol.  After incubation with the target and phage, a HRP 
labelled secondary anti-m13 antibody was introduced to quantify the binding that 
occurred.  A significant increase in the amount of colorimetric response was observed 
ĨŽƌƚŚĞŶĞŐĂƚŝǀĞĐŽŶƚƌŽůĂƐǁĞůůĂƐƚŚĞɴϰϬĂŶĚɴϰϮ;&ŝŐƵƌĞϯ͘ϭͿ͘,ŽǁĞǀĞƌ͕ǁŚĞŶ
the no-target negatiǀĞĐŽŶƚƌŽůǁĂƐĐŽŵƉĂƌĞĚǁŝƚŚƚŚĞɴϰϬĂŶĚɴϰϮďŝŶĚĞƌƐ͕ƚŚĞƌĞ
was no significant difference so the phage were binding without any target.  A 
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blocking buffer control was also tested for binding to the BSA by using just the 
immobilisation buffer which also elicited a significant response.  However, there was 
ĂůƐŽĂƐŝŐŶŝĨŝĐĂŶƚĚŝĨĨĞƌĞŶĐĞďĞƚǁĞĞŶƚŚĞĂŵŽƵŶƚŽĨƉŚĂŐĞďŝŶĚŝŶŐƚŽƚŚĞɴϰϬĂŶĚ
ɴϰϮƚĂƌŐĞƚƐĂŶĚƚŽƚŚĞďůŽĐŬŝŶŐďƵĨĨĞƌĐŽŶƚƌŽů͘ 
 
Figure 3.1  Quantification ŽĨɴϰϮďŝŶĚŝŶŐƉŚĂŐĞƚŽƚŚĞɴϰϬĂŶĚɴϰϮtargets by  
M13 ELISA.  Isolated phage from the third round of biopanning were tested for 
ƐƉĞĐŝĨŝĐ ďŝŶĚŝŶŐ ƚŽ ƚŚĞɴϰϬĂŶĚɴϰϮ ƚĂƌŐĞƚƐ͘  dŚĞ ĨŝƌƐƚŶĞŐĂƚŝǀĞ ĐŽŶƚƌŽů ĚŝĚŶŽƚ
ĐŽŶƚĂŝŶĂŶǇƉŚĂŐĞ͘dŚĞƐĞĐŽŶĚĐŽŶƚƌŽůĚŝĚŶŽƚĐŽŶƚĂŝŶĞŝƚŚĞƌŽĨƚŚĞɴϰϬĂŶĚɴϰϮ
targets.  The last control did not contain any blocking buffer, the immobilisation 
buffer was used twice to remove BSA from the experiment. The data is represented 
as means + SE (n=3) expressed as absorbance (405nm) from a colorimetric response. 
*Denotes a significant difference (p<0.05) between experimental groups and the 
negative control (without phage).  
**Denotes a significant difference (p<0.05) between the blocking buffer control and 
the other experimental groups.  
 
3.3.2  ^ŽůƵƚŝŽŶWŚĂƐĞWĂŶŶŝŶŐďǇĨĨŝŶŝƚǇĞĂĚĂƉƚƵƌĞĨŽƌɴϰϬĂŶĚɴϰϮŝŶĚŝŶŐ
Candidates  
The phage display protocol was changed from target immobilisation to a bead 
ĐĂƉƚƵƌĞƚĞĐŚŶŝƋƵĞĂůůŽǁŝŶŐƚŚĞɴƚŽďĞĂǀĂŝůĂďůĞŝŶƐŽůƵƚŝŽŶ͘dŚĞƌĞĐŽŵďŝŶĂŶƚɴϰϬ
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ĂŶĚ ɴϰϮ ƉĞƉƚŝĚĞƐ ǁĞƌĞ ďŝŽƚŝŶǇůĂƚĞĚ ĂŶĚ ďŽƵŶĚ ƚŽ ŵĂŐŶĞƚŝĐ ďĞĂĚƐ ĐŽŶƚĂŝŶŝŶŐ
streptavidin.  The magnetic beads were used in solution containing the bound targets 
to freely bind with the phage display candidates.  The bound phage were pelleted 
along with the beads using a neodymium magnet.  Phage were eluted using the 
glycine buffer consistent with the previous biopanning experiments, except the 
beads were pelleted and discarded with the supernatant being retained. The solution 
phasĞďŝŽƉĂŶŶŝŶŐƐŚŽǁĞĚĂƐƚƌŽŶŐďŝŶĚŝŶŐƌĞƐƉŽŶƐĞƚŽďŽƚŚɴϰϬĂŶĚɴϰϮƚĂƌŐĞƚƐ
with round one titres of 2x109 and 3x109 pfu/ml, respectively.  Both targets had a 10-
fold increase in titre and were sequenced from the successful third round unamplified 
eluates. Ten samples for each target were picked from the titre plates and sequenced, 
half of the amplified phage plaques were stored for use in the M13 ELISAs 
 
Sequencing  
Phage DNA was precipitated and quantified prior to the sequencing. The 
samples were analysed using a NanoDrop spectrophotometer by comparing the 
260/280nm wavelengths producing results between the expected 1.7 and 2.1 levels. 
These positive results translated into the sequencing with clearly defined nucleotide 
ƉĞĂŬƐ͘ ŽƚŚŽĨ ƚŚĞƚĂƌŐĞƚƐŚĂĚϭϬƐĂŵƉůĞƐƐĞƋƵĞŶĐĞĚĞĂĐŚ͕ďŽƚŚɴϰϬĂŶĚɴϰϮ
produced three different sequences (Table 3.2).  The DNA inserts were identified by 
the triple glycine leader sequences and the flanking cysteine residues of the C7C 
phage display library.  The remaining amplified phage were stored and used as part 
of the M13 ELISAs. 
 
. 
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 Plaque 
Number DNA Sequence 
ɴϰϬ   
1 TGT ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻ TGC 
2 No insert 
3 TGT ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻ TGC 
4 TGT ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻ TGC 
5 No insert 
6 No insert 
7 TGT ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻ TGC 
8 No insert 
9 No insert 
10 TGT ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻ TGC 
  
ɴϰϮ   
1 TGT ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻ TGC 
2 No insert 
3 No insert 
4 No insert 
5 TGT ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻ TGC 
6 TGT ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻ TGC 
7 No insert 
8 TGT ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻ TGC 
9 No insert 
10 TGT ͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻ TGC 
 
M13 ELISA Confirming Binders from the Second Round of Biopanning 
ɴϰϬdĂƌŐĞƚ^ƉĞĐŝĨŝĐWŚĂŐĞŝŶĚŝŶŐƐƐĂǇƐĨƌŽŵŝŽƉĂŶŶŝŶŐĂŶĚŝĚĂƚĞƐ  
TŚĞɴϰϬ>/^ǁĂƐƉƌĞƉĂƌĞĚƵƐŝŶŐƉŚĂŐĞŐĞŶĞƌĂƚĞĚĨƌŽŵƚŚĞƚŚŝƌĚƌŽƵŶĚŽĨ
biopanning.  The sequenced samples correspond to the plaques that were picked and 
Table 3.2.  Biopanning round three phage ŝŶƐĞƌƚƐĞƋƵĞŶĐĞƐŽĨƚŚĞɴϰϬĂŶĚɴϰϮ
binders from the bead capture.  Blue plaques, isolated from the unamplified 
eluate of round three, were sequenced to determine the composition of the 
ƉĞƉƚŝĚĞŝŶƐĞƌƚ͘dŚĞɴϰϬƐƉĞĐŝĨŝĐƉŚĂŐĞƉƌŽĚƵĐĞĚƚŚƌĞĞĚŝĨĨĞƌĞŶƚƐĞquences, two 
ŽĨǁŚŝĐŚǁĞƌĞ ƉƌŽĚƵĐĞĚ ƚǁŝĐĞ͘  dŚĞ ɴϰϮ ƐƉĞĐŝĨŝĐ ƉŚĂŐĞ ĂůƐŽ ƉƌŽĚƵĐĞĚ ƚŚƌĞĞ
different sequences, two of which were produced twice.  
x The sequence is blocked due to intellectual property restrictions. 
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subsequently tested for binding.  The phage were tested for binding according to the 
target they were panned for.  The target was immobilised on the plate wells 
according to the direct target coating method used to originally determine a binder 
ĨŽƌ ɴϰϬ͘  The ELISA showed the isolated phage plaques corresponding to the 
ƐĞƋƵĞŶĐĞƐ ɴϰϬ͘ϭ͕ ɴϰϬ͘ϰ ĂŶĚ ɴϰϬ͘ϳ ŚĂĚ ƐŝŐŶŝĨŝĐĂŶƚ ďŝŶĚŝŶŐ ĂĐĐŽƌĚŝŶŐ ƚŽ ƚŚĞ 
colorimetric response (Figure 3.2).  The phage isolated from the original direct target 
coating phage display attempt was used as a control to monitor binding 
 
Figure 3.2. Quantification and confirmation of phage binders, selected from the 
ɴϰϬ ďĞĂĚ ĐĂƉƚƵƌĞ͕ ďǇ Dϭϯ >/^͘  Phage isolated from the third round of 
biopanning were individually confirmed for binding to thĞɴϰϬƚĂƌŐĞƚ͘dŚĞŶĞŐĂƚŝǀĞ
control did not contain any phage and served as the baseline for no binding.  The 
ƉŚĂŐĞ ĐŽŶƚƌŽů ǁĂƐ ĚĞƚĞƌŵŝŶĞĚ ďǇ ƚĞƐƚŝŶŐ ƚŚĞ ďŝŶĚĞƌ ĨƌŽŵ ƚŚĞ ĨŝƌƐƚ ƌŽƵŶĚ ŽĨ ɴ
ďŝŽƉĂŶŶŝŶŐƚŽĐŽŶĨŝƌŵĂĐƚŝǀŝƚǇ͘dŚĞɴϰϬ͘ϭ͕ɴϰϬ͘ϰĂŶĚɴϰϬ͘ϳƉŚĂŐĞ were tested 
ĨŽƌďŝŶĚŝŶŐĂĨĨŝŶŝƚǇƚŽɴϰϬ͘dŚĞĚĂƚĂŝƐƌĞƉƌĞƐĞŶƚĞĚĂƐŵĞĂŶƐ+ SE (n=3) expressed 
as absorbance (405nm) from a colorimetric response 
*Denotes a significant increase (p<0.05) between experimental groups and the 
negative control (without phage). 
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ɴϰϮdĂƌŐĞƚ^ƉĞĐŝĨŝĐWŚĂŐĞŝŶĚŝŶŐƐƐĂǇƐĨƌŽŵŝŽƉĂŶŶŝŶŐĂŶĚŝĚĂƚĞƐ 
dŚĞɴϰϮ>/^ǁĂƐƉƌĞƉĂƌĞĚƵƐŝŶŐƉŚĂŐĞŐĞŶĞƌĂƚĞĚĨƌŽŵƚŚĞƚŚŝƌĚƌŽƵŶĚŽĨ
biopanning.  The sequenced samples correspond to the plaques that were picked and 
subsequently tested for binding.  The phage were tested for binding according to the 
target they were panned for.  The target was immobilised on the plate wells 
according to the direct target coating method used to originally determine a binder 
ĨŽƌ ɴϰϮ͘  dŚĞ >/^ ƐŚŽǁĞĚ ƚŚĞ isolated phage plaques corresponding to the 
ƐĞƋƵĞŶĐĞƐ ɴϰϮ͘ϭ͕ ɴϰϮ͘ϱ ĂŶĚ ɴϰϮ͘ϲ ŚĂĚ ƐŝŐŶŝĨŝĐĂŶƚ ďŝŶĚŝŶŐ ĂĐĐŽƌĚŝŶŐ ƚŽ ƚŚĞ
colorimetric response (Figure 3.3).  The phage isolated from the original direct target 
coating phage display attempt was used as a control to monitor binding. 
Figure 3.3.  Quantification and confirmation of phage binders, selected from the 
ɴϰϮďĞĂĚĐĂƉƚƵƌĞ͕ďǇDϭϯ>/^͘ Phage isolated from the third round of biopanning 
ǁĞƌĞŝŶĚŝǀŝĚƵĂůůǇĐŽŶĨŝƌŵĞĚĨŽƌďŝŶĚŝŶŐƚŽƚŚĞɴϰϮƚĂƌŐĞƚ͘dŚĞŶĞgative control did 
not contain any phage and served as the baseline for no binding.  The phage control 
ǁĂƐ ĚĞƚĞƌŵŝŶĞĚ ďǇ ƚĞƐƚŝŶŐ ƚŚĞ ďŝŶĚĞƌ ĨƌŽŵ ƚŚĞ ĨŝƌƐƚ ƌŽƵŶĚ ŽĨ ɴ ďŝŽƉĂŶŶŝŶŐ ƚŽ
ĐŽŶĨŝƌŵ ĂĐƚŝǀŝƚǇ͘  dŚĞ ɴϰϮ͘ϭ͕ ɴϰϮ͘ϱ ĂŶĚ ɴϰϮ͘ϲ ƉŚĂŐĞ ǁĞƌĞ ƚĞƐƚĞĚ ĨŽƌ ďŝŶĚing 
ĂĨĨŝŶŝƚǇ ƚŽ ɴϰϮ͘ dŚĞ ĚĂƚĂ ŝƐ ƌĞƉƌĞƐĞŶƚĞĚ ĂƐ ŵĞĂŶƐ + SE (n=3) expressed as 
absorbance (405nm) from a colorimetric response.  
*Denotes a significant increase (p<0.05) between experimental groups and the 
negative control (without phage). 
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Target Cross Reactivity Test 
ɴϰϬ^ƉĞĐŝĨŝĐWŚĂŐĞŝŶĚŝŶŐĨĨŝŶŝƚǇĨŽƌƚŚĞɴϰϮdĂƌŐĞƚ 
Testing for target cross reactivity, the isolated phage plaques, corresponding 
ƚŽƚŚĞƐĞƋƵĞŶĐĞƐɴϰϬ͘ϭ͕ɴϰϬ͘ϰĂŶĚɴϰϬ͘ϳ͕ǁĞƌĞƚĞƐƚĞĚĨŽƌďŝŶĚŝŶŐƚŽɴϰϮ͘dŚĞ
plaques had shown stronŐďŝŶĚŝŶŐƚŽƚŚĞƉƌŝŵĂƌǇɴϰϬƚĂƌŐĞƚŝŶƚŚĞ>/^ďƵƚĨŽƌĂŶ
ŝŶŚŝďŝƚŽƌƚŽďĞƵŶŝǀĞƌƐĂů͕ŚĂĚƚŽƐŚŽǁďŝŶĚŝŶŐƚŽɴƐƵďƚǇƉĞƐ͘dŚĞɴϰϮƚĂƌŐĞƚǁĂƐ
immobilised on the plate wells according to the direct target coating method used to 
originally determine a binĚĞƌ͘  dŚĞ ɴϰϬ͘ϭ͕ ɴϰϬ͘ϰ ĂŶĚ ɴϰϬ͘ϳ ƉŚĂŐĞ Ăůů ƐŚŽǁĞĚ
significant binding in comparison to the negative control (Figure 3.4).   
 
 
&ŝŐƵƌĞϯ͘ϰ͘ YƵĂŶƚŝĨŝĐĂƚŝŽŶŽĨĐƌŽƐƐ ƌĞĂĐƚŝǀĞďŝŶĚŝŶŐƉŚĂŐĞƚŽƚŚĞɴϰϮƚĂƌŐĞƚďǇ
M13 ELISA.  WŚĂŐĞŝƐŽůĂƚĞĚĨƌŽŵƚŚĞƚŚŝƌĚƌŽƵŶĚŽĨďŝŽƉĂŶŶŝŶŐĨŽƌƚŚĞɴϰϬƚĂƌŐĞƚ
ǁĞƌĞŝŶĚŝǀŝĚƵĂůůǇĐŽŶĨŝƌŵĞĚĨŽƌďŝŶĚŝŶŐƚŽɴϰϮ͘dŚĞŶĞŐĂƚŝǀĞĐŽŶƚƌŽůĚŝĚŶŽƚĐŽŶƚĂŝŶ
ĂŶǇƉŚĂŐĞĂŶĚƐĞƌǀĞĚĂƐƚŚĞďĂƐĞůŝŶĞĨŽƌŶŽďŝŶĚŝŶŐ͘dŚĞɴϰϬ͘ϭ͕ɴϰϬ͘ϰĂŶĚɴϰϬ͘ϳ
phage were testĞĚĨŽƌďŝŶĚŝŶŐĂĨĨŝŶŝƚǇƚŽɴϰϮ͘dŚĞĚĂƚĂŝƐƌĞƉƌĞƐĞŶƚĞĚĂƐŵĞĂŶƐ+ 
SE (n=3) expressed as absorbance (405nm) from a colorimetric response. 
*Denotes a significant increase (p<0.05) between experimental groups and the 
negative control (without phage). 
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ɴϰϮ^ƉĞĐŝĨŝĐWŚĂŐĞŝŶĚŝŶŐĨĨŝŶŝƚǇĨŽƌƚŚĞɴϰϬdĂƌŐĞƚ  
Testing for target cross reactivity, the isolated phage plaques corresponding 
ƚŽƚŚĞƐĞƋƵĞŶĐĞƐɴϰϮ͘ϭ͕ɴϰϮ͘ϱĂŶĚɴϰϮ͘ϲǁĞƌĞƚĞƐƚĞĚĨŽƌďŝŶĚŝŶŐƚŽɴϰϬ͘dŚĞ
plaques exhibited strong binding to the pƌŝŵĂƌǇɴϰϮƚĂƌŐĞƚŝŶƚŚĞ>/^ďƵƚĨŽƌĂŶ
ŝŶŚŝďŝƚŽƌƚŽďĞƵŶŝǀĞƌƐĂů͕ ŝƚ ŝƐ ƌĞƋƵŝƌĞĚƚŽƐŚŽǁďŝŶĚŝŶŐƚŽɴƐƵďƚǇƉĞƐ͘ dŚĞɴϰϬ
target was immobilised on the plate wells according to the direct target coating 
method used to originally determine a binder.  TŚĞɴϰϮ͘ϭ͕ɴϰϮ͘ϱĂŶĚɴϰϮ͘ϲƉŚĂŐĞ
all showed significant binding in comparison to the negative control (Figure 3.5).  
 
&ŝŐƵƌĞϯ͘ϱ͘ YƵĂŶƚŝĨŝĐĂƚŝŽŶŽĨĐƌŽƐƐ ƌĞĂĐƚŝǀĞďŝŶĚŝŶŐƉŚĂŐĞƚŽƚŚĞɴϰϬƚĂƌŐĞƚďǇ
M13 ELISA.  Phage isolated from the third round of biŽƉĂŶŶŝŶŐĨŽƌƚŚĞɴϰϮƚĂƌŐĞƚ
ǁĞƌĞŝŶĚŝǀŝĚƵĂůůǇĐŽŶĨŝƌŵĞĚĨŽƌďŝŶĚŝŶŐƚŽɴϰϬ͘dŚĞŶĞŐĂƚŝǀĞĐŽŶƚƌŽůĚŝĚŶŽƚĐŽŶƚĂŝŶ
ĂŶǇƉŚĂŐĞĂŶĚƐĞƌǀĞĚĂƐƚŚĞďĂƐĞůŝŶĞĨŽƌŶŽďŝŶĚŝŶŐ͘dŚĞɴϰϮ͘ϭ͕ɴϰϮ͘ϱĂŶĚɴϰϮ͘ϲ
ƉŚĂŐĞǁĞƌĞƚĞƐƚĞĚĨŽƌďŝŶĚŝŶŐĂĨĨŝŶŝƚǇƚŽɴϰϬ͘dŚĞĚĂƚĂ is represented as means + 
SE (n=3) expressed as absorbance (405nm) from a colorimetric response. *Denotes a 
significant increase (p<0.05) between experimental groups and the negative control 
(without phage). 
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Control ELISA without Target  
To test for non-ƐƉĞĐŝĨŝĐďŝŶĚŝŶŐ͕ĂůůƉƌĞǀŝŽƵƐůǇƚĞƐƚĞĚƉŚĂŐĞďŝŶĚĞƌƐ;ɴϰϬ͘ϭ͕
ɴϰϬ͘ϰ͕ɴϰϬ͘ϳ͕ɴϰϮ͘ϭ͕ɴϰϮ͘ϱĂŶĚɴϰϮ͘ϲͿǁĞƌĞĂĚĚĞĚƚŽĂƉůĂƚĞƚŚĂƚŚĂĚďĞĞŶ
blocked without target.  The binding of all isolated phage, determined in the previous 
ELISAs, had shown a consistent response to both targets.  The possibility of non-
ƐƉĞĐŝĨŝĐ ďŝŶĚŝŶŐ ǁĂƐ ƚĞƐƚĞĚ ďǇ ƌĞŵŽǀŝŶŐ ƚŚĞ ɴϰϬ ĂŶĚ ɴϰϮ ƚĂƌŐĞƚƐ ĂŶĚ ũƵƐƚ
ŝŵŵŽďŝůŝƐŝŶŐǁŝƚŚƚŚĞďůŽĐŬŝŶŐďƵĨĨĞƌ͘dŚĞɴϰϬ͘ϭ͕ɴϰϬ͘ϰ͕ɴϰϬ͘ϳ͕ɴϰϮ͘ϭ͕ɴϰϮ͘ϱ
ĂŶĚɴϰϮ͘ϲƉŚĂŐĞ ƐĂŵƉůĞƐ ƐŚŽwed significant colorimetric responses without any 
target immobilised (Figure 3.6).   
&ŝŐƵƌĞϯ͘ϲ͘YƵĂŶƚŝĨŝĐĂƚŝŽŶŽĨɴϰϬĂŶĚɴϰϮďŝŶĚŝŶŐƉŚĂŐĞƚŽƚŚĞďůŽĐŬŝŶŐďƵĨĨĞƌ
without target by M13 ELISA.  Phage isolated from the third round of biopanning for 
both ƚŚĞ ɴϰϬ ĂŶĚ ɴϰϮ ƚĂƌŐĞƚƐ ǁĞƌĞ ŝŶĚŝǀŝĚƵĂůůǇ ĐŽŶĨŝƌŵĞĚ ĨŽƌ ďŝŶĚŝŶŐ ƚŽ ƚŚĞ
blocking buffer as there was no target added for immobilisation. The negative control 
ĚŝĚŶŽƚĐŽŶƚĂŝŶĂŶǇƉŚĂŐĞĂŶĚƐĞƌǀĞĚĂƐƚŚĞďĂƐĞůŝŶĞĨŽƌŶŽďŝŶĚŝŶŐ͘dŚĞɴϰϬ͘ϭ͕
ɴϰϬ͘ϰ͕ɴϰϬ͘ϳ͕ɴϰϮ͘ϭ͕ɴϰϮ͘ϱĂŶĚɴϰϮ͘ϲƉŚĂŐĞǁĞƌĞĂůůƚĞƐƚĞĚĨŽƌďŝŶĚŝŶŐĂĨĨŝŶŝƚǇ
to blocking buffer.  The data is represented as means + SE (n=3) expressed as 
absorbance (405nm) from a colorimetric response.  
*Denotes a significant increase (p<0.05) between experimental groups and the 
negative control (without phage). 
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Alternative Protocol Test 
A second protocol was tested to confirm the binding that occurred in the 
negative control phage ELISA outlined previously by not immobilising any specific 
target and just blocking the plate with buffer.  As an alternative, a new anti-M13 
antibody was used and the plate wells were blocked with non-fat milk instead of the 
buffer used in the phage display. 
 
ɴϰϬ͘ϭ>/^ǁŝƚŚƚŚĞɴϰϬdĂƌŐĞƚ 
dŚĞɴϰϬ͘ϭƉŚĂŐĞǁĞƌĞĂŶĂůǇƐĞĚĨŽƌďŝŶĚŝŶŐƚŽƚŚĞŝŵŵŽďŝůŝƐĞĚɴϰϬƚĂƌŐĞƚ͕
which was originally defined in the phage display rounds.  Instead of using the BSA 
based blocking buffer, a no-fat skim milk was used to block the plate wells and to 
ĚŝůƵƚĞ ƚŚĞɴϰϬ͘ϭ ƉŚĂŐĞ͘  dŚĞ ɴϰϬ͘ϭ ƉŚĂŐĞ ƐŚŽǁĞĚ Ă ƐŝŐŶŝĨŝĐĂŶƚ ŝŶĐƌĞĂƐĞ ŝŶ ƚŚĞ
ĐŽůŽƌŝŵĞƚƌŝĐ ƌĞƐƉŽŶƐĞ ŝŶ ƚŚĞ ǁĞůůƐ ĐŽŶƚĂŝŶŝŶŐ ŝŵŵŽďŝůŝƐĞĚ ɴϰϬ ĂŶĚ ɴϰϮ ǁŚĞŶ
compared with the negative control (Figure 3.7).  However, there was also a 
significant response shown in the no target control well.  There was no significant 
ĚŝĨĨĞƌĞŶĐĞďĞƚǁĞĞŶƚŚĞɴϰϬ͕ɴϰϮĂŶĚŶĞŐĂƚŝǀĞĐŽŶƚƌŽůƌĞƐƉŽŶƐĞƐ͘ 
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Figure 3.7.  Quantification binding phage sĂŵƉůĞ ɴϰϬ͘ϭ ƚŽ ƚŚĞ ɴϰϬ ĂŶĚɴϰϮ
targets by the alternate M13 ELISA.  The phage isolated from the third round of 
ďŝŽƉĂŶŶŝŶŐ͕ĨŽƌƚŚĞɴϰϬƚĂƌŐĞƚ͕ǁĞƌĞŝŶĚŝǀŝĚƵĂůůǇĐŽŶĨŝƌŵĞĚĨŽƌďŝŶĚŝŶŐƚŽɴϰϬ͘dŚĞ
ƉůĂƋƵĞƐĞƋƵĞŶĐĞĚĂƐɴϰϬ͘ϭǁĂƐƵƐĞĚƚŽƚĞƐƚƚŚĞĂůƚĞƌŶĂƚŝǀĞDϭϯ>/^ǁŝƚŚɴϰϬ
ĂŶĚɴϰϮŝŵŵŽďŝůŝƐĞĚ͘dŚĞŶĞŐĂƚŝǀĞĐŽŶƚƌŽůĚŝĚŶŽƚĐŽŶƚĂŝŶĂŶǇƉŚĂŐĞĂnd served 
ĂƐƚŚĞďĂƐĞůŝŶĞĨŽƌŶŽďŝŶĚŝŶŐ͘dŚĞɴϰϬ͘ϭƉŚĂŐĞǁĞƌĞƚĞƐƚĞĚĨŽƌďŝŶĚŝŶŐĂĨĨŝŶŝƚǇƚŽ
ɴϰϬ ĂŶĚ ɴϰϮ͘  dŚĞ ĚĂƚĂ ŝƐ ƌĞƉƌĞƐĞŶƚĞĚ ĂƐ ŵĞĂŶƐ + SE (n=3) expressed as 
absorbance (405nm) from a colorimetric response. 
*Denotes statistical significance (p<0.05) between experimental groups and the 
negative control (without phage). 
 
 
ɴϰϮ͘ϭ>/^ǁŝƚŚƚŚĞɴϰϮdĂƌŐĞƚ  
dŚĞɴϰϮ͘ϭƉŚĂŐĞǁĞƌĞĂŶĂůǇƐĞĚ ĨŽƌďŝŶĚŝŶŐ ƚŽ ƚŚĞ ŝŵŵŽďŝůŝƐĞĚɴϰϬĂŶĚ
ɴϰϮƚĂƌŐĞƚƐ͕ǁŚŝĐŚǁĂƐŽƌŝŐŝŶĂůůǇĚĞĨŝŶĞĚŝŶƚŚĞƉŚĂŐĞĚŝƐƉůĂǇƌŽƵŶĚƐ͘As previously, 
the BSA based blocking buffer was substituted for a no-fat skim milk, which was used 
ƚŽďůŽĐŬƚŚĞƉůĂƚĞǁĞůůƐĂŶĚƚŽĚŝůƵƚĞƚŚĞɴϰϮ͘ϭƉŚĂŐĞ͘dŚĞɴϰϮ͘ϭƉŚĂŐĞƐŚŽǁĞĚĂ
significant increase in the colorimetric response in the wells containing immobilised 
ɴϰϬĂŶĚɴϰϮǁŚĞŶĐŽŵƉĂƌĞĚǁŝƚŚƚŚĞŶĞŐĂƚŝǀĞĐŽŶƚƌŽů͘,ŽǁĞǀĞƌ͕ƚŚĞƌĞǁĂƐĂůƐŽ
a significant response shown in the no target control well.  There was no significant 
ĚŝĨĨĞƌĞŶĐĞďĞƚǁĞĞŶƚŚĞɴϰϬ͕ɴϰϮĂŶĚŶĞŐĂƚŝǀĞĐŽŶƚƌŽůƌĞƐƉŽŶƐĞƐ;&ŝŐƵƌĞϯ͘ϴ). 
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&ŝŐƵƌĞϯ͘ϴ͘YƵĂŶƚŝĨŝĐĂƚŝŽŶďŝŶĚŝŶŐƉŚĂŐĞƐĂŵƉůĞɴϰϮ͘ϭƚŽƚŚĞɴϰϬĂŶĚɴϰϮ
targets by the alternate M13 ELISA.  The phage isolated from the third round of 
ďŝŽƉĂŶŶŝŶŐ͕ĨŽƌƚŚĞɴϰϮƚĂƌŐĞƚ͕ǁĞƌĞŝŶĚŝǀŝĚƵĂůůǇĐŽŶĨŝƌŵĞĚĨŽƌďŝŶĚŝŶŐƚŽɴϰϮ͘
The plaque sĞƋƵĞŶĐĞĚĂƐɴϰϬ͘ϭǁĂƐƵƐĞĚƚŽƚĞƐƚƚŚĞĂůƚĞƌŶĂƚŝǀĞDϭϯ>/^ǁŝƚŚ
ɴϰϬĂŶĚɴϰϮŝŵŵŽďŝůŝƐĞĚ͘dŚĞŶĞŐĂƚŝǀĞĐŽŶƚƌŽůĚŝĚŶŽƚĐŽŶƚĂŝŶĂŶǇƉŚĂŐĞĂŶĚ
ƐĞƌǀĞĚĂƐƚŚĞďĂƐĞůŝŶĞĨŽƌŶŽďŝŶĚŝŶŐ͘dŚĞɴϰϮ͘ϭƉŚĂŐĞǁĞƌĞƚĞƐƚĞĚĨŽƌďŝŶĚŝŶŐ
ĂĨĨŝŶŝƚǇƚŽɴϰϬĂŶĚɴϰϮ͘dhe data is represented as means + SE (n=3) expressed 
as absorbance (405nm) from a colorimetric response. 
*Denotes a significant increase (p<0.05) between experimental groups and the 
negative control (without phage). 
 
 
3.3.3  Inhibition of BACE1 Activity QuĂŶƚŝĨŝĞĚ ďǇ ɴ WƌŽĚƵĐƚŝŽŶ ŝŶ ƚŚĞ ^zϱz
Neuroblastoma Cell Line 
SY5Y Cell Viability Test for BACE1 Inhibitor Treatment 
SY5Y cells were treated with 1nM, 10nM and 100nM of BACE1 specific 
peptide, identified in Chapter 2, to determine a potential apoptotic response.  Cell 
viability was measured using Trypan blue to confirm live cell numbers.  The 1nM, 
10nM and 100nM treatments of BACE1 specific peptide did not show any significant 
difference in the percentage of live cell numbers when compared with the no 
treatment, negative control (Figure 3.9). 
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Figure 3.9.  Cell viability response to treatments with the BACE1 inhibitor.  SY5Y cells 
were treated with varying concentrations of BACE1 inhibitor (1nM, 10nM and 
100nM) and incubated for 24 hours.  The cells were harvested and tested for viability 
in response to the treatment.  With the trypan blue indicator, viable cells were 
determined as a percentage of live cells. No significant difference was observed 
between control and treated cells.  The data is represented as means + SE (n=3).  No 
significant difference was observed (p<0.05). 
 
SY5Y Cell Viability Test for H2O2 and BACE1 Inhibitor Treatment 
Treatment of SY5Y cells with H2O2 causes oxidative stress and an increase in 
ƚŚĞĂŵŽƵŶƚŽĨŝŶƚƌĂĐĞůůƵůĂƌɴ͘dŚĞincrease of oxidative stress on the cell can cause 
an apoptotic response leading to a decrease in viability.  The aim of this study was to 
ŝŶĐƌĞĂƐĞƚŚĞĂŵŽƵŶƚŽĨɴƌĞůĞĂƐĞĚďǇƚŚĞĐĞůůƐĐĂƵƐĞĚďǇŽǆŝĚĂƚŝǀĞƐƚƌĞƐƐƚŚĞŶƚƌĞĂƚ
them with the BACE1 inhibitor.  The cells were treated with both H2O2 and one of the 
1nM, 10nM and 100nM concentrations of BACE1 specific peptide for 24 hours.  
Viability, as a result of the BACE1 inhibitor treatments, was not compromised as there 
was no significant increase or decrease in the number of live cells (Figure 3.10). 
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Figure 3.10.  Cell viability response of SY5Y cells with treatments of H2O2 and the 
BACE1 inhibitor.  ^zϱz ĐĞůůƐ ǁĞƌĞ ƚƌĞĂƚĞĚ ǁŝƚŚ ϮϬϬʅD ŽĨ ,2O2 and varying 
concentrations of BACE1 inhibitor (1nM, 10nM and 100nM) then incubated for 24 
hours.  The cells were harvested and tested for viability in response the BACE1 
inhibitor treatment.  With the trypan blue indicator, viability was determined as the 
percentage of live cells for the treatment.  The 10nM BACE1 inhibitor treatment 
group showed a significant increase in the amount of live cells when compared with 
the other samples.  The data is represented as means + SE (n=3).  
*Denotes a significant increase (p<0.05) in the amount of live cells from the no-BACE1 
inhibitor treatment control. 
 
ɴWƌŽĚƵĐƚŝŽŶďǇ^zϱzĞůůƐĂƌĞZĞĚƵĐĞĚǁŝƚŚϭŝŶŚŝďŝƚŽƌdƌĞĂƚŵĞŶƚ 
dŚĞ ^zϱz ĐĞůůƐ ŶĂƚƵƌĂůůǇ ƉƌŽĚƵĐĞ ɴ ŝŶ ĐƵůƚƵƌĞǁŚŝĐŚ ĐĂŶ ďĞ ŝĚĞŶƚŝĨŝĞĚ ďǇ
ELISA. The capture antibodies biŶĚƚŽĨƌĞĞɴƚŚĂƚŐĞƚƐƌĞůĞĂƐĞĚǁŚĞŶƚŚĞĐĞůůƐĂƌĞ
lysed.  The fluctuations in APP processing by BACE1 determine an increase or 
ĚĞĐƌĞĂƐĞŝŶĞŶǌǇŵĞĂĐƚŝǀŝƚǇďĞĐĂƵƐĞŽĨƚŚĞƌŽůĞŝƚƉůĂǇƐŝŶƚŚĞɴƉƌŽĚƵĐƚŝŽŶ͘dŚĞ
cells were treated with the BACE1 inhibitor to influence these fluctuations and to 
ƌĞĚƵĐĞƚŚĞɴůŽĂĚŝŶŐ͘dŚĞŝŶŚŝďŝƚŝŽŶŽĨϭƉƌĞǀĞŶƚƐƚŚĞĐůĞĂǀĂŐĞŽĨWWĂƚƚŚĞ
ɴ-site creating that longer N-ƚĞƌŵŝŶĂůĨƌĂŐŵĞŶƚŽĨƐWWɴĂŶĚůĞĂǀŝŶŐɴƚŽďĞĐůĞĂǀĞĚ
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ďǇɶ-secretase.  The inhibition of BACE1 results in the production of the p3 fragment 
(non-amyloidogenic) ĂƐɲ-ƐĞĐƌĞƚĂƐĞĐůĞĂǀĞƐWWĂƚƚŚĞɲ-site.   
  
dŚĞ ƉƌŽĚƵĐƚŝŽŶ ŽĨ ɴϰϮ ŝƐ ĚĞƉĞŶĚĞŶƚ ŽŶ ƚŚĞ W^ϭ ŽĨ ɶ-secretase as it 
ĚŝĨĨĞƌĞŶƚŝĂƚĞƐƚŚĞůĞŶŐƚŚŽĨƚŚĞɴŵŽŶŽŵĞƌ͘dŚĞɴϰϮĨƌĂŐŵĞŶƚŝƐƉƌŽĚƵĐĞĚĂůŽƚ
ůĞƐƐƚŚĂŶɴϰϬďƵƚŝƐŵŽƌĞƌĞĂĐƚŝǀĞĚƵƌŝŶŐĂŵǇůŽŝĚŽŐĞŶĞƐŝƐĂŶĚƉůĂƋƵĞƉƌŽĚƵĐƚŝŽŶ͘
dŚĞƌĞĚƵĐƚŝŽŶŽĨɴϰϮŝƐŵŽƌĞŝŵƉŽƌƚĂŶƚƚŚĂŶɴϰϬĂƐŝƚŝŶĨůƵĞŶĐĞƐĂŐŐƌĞŐĂƚŝŽŶŽĨ
monomers and oligomers.      
 
EĂƚƵƌĂůɴϰϬ>ĞǀĞůƐĂre Decreased by BACE1 Inhibitor 
dŚĞɴϰϬƉƌŽĚƵĐĞĚďǇƚŚĞĐĞůůƐǁĂƐƐŝŐŶŝĨŝĐĂŶƚůǇƌĞĚƵĐĞĚĂĨƚĞƌƚŚĞƚƌĞĂƚŵĞŶƚ
with BACE1 inhibitor (Figure 3.11).  The 10-fold increase in peptide treatment, from 
ϭϬŶDƚŽϭϬϬŶD͕ƌĞĚƵĐĞĚƚŚĞĂŵŽƵŶƚŽĨɴƐŝŐŶŝĨŝĐĂŶƚůǇĂŐĂŝŶ͘dŚĞɴƉƌŽĚƵĐĞĚǁĂƐ
a representation of the amount of enzyme activity, which was reduced significantly 
after treatment with the BACE1 enzyme (Figure 3.12). The amount of inhibitor added 
ŝŶƚƌĞĂƚŵĞŶƚŽĨƚŚĞĐĞůůƐǁĂƐŝŶǀĞƌƐĞůǇƉƌŽƉŽƌƚŝŽŶĂůƚŽƚŚĞɴďĞŝŶŐƉƌŽĚƵĐĞĚ͘ 
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Figure 3.11 Effect of BACE1 inhibitor treatment on SY5Y cells on cellular levels of  
ɴϰϬ.  SY5Y cells were harvested at 1x106 cells/ml and treated with varying 
concentrations (1nM, 10nM and 100nM) of BACE1 inhibitor.  The graph columns 
represent the individual BACE1 inhibitor treatments. All treatment groups evoked a 
significant decrease in thĞɴϰϬůŽĂĚŝŶŐǁŚĞŶĐŽŵƉĂƌĞĚƚŽƚŚĞƵŶƚƌĞĂƚĞĚĐĞůůƐ͘dŚĞ
data is represented as means + SE (n=2). 
ΎĞŶŽƚĞƐĂƐŝŐŶŝĨŝĐĂŶƚĚĞĐƌĞĂƐĞ;ƉфϬ͘ϬϱͿ ŝŶɴϰϬƉƌŽĚƵĐƚŝŽŶǁŚĞŶĐŽŵƉĂƌĞĚǁŝƚŚ
the negative control. 
**Denotes a significant decrease (p<0.05) in the amount ĨƌŽŵ ƚŚĞ ɴϰϬ ŝŶ
comparison with all other samples. 
 
Figure 3.12 Percentage inhibition of BACE1 treated SY5Y cells by the quantification 
ŽĨ ɴϰϬ ƉƌŽĚƵĐƚŝŽŶ͘  dŚĞ ϭ ŝŶŚŝďŝƚŽƌ ƚƌĞĂƚĞĚ ^zϱz ĐĞůůƐ ǁĞƌĞ ƚĞƐƚĞĚ ĨŽƌ ɴ
loading as a representation of enzyme activity (Figure 3.11).  The cells were treated 
with varying concentrations of BACE1 inhibitor (1nM, 10nM and 100nM), which all 
showed a significant reduction iŶɴϰϬůŽĂĚŝŶŐ͘dŚĞƉĞƌĐĞŶƚĂŐĞŝŶŚŝďŝƚŝŽŶŝƐƐŚŽǁŶ
above for the 1nM, 10nM and 100nM samples.  This data represents the percentage 
inhibition of BACE1 + SD (n=2). 
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EĂƚƵƌĂůɴϰϮ>ĞǀĞůƐĂre Decreased by BACE1 Inhibitor 
The untreated lysates did not produce aƐŵƵĐŚɴϰϮĂƐɴϰϬ͕ ĂƐ ŝƚ ŝƐ ŶŽƚ
usually translated at the same rate.  However, the amount that was produced 
decreased significantly after the SY5Y cells were treated with the BACE1 inhibitor 
(Figure 3.13). The amount of BACE1 activity, causing the releasĞŽĨɴϰϮ͕ǁĂƐƌĞĚƵĐĞĚ
significantly after the 10-fold increase in inhibitor concentration from 10nM to 
100nM (Figure 3.14). 
 
&ŝŐƵƌĞ ϯ͘ϭϯ͘  ϭ ŝŶŚŝďŝƚŽƌ ƚƌĞĂƚŵĞŶƚ ŽĨ ^zϱz ĐĞůůƐ ĚĞĐƌĞĂƐĞ ŶĂƚƵƌĂů ɴϰϮ
production.  SY5Y cells were harvested at 1x106 cells/ml and treated with varying 
concentrations (1nM, 10nM and 100nM) of BACE1 inhibitor.  The graph columns 
represent the individual BACE1 inhibitor treatments. All treatment groups evoked a 
ƐŝŐŶŝĨŝĐĂŶƚĚĞĐƌĞĂƐĞŝŶƚŚĞɴϰϮůŽĂĚŝŶŐǁŚĞŶĐŽŵƉĂƌĞĚƚŽƚŚĞƵŶƚƌĞĂted cells.  The 
data is represented as means + SE (n=2). 
ΎĞŶŽƚĞƐĂƐŝŐŶŝĨŝĐĂŶƚĚĞĐƌĞĂƐĞ;ƉфϬ͘ϬϱͿ ŝŶɴϰϮƉƌŽĚƵĐƚŝŽŶǁŚĞŶĐŽŵƉĂƌĞĚǁŝƚŚ
the negative control. 
ΎΎĞŶŽƚĞƐ Ă ƐŝŐŶŝĨŝĐĂŶƚ ĚĞĐƌĞĂƐĞ ;ƉфϬ͘ϬϱͿ ŝŶ ƚŚĞ ĂŵŽƵŶƚ ĨƌŽŵ ƚŚĞ ɴϰϮ ŝŶ
comparison with all other samples. 
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Figure 3.14 Percentage inhibition of BACE1 in treated SY5Y cells by the 
ƋƵĂŶƚŝĨŝĐĂƚŝŽŶ ŽĨ ɴϰϮ ƉƌŽĚƵĐƚŝŽŶ͘  The BACE1 inhibitor treated SY5Y cells were 
ƚĞƐƚĞĚĨŽƌɴůŽĂĚŝŶŐĂƐĂƌĞƉƌĞƐĞŶƚĂƚŝŽŶŽĨĞŶǌǇŵĞĂĐƚŝǀŝƚǇ;&ŝŐƵƌĞϯ͘ϭϯͿ͘dŚĞĐĞůůƐ
were treated with varying concentrations of BACE1 inhibitor (1nM, 10nM and 
100nM), which all showed a significant reduction iŶɴϰϮůŽĂĚŝŶŐ͘dŚĞƉĞƌĐĞŶƚĂŐĞ
inhibition is shown by the 1nM, 10nM and 100nM samples.  This data represents the 
percentage inhibition of BACE1 + SD (n=2). 
 
 
H2O2 dƌĞĂƚŵĞŶƚ ŽĨ ^zϱz ĞůůƐ /ŶĐƌĞĂƐĞ ɴ WƌŽĚƵĐƚŝŽŶ ďƵƚ ŝƐ ZĞĚƵĐĞĚ ďǇ ϭ
Inhibitor 
Oxidative stress placed on the SY5Y cells produces an increase in the amount 
ŽĨɴŵŽŶŽŵĞƌƐ͘ƐĂƌĞƐƉŽŶƐĞ͕ɴŚĂƐďĞĞŶƐŚŽǁŶƚŽĂůƐŽŝŶĐƌĞĂƐĞZK^ĐĂƵƐŝŶŐĂ
destructive feedback system furthering AD symptoms.  The cell treatment with H2O2 
ŝŶĐƌĞĂƐĞĚƚŚĞĂŵŽƵŶƚɴ͕ĂƐ this production is regulated by BACE1 cleavage of APP.  
The BACE1 inhibitor was added as a co-treatment with H2O2 ƚŽŵŝŶŝŵŝƐĞ ƚŚĞ ɴ
proliferation. 
 
ɴϰϬ/ƐZĞŐƵůĂƚĞĚďǇƚŚĞϭ/ŶŚŝďŝƚŽƌĨƚĞƌƚŚĞ,2O2 Treatment 
The treatment of SY5Y cells with H2O2 ŝŶĐƌĞĂƐĞĚ ƚŚĞ ĂŵŽƵŶƚ ŽĨ ɴϰϬ
produced when compared to the untreated groups.  The BACE1 Inhibitor significantly 
ƌĞĚƵĐĞĚƚŚŝƐĂŵŽƵŶƚŽĨɴŝŶĂůůĞǆƉĞƌŝŵĞŶƚĂůŐƌŽƵƉƐǁŚŝĐŚĐŽŶƚĂŝŶĞĚϭŶD͕ϭϬŶD
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and 100nM (Figure 3.15).  The 10-fold increase of inhibitor concentration from 10nM 
ƚŽϭϬϬŶDƌĞƐƵůƚĞĚŝŶĂƐŝŐŶŝĨŝĐĂŶƚĚĞĐƌĞĂƐĞŝŶɴϰϬƉƌŽĚƵĐƚŝŽŶ͘dŚĞŵŽƌĞƉĞƉƚŝĚĞ
ďĞŝŶŐĂĚĚĞĚ͕ƚŚĞůĞƐƐɴϰϬǁĂƐďĞŝŶŐƉƌŽĚƵĐĞĚďƵƚ ŝƚǁĂƐŶŽƚŐĞƚƚŝŶŐďĂĐŬƚŽƚŚĞ
natural levels exhibited in the non-H2O2 treatment groups (Figure 3.16).   
 
Figure 3.15 H2O2 ƚƌĞĂƚĞĚ ^zϱz ĐĞůůƐ ɴϰϬ ůĞǀĞůƐ ĚĞĐƌĞĂƐĞ ǁŝƚŚ ϭ ŝŶŚŝďŝƚŽƌ
treatment.  SY5Y cells were co-treated with H2O2 and the BACE1 inhibitor for 24 hours 
ĂŶĚ ƚĞƐƚĞĚ ĨŽƌ ƚŚĞ ɴϰϬ ůŽĂĚŝŶŐ ďǇ ƐĂŶĚǁŝĐŚ >/^͘  dŚĞ ĐĞůůƐǁĞƌĞ ƚƌĞĂƚĞĚǁŝƚŚ
varying concentrations of BACE1 inhibitor, all of which influenced a significant 
ƌĞĚƵĐƚŝŽŶ ;ƉфϬ͘ϬϱͿ ŝŶ ƚŚĞ ĂŵŽƵŶƚ ŽĨ ɴϰϬ ƚŚĂƚ ǁĂƐ ƉƌŽĚƵĐĞĚ ;ΎͿ͘  dŚĞ ϭϬϬŶD
ƚƌĞĂƚŵĞŶƚƐŚŽǁĞĚƐŝŐŶŝĨŝĐĂŶƚůǇƌĞĚƵĐĞĚɴϰϬůĞǀĞůƐǁŚĞŶĐŽŵƉĂƌĞĚǁŝƚŚƚŚĞϭϬŶD
(**). The data is represented as means + SE (n=2). 
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Figure 3.16 Percentage inhibition of BACE1 in co-treated (H2O2 and inhibitor) 
ƉĞƉƚŝĚĞ^zϱzĐĞůůƐďǇƚŚĞƋƵĂŶƚŝĨŝĐĂƚŝŽŶŽĨɴϰϬƉƌŽĚƵĐƚŝŽŶ͘  The BACE1 inhibitor 
ƚƌĞĂƚĞĚ^ zϱzĐĞůůƐǁĞƌĞƚĞƐƚĞĚĨŽƌɴϰϬůŽĂĚŝŶŐĂƐĂƌĞƉƌĞƐentation of enzyme activity 
(Figure 3.15).  The cells were co-treated with both H2O2 and varying concentrations 
of BACE1 inhibitor (1nM, 10nM and 100nM).  All samples showed a significant 
ƌĞĚƵĐƚŝŽŶŝŶɴϰϬůŽĂĚŝŶŐ;&ŝŐƵƌĞϯ͘ϭϱͿǁŝƚŚƚŚĞƉĞƌĐĞŶƚĂŐĞŝŶŚŝďŝƚŝon shown above 
each treatment.  This data represents the percentage inhibition of BACE1 + SD (n=2).  
 
 
ɴϰϮ/ƐZĞŐƵůĂƚĞĚďǇƚŚĞϭ/ŶŚŝďŝƚŽƌĂĨƚĞƌ,2O2 Induced Oxidative Stress 
The treatment of SY5Y cells with H2O2 ŝŶĐƌĞĂƐĞĚ ƚŚĞ ĂŵŽƵŶƚ ŽĨ ɴϰϮ
produced when compared with the untreated samples.  When co-treated with the 
ϭ /ŶŚŝďŝƚŽƌ͕ ɴϰϮ ůĞǀĞůƐ ǁĞƌĞ ƐŝŐŶŝĨŝĐĂŶƚůǇ ƌĞĚƵĐĞĚ ĂĐƌŽƐƐ Ăůů ĐŽŶĐĞŶƚƌĂƚŝŽŶƐ
(1nM, 10nM and 100nM) (Figure 3.17).  The 10-fold increase of inhibitor 
ĐŽŶĐĞŶƚƌĂƚŝŽŶ͕ ĨƌŽŵ ϭϬŶD ƚŽ ϭϬϬŶD͕ ƌĞƐƵůƚĞĚ ŝŶ Ă ƐŝŐŶŝĨŝĐĂŶƚ ĚĞĐƌĞĂƐĞ ŝŶ ɴϰϮ
ƉƌŽĚƵĐƚŝŽŶ͘dŚĞŵŽƌĞŝŶŚŝďŝƚŽƌĂĚĚĞĚ͕ƚŚĞůĞƐƐɴǁĂƐƉƌŽĚƵĐĞĚďƵƚŝƚǁĂƐŶŽƚƚŽ
the natural levels exhibited in the non-H2O2 treatment groups (Figure 3.18). 
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Figure 3.17 H2O2 ƚƌĞĂƚĞĚ ^zϱz ĐĞůůƐ ɴϰϮ ůĞǀĞůƐ ĚĞĐƌĞĂƐĞ ǁŝƚŚ ϭ ŝŶŚŝďŝƚŽƌ
treatment.  SY5Y cells were co-treated with H2O2 and the BACE1 inhibitor for 24 hours 
ĂŶĚ ƚĞƐƚĞĚ ĨŽƌ ƚŚĞ ɴϰϮ ůŽĂĚŝŶŐ ďǇ ƐĂŶĚǁŝĐŚ >/^͘  dŚĞ ĐĞůůƐǁĞƌĞ ƚƌĞĂƚĞĚǁŝƚŚ
varying concentrations of BACE1 inhibitor, all of which influenced a significant 
ƌĞĚƵĐƚŝŽŶ ;ƉфϬ͘ϬϱͿ ŝŶ ƚŚĞ ĂŵŽƵŶƚ ŽĨ ɴϰϮ ƚŚĂƚ ǁĂƐ ƉƌŽĚƵĐĞd (*).  The 100nM 
ƚƌĞĂƚŵĞŶƚƐŚŽǁĞĚƐŝŐŶŝĨŝĐĂŶƚůǇƌĞĚƵĐĞĚɴϰϮůĞǀĞůƐǁŚĞŶĐŽŵƉĂƌĞĚǁŝƚŚƚŚĞϭϬŶD
(**). The data is represented as means + SE (n=2). 
 
Figure 3.18 Percentage inhibition of BACE1 in co-treated (H2O2 and inhibitor) 
peptide SY5Y cells by the quĂŶƚŝĨŝĐĂƚŝŽŶŽĨɴϰϮƉƌŽĚƵĐƚŝŽŶ͘  The BACE1 inhibitor 
ƚƌĞĂƚĞĚ^ zϱzĐĞůůƐǁĞƌĞƚĞƐƚĞĚĨŽƌɴϰϮůŽĂĚŝŶŐĂƐĂƌĞƉƌĞƐĞŶƚĂƚŝŽŶŽĨĞŶǌǇŵĞĂĐƚŝǀŝƚǇ
(Figure 3.17).  The cells were co-treated with both H2O2 and varying concentrations 
of BACE1 inhibitor (1nM, 10nM and 100nM).  All samples showed a significant 
ƌĞĚƵĐƚŝŽŶŝŶɴϰϮůŽĂĚŝŶŐ;&ŝŐƵƌĞϯ͘ϭϳͿǁŝƚŚƚŚĞƉĞƌĐĞŶƚĂŐĞŝŶŚŝďŝƚŝŽŶƐŚŽǁŶĂďŽǀĞ
each treatment.  This data represents the percentage inhibition of BACE1 + SD (n=2). 
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3.4  Discussion  
dŚĞƉƌŽĚƵĐƚŝŽŶŽĨɴŐĞŶĞrated in human neuronal cells, maintains the ability 
to aggregate into dimers, trimers and oligomers leading to amyloid plaque 
formation.185 dŚĞďŝŶĚŝŶŐĂĨĨŝŶŝƚǇŽĨɴĨƌĂŐŵĞŶƚƐƌĞƐƵůƚƐŝŶĂƋƵŝĐŬƚƌĂŶƐŝƚŝŽŶĨƌŽŵ
the monomeric state to the more formal protofibrils, spheres, ADDL and 
micelles.56,185,186 These more functional three-dimensional structures resulting from 
ɴƉƌŽĚƵĐƚŝŽŶ͕ůĞĂĚƚŽƚŚĞŵŽƌĞĐŽŵƉůĞǆĞĨĨĞĐƚŽĨĐĞůůĂƉŽƉƚŽƐŝƐĂŶĚƚŚĞĞǀĞŶƚƵĂů
consequences of Alzheimer’s disease related symptoms.  This study was aimed to 
ĐŚĂƌĂĐƚĞƌŝƐĞ ƚŚĞ ϭ ŝŶŚŝďŝƚŽƌ͛Ɛ ;ŝĚĞŶƚŝĨŝĞĚ ŝŶ ŚĂƉƚĞƌ ϮͿ ĂďŝůŝƚǇ ƚŽ ƌĞĚƵĐĞ ɴ
loading in a human neuronal cell line. The use of a neuronal cell line creates an 
environment that potentially simulates the natural processing events likely to occur 
in vivo, but just on a smaller scale.  Determining efficacy of the inhibitor relies on the 
ability to calculate the desired outcome.   
 
dŚĞ ĚĞǀĞůŽƉŵĞŶƚ ŽĨ ĂŶ ɴϰϬ ĂŶĚ ɴϰϮ ƐƉĞĐŝĨŝĐ >/^ ƵƚŝůŝƐĞĚ ƚŚĞ ƉŚĂŐĞ
display and biopanning techniques to identify peptide specific binders, the same that 
were used successfully to identify an inhibitor for BACE1.  The biopanning rounds 
were completed using the circular heptapeptide phage display library as opposed the 
dodecapeptide (used in Chapter 2) because it was almost a quarter the length of the 
target.  The first round of biopanning provided viable eluate sizes for both targets and 
were continued to the second round to amplify the candidates.  However, the second 
ƌŽƵŶĚĞůƵĂƚĞĨŽƌ ƚŚĞɴϰϬƚĂƌŐĞƚ ƌĞŐƌĞƐƐĞĚƐƵŐŐĞƐƚŝŶŐ ƚŚĞĐĂŶĚŝĚĂƚĞƐǁĞƌĞĞŝƚŚĞƌ
adhering non-specifically to the target or the affinity was not adequate enough to 
104 
 
ǁŝƚŚƐƚĂŶĚ ƚŚĞ ŝŶĐƌĞĂƐĞ ŝŶ ǁĂƐŚ ďƵĨĨĞƌ ĐŽŶĐĞŶƚƌĂƚŝŽŶ͘  dŚĞ ɴϰϮ ƚĂƌŐĞƚ ĞůƵĂƚĞ
increased as the binding phage were pooled an amplified with each round. The final 
round plaques were picked and sequenced for identification of the peptide amino 
acid residues.   
 
The sequenced DNA provided a motif across all candidates and the remaining 
ƉŚĂŐĞǁĞƌĞƵƐĞĚĨŽƌƚŚĞ>/^ ƚŽĐŽŶĨŝƌŵďŝŶĚŝŶŐ͘ ŽƚŚɴƚĂƌŐĞƚƐǁĞƌĞƵƐĞĚƚŽ
confirm this binding as the aim was to find a universal candidate.  Both candidate 
samples showed significant binding to the target when compared to the no phage 
negative control.  However, when compared with the no target control, the same 
result of significant binding was achieved.  The no target control did not contain any 
ɴĚƵƌŝŶŐƚŚĞŝŵŵŽďilisation stage of the ELISA which means the phage were binding 
non-specifically.  A blocking buffer control was also conducted to remove the BSA 
from experiment as it is a large protein and could have been overshadowing the 
ƐŵĂůůĞƌ ɴϰϬ ĂŶĚ ɴϰϮ ƚĂƌŐĞƚƐ͘  dŚĞ ƌĞƐƵůƚŝŶŐ ďŝŶĚŝŶŐ ǁĂƐ ůĞƐƐ ƚŚĂŶ ƚŚĞ ɴ
experimental samples but it was still significantly higher than the no phage negative 
control.  Unfortunately, the candidate did not adequately bind to the target and was 
not investigated further. 
   
An alternative phage display technique using magnetic bead capture was used 
to provide the small 40 and 42 residue targets better access to the phage candidates.  
The direct target coating method required the use of BSA to block the remaining area 
around the immobilisĞĚɴ͕ďƵƚĐĂŶŝŶƚĞƌĨĞƌĞǁŝƚŚĂĐĐĞƐƐŝďŝůŝƚǇĨŽƌƚŚĞĐĂŶĚŝĚĂƚĞƐ͘
dŚĞďĞĂĚĐĂƉƚƵƌĞĂƉƉƌŽĂĐŚƌĞŵŽǀĞĚƚŚĞƌĞůŝĂŶĐĞŽĨ^ďůŽĐŬŝŶŐďǇŬĞĞƉŝŶŐƚŚĞɴ
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targets in solution where they had a better area to interact with the phage.  After the 
first round of biopanning, the eluate size for both targets had increased to viable 
levels and the subsequent rounds were completed.   
 
The subsequent rounds of biopanning provided three candidate sequences 
for each target.  All candidates were tested to confirm binding by M13 phage ELISA, 
ǁŚŝĐŚƐŚŽǁĞĚƐŝŐŶŝĨŝĐĂŶƚďŝŶĚŝŶŐƚŽƚŚĞƌĞƐƉĞĐƚŝǀĞɴƉĞƉƚŝĚĞĂŶĚĨŽƌĐƌŽƐƐƌĞĂĐƚŝǀŝƚǇ
to the other target.  While the results showed universally significant binding to the 
targets, when tested as a no-target control there was also significant results.  The 
candidates were again binding non-specifically.  As an alternative, a different M13 
ELISA protocol was performed with a different antibody but the same results 
eventuated, the phage were not binding to the targets.  With the targets being just 
40 and 42 amino acids long, the immobilisation techniques were not sensitive enough 
to provide a valid candidate.   
  
The current inhibitors of Solanzumab and Gantenerumab are both utilising 
ĂŶƚŝďŽĚǇƐƉĞĐŝĨŝĐƚƌĞĂƚŵĞŶƚĨŽƌɴǁŝƚŚƐƵĐĐĞƐƐ͘162,163  The current late phase trials 
are testing for specific binding affinity of the antibodies and also the ability to clear 
ƚŚĞĂůƌĞĂĚǇĨŽƌŵĞĚƉůĂƋƵĞƐ͘dŚĞƐƵĐĐĞƐƐŽĨɴƐƉĞĐŝĨŝĐĂŶƚŝďŽĚŝĞƐĐŽƵůĚƉƌŽǀŝĚĞĂŶ
alternative by using antibody display to identify a new candidate.  Since a successful 
ƉĞƉƚŝĚĞůŝŐĂŶĚǁĂƐŶŽƚŝĚĞŶƚŝĨŝĞĚǀŝĂƉŚĂŐĞĚŝƐƉůĂǇ͕ĐŽŵŵĞƌĐŝĂůůǇĂǀĂŝůĂďůĞɴϰϬĂŶĚ
ɴϰϮƐƉĞĐŝĨŝĐ>/^ŬŝƚƐǁĞƌĞƵƐĞĚĂƐĂŶĂůƚĞƌŶĂƚŝǀĞƚŽĚĞƚĞƌŵŝŶĞϭĂĐƚŝǀŝƚǇŝŶ
SY5Y cells.   
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The onset of AD is met by the accumulation of NFTs and amyloid plaques with 
the underlying pressure of oxidative stress.204  The deposition of plaques and tangles 
cause significant damage to surrounding cells by triggering an increase in oxidative 
stress.  Under oxidative stress, the SY5Y cells have been reported to influence APP 
ƉƌŽĐĞƐƐŝŶŐďǇŝŶĐƌĞĂƐŝŶŐƚŚĞĂŵŽƵŶƚŽĨĐǇƚŽƐŽůŝĐɴ͘200 In this study, SY5Y cells were 
treated with H2O2 to simulate oxidative stress to increase the cleavage of APP.  The 
cells were tested both with and without H2O2 and both produced a significant amount 
ŽĨɴϰϬĂŶĚɴϰϮ͘dŚĞƚƌĞĂƚŵĞŶƚŽĨ,2O2 did not affect cell viability, even with the 
eǆƚƌĂƐƚƌĞƐƐ͕ďƵƚĚŝĚƐŝŐŶŝĨŝĐĂŶƚůǇŝŶĐƌĞĂƐĞƚŚĞĂŵŽƵŶƚŽĨɴƉƌŽĚƵĐĞĚĂďŽǀĞƚŚĂƚŽĨ
the untreated cells.   
 
dŚĞ ƵŶƚƌĞĂƚĞĚ ^zϱz ĐĞůůƐ ƉƌŽĚƵĐĞĚ ƐŝŐŶŝĨŝĐĂŶƚ ĂŵŽƵŶƚƐ ŽĨ ďŽƚŚ ɴϰϬ ĂŶĚ
ɴϰϮ ďƵƚ ƚŚŝƐ ĂŵŽƵŶƚ ǁĂƐ ƌĞĚƵĐĞĚ ƐŝŐŶŝĨŝĐĂŶƚůǇ ĂĨƚĞƌ ƚƌĞĂƚŵĞŶƚ ǁŝƚŚ ƚŚĞ ϭ 
inhibitor.  The sample containing a 100nM concentration of BACE1 inhibitor 
incorporated into the media, did not affect cell viability but maintained the highest 
ĂŵŽƵŶƚ ŽĨ ŝŶŚŝďŝƚŝŽŶ ĂďŽǀĞ ƚŚĞ ϭŶD ĂŶĚ ϭϬŶD ƚƌĞĂƚŵĞŶƚƐ͘ dŚĞ ĂŵŽƵŶƚ ŽĨ ɴ
produced was a direct result of APP cleavage by BACE1, with a reduction of 25% for 
ɴϰϬĂŶĚϮϮйŽĨɴϰϮĂƐĂƌĞƐƉŽŶƐĞƚŽƚŚĞϭŝŶŚŝďŝƚŽƌƚƌĞĂƚŵĞŶƚ͘ 
 
 dŚĞŝŶĐƌĞĂƐĞĚĂŵŽƵŶƚŽĨɴĚƵĞƚŽŽǆŝĚĂƚŝǀĞƐƚƌĞƐƐĐĂƵƐĞĚĞůĞǀĂƚĞĚůĞǀĞůƐŽĨ
APP cleavage by BACE1, but BACE1 inhibitor treatments of 100nM concentration 
ĐĂƵƐĞĚĂϭϮйƌĞĚƵĐƚŝŽŶŽĨɴϰϬĂŶĚϮϭйŽĨɴϰϮ͘dŚĞɴϰϮ͕ǁŚŝůĞƉƌŽĚƵĐĞĚŝŶůĞƐƐ
ĂŵŽƵŶƚƐ͕ ŝƐŵŽƌĞĂŵǇůŽŝĚŽŐĞŶŝĐŵĂŝŶƚĂŝŶŝŶŐĂŚŝŐŚĞƌďŝŶĚŝŶŐĂĨĨŝŶŝƚǇĨŽƌŽƚŚĞƌɴ
fragments (38-43) causing acute plaque generation.205,206 
107 
 
 For the treatments to be successful by preventing this pathway, the inhibitor 
would need to remain unchanged within the media for the 24 hour time period.  To 
apply maximum effectiveness, the peptide needed to bind to naturally produced 
BACE1 and inhibit the cleavage of APP while still being able to transport across the 
membrane into the cell.   The BACE1 inhibitor peptide was able to reduce BACE1 
activity within the SY5Y neuronal cell line while under oxidative stress, thus 
generating less of the oligomer ƉƌŽĚƵĐŝŶŐɴ͘  dŚĞ ƌĞĚƵĐƚŝŽŶŽĨ ĐĞůůƵůĂƌɴ ĐŽƵůĚ
therefore, reduce the potential for plaque generation but would need to be tested in 
an in vivo model.  
 
3.5  Conclusion 
The biopanning and phage display techniques were used to identify binders 
ƚŽƚŚĞɴƉĞƉƚŝĚĞƐĂƐƐŽĐŝĂƚĞĚǁŝƚŚƉůĂƋƵĞŐĞŶĞƌĂƚŝŽŶŝŶƉĂƚŝĞŶƚƐǁŝƚŚ͘dŚĞ
ƵŶŝǀĞƌƐĂůɴϰϬĂŶĚɴϰϮƉĞƉƚŝĚĞƐŝƐŽůĂƚĞĚĚŝĚŶŽƚĞǆŚŝďŝƚƚŚĞƐƉĞĐŝĨŝĐƌĞƋƵŝƌĞŵĞŶƚƐ
needed to manufacture an ELISA measurŝŶŐϭĂĐƚŝǀŝƚǇŝŶŶĞƵƌŽŶĂůĐĞůůƐ͘ɴϰϬ
ĂŶĚɴϰϮƐƉĞĐŝĨŝĐ>/^ƐǁĞƌĞƵƐĞĚŝŶƐƚĞĂĚƚŽĚĞƚĞƌŵŝŶĞǁŚĞƚŚĞƌƚŚĞϭ
inhibitor could inhibit APP cleavage upregulation.  The BACE1 inhibitor was able to 
ƌĞĚƵĐĞɴƉƌŽĚƵĐƚŝŽŶŝŶŶĞƵƌŽŶĂů^zϱzĐĞůůƐďǇƉƌĞǀĞŶƚing the cleavage of APP, 
thereby providing an exciting promise for future studies.
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Chapter 4 
 
Characterisation of BACE1 Inhibitor Effects on mRNA and 
Protein Levels in Human Neuronal Cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
Aims 
This chapter aimed to define the proteomic and genomic changes of BACE1 
and APP in response to the BACE1 inhibitor.  With the increase of inhibitor 
concentration, and reduction in enzyme activity, the first aim is to determine whether 
a genomic compensation would regenerate levels of active BACE1.  With the reduced 
activity of BACE1, unable to process APP, the second aim is to determine whether 
translation and protein levels would compensate and increase transcription. 
 
Methods 
SY5Y cells were treated for 24 hours with varying concentrations of BACE1 
inhibitor (1nM, 10nM and 100nM) and lysed on the plate and proteins removed.  The 
lysates were separated on 1-dimentional gel electrophoresis and transferred to a 
nitrocellulose membrane following the Western blot technique. APP and BACE1 
specific monoclonal antibodies were used to detect protein levels, which were 
quantified by densitometry.  Lysates were also used to define mRNA levels by 
quantitative real-time polymerase chain reaction (qPCR) and comparison of cycle 
thresholds of cDNA for BACE1 and APP. 
 
Results 
The BACE1 inhibitor treated SY5Y cells were grown to conduct Western blots 
with fresh lysate.  BACE1 and APP proteins were transferred onto nitrocellulose and 
detected using anti-BACE1 and anti-APP antibodies.  Densitometric analysis was used 
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ƚŽĐŽŵƉĂƌĞƉƌŽĚƵĐƚŝŽŶůĞǀĞůƐǁŝƚŚƚŚĞɴ-actin housekeeping protein.  Comparison of 
gel band density did not identify any significant increase in BACE1 levels after 
treatment with the inhibitor.  However, as the peptide concentration increased there 
was significant increase in the amount of APP available.  Treated cells were lysed to 
isolate the RNA, which was reverse transcribed into cDNA.  The cDNA was analysed 
for the cycle threshold of ďŽƚŚϭĂŶĚWW͘tŚĞŶĐŽŵƉĂƌĞĚĂŐĂŝŶƐƚƚŚĞɴ-actin 
housekeeping gene, there was no significant increase in the mRNA levels of both 
BACE1 and APP. 
 
Conclusion 
The increase in BACE1 inhibitor treatment did not generate an increase in the 
amount of available BACE1 in the SY5Y cell line.  As a result, there was an increase in 
the amount of APP present in the lysates.  Even with the rapid processing of APP 
within the intermembrane space, there was an increase in amount of available 
protein as a result of the BACE1 inhibition.  From a genomic perspective, the 
fluctuation in protein amount could have developed a feedback system to maintain 
homeostasis but this was not observed from the qPCR that was performed.  BACE1 
and APP cDNA levels remained consistent over the treatment period. The added 
BACE1 inhibitor treatments did not interfere with normal processing and production 
of BACE1, just the activity that processes APP.   
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4.1  Introduction  
The production of amyloid plaques is a result of the sequential cleavage of 
APP.  The post-ƚƌĂŶƐůĂƚŝŽŶĂů ĐůĞĂǀĂŐĞ ŽĨ WW ďǇ ϭ͕ ŝŶƐƚĞĂĚ ŽĨ ɲ-secretase, 
extends the released p3 peptide fragment to the 38-ϰϮĂŵŝŶŽĂĐŝĚɴ͘207  While the 
Ɖϯ ĨƌĂŐŵĞŶƚ ĚŽĞƐŶŽƚ ĐĂƵƐĞĚŝƐĞĂƐĞ͕ ƚŚĞɴ ĨƌĂŐŵĞŶƚƐ ĐĂŶĂŐŐƌĞŐĂƚĞ ƚŽ ĨŽƌŵ ĂŶ
amyloid plaque causing the symptoms associated with AD.207 
 
The enzymatic activity of BACE1 is fƵŶĚĂŵĞŶƚĂů ƚŽ ƚŚĞ ƉƌŽĚƵĐƚŝŽŶ ŽĨ ɴ͘
Single gene knock-in of human BACE1 (BACE1+/-) to a murine model, that would 
otherwise not develop amyloidogenesis, reported AD like pathologies.208 However, 
BACE1 haploinsufficiency (BACE1 +/-) in 5XFAD mice, resulted in a reduction of APP 
cleavage and an inĐƌĞĂƐĞŽĨƐWWɲŵĂŝŶƚĂŝŶŝŶŐɲ-secretase activity.  As a result, this 
ĂůƐŽ ĐƌĞĂƚĞĚĂĚĞĐƌĞĂƐĞ ŝŶ ƚŚĞƉƌŽĚƵĐƚŝŽŶŽĨϵϵĂŶĚ ƐWWɴ͕ ŝŶĐůƵĚŝŶŐɴ͘209 The 
reduction of BACE1 production was able to prompt a delay in disease progression but 
could not prevent the deposition of plaques at a later age.  The availability of BACE1 
ĐůĞĂǀĞĚƉƌŽĚƵĐƚƐ ;ϵϵĂŶĚɴͿ ŝŶĂďƌĂŝŶƚŚĂƚ ŝƐ ŝŶĐŽŐŶŝƚŝǀĞĚĞĐůŝŶĞ͕ ŝŶƐƵĨĨŝĐŝĞŶƚůǇ
regulates plaque deposition and disease development. 
  
The complete knockdown of BACE1 (BACE1-/-) in normally producing mice 
demonstrates poor development after birth, increasing the frequency of death.108 
Surviving mice with the knockdown remained smaller and presented hyperactive 
behaviours. The detrimental effect resulting from the complete removal of BACE1 is 
ŽďǀŝŽƵƐ ďƵƚ Ăƚ ƚŚĞ ƐĂŵĞ ƚŝŵĞ͕ ƉƌŽĚƵĐƚŝŽŶ ŽĨ ɴ ǁĂƐ ĚĞƉůĞƚĞĚ ŝŶ ŶĞƵƌŽŶƐ͘ dŚĞ
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overexpression of BACE1 has been found to compliment neurite outgrowth by 
ĐůĞĂǀŝŶŐ ƚŚĞ ɴϰ ƐƵďƵŶŝƚ ŽĨ ǀŽůƚĂŐĞ-gated sodium channels.210 BACE1 also has an 
ƵƉƐƚƌĞĂŵĞĨĨĞĐƚŽŶŵĞŵďƌĂŶĞ ƐŽĚŝƵŵĐƵƌƌĞŶƚƐ͕ ŝŶĨůƵĞŶĐŝŶŐ ƚŚĞɴϮ ƐƵďƵŶŝƚŽĨ ƚŚĞ
voltage-gated sodium channels, which stimulates neuronal activity.211 The increase 
in the cellular BACE1 would also result ŝŶƚŚĞƉƌŽůŝĨĞƌĂƚŝŽŶŽĨɴ͘ 
 
The localised response to plaque generation promotes BACE1 production and 
ƚŚĞƌĞĨŽƌĞ͕ĂĐƚŝǀŝƚǇŝŶĐƌĞĂƐŝŶŐƚŚĞƉƌŽĚƵĐƚŝŽŶŽĨɴ͘dŚĞĂŵŽƵŶƚŽĨϭĐEĚŽĞƐ
not fluctuate in the surrounding areas of the general neuronal populous but there is 
ĂŶŝŶĐƌĞĂƐĞŝŶϭĂĐƚŝǀŝƚǇƐƵƌƌŽƵŶĚŝŶŐɴϰϮŐĞŶĞƌĂƚĞĚƉůaques.90 The increase in 
activity, but not gene translation, suggests that a feedback mechanism could be 
activating BACE1 rather than increasing enzyme numbers.  This feedback could be a 
ƌĞƐƉŽŶƐĞƚŽƚŚĞĂŵŽƵŶƚŽĨϭĂůƌĞĂĚǇƉƌŽĚƵĐĞĚŽƌɴϰϮĐŽƵůĚďĞŝŶĨůƵĞŶĐŝŶŐƚŚĞ
cleavage of APP.   
 
WWŝƐƚŚĞŽŶůǇĨĂŵŝůǇŵĞŵďĞƌƚŚĂƚĐĂŶƉƌŽĚƵĐĞɴ but a reduction of total 
protein expression can influence synaptic formation.212 An APP triple knockout (APP, 
APP like protein 1 (APLP1) and 2 (APLP2)) caused underdevelopment of 
neuromuscular synapses and cortical dysplasia involving the Cajal-Retzuis cells 
implicating functional brain development.212-214 However, the increased expression 
of APP in Down syndrome patients causes early onset AD symptoms.  Individuals with 
trisomy 21 have a third copy of the APP as it is located within that chromosome.215 
The increase in APP translation, as a consequence of the extra chromosome, 
ŝŶĐƌĞĂƐĞƐƚŚĞĂŵŽƵŶƚŽĨɴǁŝƚŚϭŵĂŝŶƚĂŝŶŝŶŐnormal activity levels.   
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The importance of both BACE1 and APP to other alternative pathways equally 
cause detrimental effects.  The up and down regulation of activity could cause 
detrimental effects for the patient who is the one that needs to be treated.  In this 
chapter, the aim is to determine the in vitro gene expression response to BACE1 
inhibition and if it causes a compensation effect to maintain homeostasis. 
 
4.2  Materials and Methods 
4.2.1  SY5Y Cell Treatments 
SY5Y cells were grown to 80% confluence and removed from the flask using 
3ml of 0.25% trypsin/EDTA/PBS and quenched with 7ml of media.  The cells were 
transferred to a six-well plate at a density of 1x106 cells/ml and allowed to adhere 
overnight.  Media was pre-treated for 24 hours with the BACE1 peptide inhibitor 
(characterised in Chapter 2) to 1, 10 and 100nM in media.  The old media was 
replaced with the treatment media and the cells incubated for 24 hours.  The media 
was removed and the monolayer washed with PBS.  The cells were lysed in the wells 
with CelLytic MT (Sigma-Aldrich, Australia) and protein concentration determined 
with a Qubit fluorometer (Life Technologies, Australia).  The lysates were used 
immediately for Western blots. 
 
4.2.2  Western Blot Analysis of BACE1 Inhibitor Treated SY5Y with BACE1 and APP 
Monoclonal Antibodies   
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS PAGE) 
Novex Tris-glycine, 10-well, 1mm mini-gels (Life Technologies, Australia) were 
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brought to room temperature and wells rinsed with dH2O.  Samples were prepared 
ďǇ ŵŝǆŝŶŐ ϱʅů dƌŝƐ-ŐůǇĐŝŶĞ ^^ ƐĂŵƉůĞ ďƵĨĨĞƌ͕ ϭʅů EƵW' ZĞĚƵĐŝŶŐ ŐĞŶƚ ;>ŝĨĞ
Technologies) aŶĚƐĂŵƉůĞůǇƐĂƚĞƐĂŵƉůĞƚŽϭϬʅů͘dŚĞĐĞůůůǇƐĂƚĞƐǁĞƌĞƐƚĂŶĚĂƌĚŝƐĞĚ
to 15μŐƉĞƌǁĞůůĂŶĚĂĚũƵƐƚĞĚƚŽϱʅůǁŝƚŚĞǆƚƌĂĞů>ǇƚŝĐDd͘WƌŝŽƌƚŽĨŝůůŝŶŐƚŚĞǁĞůůƐ͕
samples were mixed thoroughly and heated to 85°C for two minutes.  
 
The gels were brought to room temperature and the samples added with a 
SeeBlue Pre-stained Standard in lane 1.  Gels were added to the X-Cell SureLock (Life 
Technologies, Australia) electrophoresis tank with Novex Tris-glycine SDS running 
buffer (Life Technologies, Australia) in the upper and lower chambers.  The 
electrophoresis was run over approximately 90 minutes at a constant 125V.   
 
Protein Transfer 
The gels were removed from the X-Cell SureLock electrophoresis tank and 
washed with dH2O.  Six blotting pads and two filter papers were immersed in transfer 
buffer solution, NuPAGE transfer buffer, NuPAGE antioxidant, methanol and dH2O, 
and all the bubbles removed.  Using a chisel, the gel cassettes were disassembled and 
the gel foot removed.  The transfer sandwich was constructed by first adding three 
blotting pads to the base of the transfer core, followed by one of the pieced of 
blotting paper, the freshly run gel and the nitrocellulose membrane with all the 
bubbles removed with a Western blot roller.  On top of the membrane was another 
piece of blotting paper and the last three blotting pads.  The core was squeezed 
together, placed into the X-Cell SureLock tank and filled to the top with transfer 
buffer; the lower chamber filled with dH2O.  The proteins were transferred for two 
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hours at a constant 25V.  The core was removed and disassembled with BACE1 and 
APP to be identified with the WesternBreeze chromogenic Western blot 
immunodetection kit.  The membrane was placed in a blocking buffer for 30 minutes 
on a rotary shaker.  The excess blocking buffer was washed off twice for five minutes 
with dH2O and replaced with a primary antibody solution (BACE1 and APP 
monoclonal antibodies were diluted 1:5000 in blocking buffer) for one hour.  The 
membrane was washed three times for five minutes with the antibody wash solution 
prior to a 30-minute incubation with a secondary antibody (anti-mouse).  The 
membrane was washed another three times for five minutes with wash buffer then 
a further two times for two minutes each with dH2O.  The NBT/BCIP (nitro-blue 
tetrazolium and 5-bromo-4-chloro-3'-indolyphosphate) chromogen was added for 60 
minutes then washed twice for two minutes with dH2O.  Until scanned with the 
ImageQuant LAS-4000 chemidoc (GE Healthcare Life Sciences, Australia), the 
membranes were ƐƚŽƌĞĚŝŶW^Ăƚϰȗ͘ 
 
4.2.3  qPCR of cDNA from BACE1 Inhibitor Treated SY5Y Cells 
SY5Y Cell Treatments 
SY5Y cells were grown to 80% confluence and removed from the flask using 
3ml of 0.25% trypsin/EDTA/PBS and quenched with 7ml of media.  The cells were 
transferred to a six-well plate and allowed to adhere overnight.  Media was pre-
treated for 24 hours with the BACE1 peptide inhibitor (characterised in Chapter 2) to 
1, 10 and 100nM in media.  The old media was replaced with the treatment media 
and the cells incubated for 24 hours.  The media was removed and the monolayer 
washed twice with PBS.  The cells were removed from the wells with 
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trypsin/EDTA/PBS and quenched with media.  The cells were pelleted at 1,200xg for 
five minutes and the media discarded.  The pellet was suspended in 1ml PBS and 
transferred to a microcentrifuge tube.  The cells were pelleted again at 1,200xg for 
five minutes and the PBS removed.  The pellets were stored in the -ϴϬȗĨƌĞĞǌĞƌƵŶƚŝů
ready to be used. 
 
Isolation of RNA 
tŝƚŚƚŚĞĐĞůůƐƐƚŽƌĞĚĂƐĂĨƌŽǌĞŶƉĞůůĞƚ͕ϮϬʅůɴ-mercaptoethanol was added 
to for every 2ml of lysis buffer (PureLŝŶŬZEŵŝĐƌŽŬŝƚͿĂŶĚϯϱϬʅůĂĚĚĞĚƚŽƚŚĞƚƵďĞ͘
The cells were mixed by vortexing then passed through a 18-21 gauge syringe 5-10 
ƚŝŵĞƐƚŽƚŚŽƌŽƵŐŚůǇŚŽŵŽŐĞŶĂƚĞƚŚĞůǇƐĂƚĞ͘ϯϱϬʅůŽĨϳϬйĞƚŚĂŶŽůǁĂƐĂĚĚĞĚƚŽĞĂĐŚ
lysate and vortexed again briefly.  The lysate was transferred to the top of a PureLink 
Column with collection tube and centrifuged at 12,000xg for 1minute at room 
ƚĞŵƉĞƌĂƚƵƌĞ͕ĚŝƐĐĂƌĚŝŶŐƚŚĞĨůŽǁƚŚƌŽƵŐŚ͘dŚĞŵĞŵďƌĂŶĞǁĂƐǁĂƐŚĞĚǁŝƚŚϯϱϬʅůŽĨ
buffer 1 and centrifuged at 12,000xg for 1 minute, discarding the follow through.  
dŚĞŶϮϬʅůŽĨEĂƐĞďƵĨĨĞƌ;ϭ͗ϭWƵƌĞ>ŝŶŬEĂƐĞƐŽůƵƚŝŽŶĂŶĚEĂƐĞďƵĨĨĞƌͿǁĂƐĂĚĚĞĚ
ƚŽƚŚĞĐĞŶƚƌĞŽĨƚŚĞĐŽůƵŵŶŵĞŵďƌĂŶĞĂŶĚŝŶĐƵďĂƚĞĨŽƌϭϱŵŝŶƵƚĞƐ͘ϯϱϬʅůŽĨǁĂƐŚ
buffer 1 was added to the DNase buffer and centrifuged at 12,000xg for 15 seconds.  
ϱϬϬʅů ŽĨ ǁĂƐŚ ďƵĨĨĞƌ Ϯ (15ml wash buffer 2 with 60ml with 100% ethanol) was 
pipetted onto the membrane and centrifuged at 12,000xg for 15 seconds, discarding 
the flow through and repeating once.  The column was centrifuged for a further 1 
minute at 12,000xg to dry the membrane and transferred to a recovery tube.  RNA 
ǁĂƐĞůƵƚĞĚďǇĂĚĚŝŶŐϭϰʅůŽĨZEĂƐĞ-free water to the membrane and incubated for 
1min at room temperature.  The column was centrifuged for 2mins at 17,000xg to 
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retain RNA. The total RNA was determined using a NanoDrop spectrophotometer.  
The samples were stored at -20°C until ready to use. 
 
Reverse Transcription from RNA to cDNA 
The RNA samples from previous section above were combined with the 
components of the High Capacity cDNA Reverse transcription kit (Life Technologies, 
ƵƐƚƌĂůŝĂͿ͘ &ƌŽŵƚŚĞŬŝƚ͕ĐŽŵďŝŶĞĚŝŶWZƚƵďĞƐ͕ϭϬʅůŽĨϭϬǆƌĞǀĞƌƐĞƚƌĂŶƐĐƌŝƉƚĂƐĞ
;ZdͿďƵĨĨĞƌ͕Ϭ͘ϴʅůŽĨϮϱǆĚĞŽǆǇŶƵĐůĞŽƐŝĚĞ ƚƌŝƉŚŽƐƉŚĂƚĞ ;ĚEdWͿ͕ϭʅůDƵůƚŝ^ĐƌŝďĞZd͕
ϭʅůŽĨZEĂƐĞŝŶŚŝďŝƚŽƌĂŶĚϯ͘ϮʅůŽĨŶƵĐůĞĂƐĞĨƌĞĞǁĂƚĞƌ͘dŚĞZdŵĂƐƚĞƌŵŝǆǁĂƐĂĚĚĞĚ
ƚŽϭϬʅůŽĨZEƐĂŵƉůĞĂŶĚŵŝǆĞĚďǇƉŝƉĞƚƚĞ͘ dŚĞ ƚƵďĞƐǁĞƌĞĂĚĚĞĚƚŽĂWd-10 
thermocycler (MJ Research) and run at 25°C for 10 minutes, 37°C for 120 minutes, 
85°C for 5 minutes and then held at 4°C.   
 
qPCR of SY5Y BACE1 Inhibitor Treated cDNA 
Reagents were combined according to the Sigma KiCqStart SYBR green qPCR 
kit in flat lid PCR tubes and analysed in a Corbett Research Rotor-Gene 3000 thermal 
cycler.  For each reaction, the following primers were used according the Sigma-
Aldrich (Australia) KiCqStart primer selection.  The primers were referenced for cross 
reactivity by using Basic Local Alignment Search Tool (BLAST) from the NCBI website.  
Gene &ŽƌǁĂƌĚ;ϱΖїϯΖͿ ZĞǀĞƌƐĞ;ϱΖїϯΖͿ 
BACE1 GCAAGGAGTACAACTATGAC AGCTTCAAACACTTTCTTGG 
APP ATTGCCAAGAAGTCTACCC AGTTCTGGATGGTCACTG 
ɴ-Actin GACGACATGGAGAAAATCTG ATGATCTGGGTCATCTTCTC 
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To each reaction, components were added according to the KiCqStart SYBR 
green qPCR ReadyMix (Sigma-Aldrich, Australia) protocol using 300nM of forward 
and reverse primer as a final concentration.  The reaction was for forty cycles using 
the fast three-step cycling process to minimise potential dimerization of the primers. 
dŚĞɴ-actin housekeeping gene was used as the endogenous control.  Expression 
ůĞǀĞůƐǁĞƌĞĐĂůĐƵůĂƚĞĚďǇĐŽŵƉĂƌŝƐŽŶŽĨƚŚĞȴƚůĞǀĞůƐƉƌŽĚƵĐĞĚďǇƚŚĞƋWZ͘dŚĞ
calculations were determined by the difference in BACE1 peptide treatments. The 
fold change was calculated as 2-ȴȴƚ ǁŚĞƌĞƚŚĞȴȴƚŝƐƚŚĞĚŝĨĨĞƌĞŶĐĞďĞƚǁĞĞŶƚŚĞĐĞůů
ƚƌĞĂƚŵĞŶƚĂŶĚƚŚĞĐŽŶƚƌŽůŚŽƵƐĞŬĞĞƉŝŶŐŐĞŶĞ͘^ŝŐŶŝĨŝĐĂŶĐĞ;WчϬ͘ϬϱͿǁĂƐĚĞƚĞƌŵŝŶĞĚ
using a Student’s t-test.  
 
Statistical Analysis of qPCR 
The difference between treatment groups according to the 1, 10 and 100nM 
of BACE1 inhibitor identified in Chapter 2, was calculated using the Student’s t-test 
by using the Statistics Package for the Social Sciences (SPSS) version 22. *PчϬ͘ϬϱǁĂƐ
considered statistically significant.   
 
4.3  Results 
4.3.1  Western Blot Analysis of BACE1 Inhibitor Treated SY5Y with BACE1 and APP 
Monoclonal Antibodies 
The change in BACE1 and APP protein levels in BACE1-inhibitor-treated SY5Y 
cells was tested by western blot analysis.  Confluent SY5Y cells were treated with a 
10-fold representation of the BACE1 inhibitor at nanomolar concentrations, to 
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observe total protein output and the fluctuations that occur with both the treatment 
and the BACE1 inhibition.  The SY5Y cells were grown to 80% confluence then treated 
with the inhibitor for 24 hours before being lysed in preparation for protein 
separation by gel electrophoresis.  By separating the cell lysate, BACE1 and APP 
protein levels could be determined by using protein specific monoclonal antibodies 
and densitometric analysis.  The effect of the inhibitor over the 24-hour time period 
did not produce a significant change in BACE1 levels when isolated on the gels.  All 
three treatment groups contained either a 1, 10 or 100nM concentration of the 
inhibitor and did not yield a significant change in enzyme levels (Figures 4.1 and 4.2).  
The experiments were performed in triplicate to confirm the APP protein levels was 
corresponding to the concentration of BACE1 inhibitor added to the treatment media 
and the response to BACE1.  The gels were re-ƉƌŽďĞĚǁŝƚŚɴ-actin specific antibodies 
to determine gel loading consistency.  Furthermore, densitometric analysis of the 
ĞǆƉĞƌŝŵĞŶƚĂůƉƌŽƚĞŝŶďĂŶĚƐǁĂƐĐŽŵƉĂƌĞĚǁŝƚŚƚŚĞɴ-actin housekeeping protein to 
indicate significant difference in protein concentration.    
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A)                    B) 
 
Figure 4.1.  BACE1 protein expression levels of BACE1-inhibitor-treated SY5Y 
neuroblastoma cells. Western blot analysis of SY5Y cell lysates (A) expression of the 
BACE1 protein when the growth media has BACE1 inhibitor added at 0nM, 1nM, 
10nM and 100nM concentrations, respectively. Molecular mass protein marker (Mr) 
ŝƐ ŝŶĚŝĐĂƚĞĚ ŽŶ ƚŚĞ ƌŝŐŚƚ ƐŝĚĞ ŽĨ ƚŚĞ ŐĞů͘  dŚĞ ɴ-actin housekeeping protein is 
represented under the corresponding band.  Densitometric analysis (B) is measured 
in arbitrary units (AU) and by mĞĂŶƌĞůĂƚŝǀĞďĂŶĚĚĞŶƐŝƚǇǁŚĞŶĐŽŵƉĂƌĞĚǁŝƚŚƚŚĞɴ-
actin housekeeping gene. Error bars are representative of the standard error, (n=3). 
Statistical significance was calculated using the Student’s t-test (p < 0.05).  No 
significant difference between the untreated control and the experimental samples 
was observed.  
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A)  
 
                  B) 
 
 
 
Figure 4.2.  APP protein expression levels of BACE1-inhibitor-treated SY5Y 
neuroblastoma cells.  Western blot analysis of SY5Y cell lysates (A) expression of the 
APP protein when the growth media has BACE1 inhibitor added at 0nM, 1nM, 10nM 
and 100nM concentrations, respectively.  Molecular mass protein marker (Mr) is 
ŝŶĚŝĐĂƚĞĚ ŽŶ ƚŚĞ ƌŝŐŚƚ ƐŝĚĞ ŽĨ ƚŚĞ ŐĞů͘  dŚĞ ɴ-actin housekeeping protein is 
represented under the corresponding band.  Densitometric analysis (B) is measured 
ŝŶĂƌďŝƚƌĂƌǇƵŶŝƚƐ;hͿĂŶĚďǇŵĞĂŶƌĞůĂƚŝǀĞďĂŶĚĚĞŶƐŝƚǇǁŚĞŶĐŽŵƉĂƌĞĚǁŝƚŚƚŚĞɴ-
actin housekeeping gene. Error bars are representative of the standard error, (n=3).  
Statistical significance was calculated using the Student’s t-test (p < 0.05). 
*Represents a significant difference between APP level in the 10nM sample and the 
negative control. 
**Represents a significant difference between APP level in the 100nM sample and 
the negative control. 
 
 
4.3.2  qPCR of BACE1 Inhibitor Treated SY5Y Cells 
The change in protein levels, determined in the Western blot analysis, 
represents the overall end product, after any post-translational modification and 
inhibition.  The increase in enzyme activity can cause changes to downstream 
translation for compensation.  To monitor the effect of the BACE1 inhibitor on 
transcription of the BACE1 and APP genes, qPCR was performed.  The BACE1 peptide 
inhibitor was investigated for the potential feedback created by the inhibition of 
BACE1.  An increase in feedback would see a rise in mRNA translation to compensate 
for the inactive BACE1.  The SY5Y cells were treated with the BACE1 inhibitor at 
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various concentrations, 1nM, 10nM and 100nM, for 24 hours.  The effect on gene 
transcription for both BACE1 and APP was examined by qPCR and standardised 
ĂŐĂŝŶƐƚ ƚŚĞ ɴ-actin housekeeping gene.  From the control sample, which did not 
contain any inhibitor treatment, the SY5Y cells did not show any significant increase 
or decrease as a response in BACE1 mRNA production. As a result, the BACE1 
substrate APP also did not have any change in mRNA levels, even with the inhibition.  
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A 
 
 
 
 
 
 
 
 
 
 
 
 
B 
Figure 4.3.  Relative mRNA expression levels as a response to SY5Y treatment of the 
BACE1 Inhibitor.  Confluent SY5Y cells in culture were treated with the BACE1 
inhibitor contained in the media at 1, 10 and 100nM. For the standard control, cells 
were not treated with peptide and just incubated with the standard media. The cells 
were tested for the changes in mRNA levels by qPCR as a response to the treatments.  
Fold difference produced by BACE1 (A) and APP (B) were analysed according to the 
relative mRNA levels produced in comparison with the control by using the 2-ȴȴƚ 
method. The data is shown as the mean + SE, n=3.  All statistical analysis comparing 
ƚŚĞƚƌĞĂƚĞĚƐĂŵƉůĞƐǁĞƌĞƚĞƐƚĞĚĂŐĂŝŶƐƚĂƉƌŽďĂďŝůŝƚǇǀĂůƵĞ;WͿŽĨчϬ͘ϬϱĐŽŵƉĂƌĞĚƚŽ
the no treatment control. 
 
 
4.4  Discussion 
Protein changes in BACE1 and APP levels can have detrimental effects when 
considering treatment that directly affect the cells.  A BACE1 complete knockdown 
affects neurogenesis and brain development while an over expression can cause 
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neuronal hyperactivity and increased cleavage of APP.108,211 The increase in APP 
concentration can cause early onset AD, like in Down syndrome patients, as there is 
more protein available for processing but a decrease in expression levels can 
ŝŶĨůƵĞŶĐĞ ŶĞƵƌŽŐĞŶĞƐŝƐ ĂƐ ƐWWɲ ĂŝĚƐ ŶĞƵƌŝƚĞ ŽƵƚŐƌŽǁƚŚ͕ ĐĞůů ƐƵƌǀŝǀĂů ĂŶĚ ĐĞůů
adhesion.216,217 The importance ĨŽƌ ƉƌĞǀĞŶƚŝŽŶ ŽĨ ĂŵǇůŽŝĚŽŐĞŶĞƐŝƐ ŝƐ ƐƚŽƉƉŝŶŐ ɴ
production but the upstream proteomic changes can have similar detrimental effects, 
such as plaque accumulation.  The key to preventing amyloidogenesis remains with 
the inhibition of BACE1 as it is responsibůĞĨŽƌƚŚĞƉƌŽĚƵĐƚŝŽŶĂŶĚƌĞĚƵĐƚŝŽŶŽĨɴ͘
The complete removal of BACE1 enzymatic activity could affect other pathways.  
 
The Western blot analysis of treated SY5Y cells, aimed to investigate the 
BACE1 inhibitor’s effect on protein and enzyme levels.  The BACE1 inhibitor had 
ƉƌĞǀŝŽƵƐůǇ ƐŚŽǁŶ ĂŶ ĂďŝůŝƚǇ ƚŽ ĞĨĨĞĐƚŝǀĞůǇ ƌĞĚƵĐĞ ɴ͕ǁŚŝĐŚǁĂƐ ƐƵƉƉŽƌƚĞĚ ďǇ ĂŶ
increase in APP protein levels.  The SY5Y cell treatments were performed with three 
concentrations of the BACE1 inhibitor (1nM, 10nM and 100nM) causing a significant 
increase across samples. The rise in APP levels can be detrimental to the cell if BACE1 
ŝƐĂĐƚŝǀĞ͕ďƵƚŝĨŝŶŚŝďŝƚĞĚ͕ƚŚĞɲ-secretase activity becomes activated, releasing more 
ƐWWɲ͕ ǁŚŝĐŚ ŝƐ ŝŵƉŽƌƚĂŶƚ ĨŽƌ ŶĞƵƌŽƉƌŽƚĞĐƚŝŽŶ͘  tŝƚŚ  ƐƉĞĐŝĨŝĐ ƉĂƚients, an 
increase in neuroprotection would be appreciated to prevent further brain 
deterioration. 
 
A slight increase in BACE1 production was observed by the Western blot 
analysis but this was not significantly different from the negative control sample.  The 
increase in gel band density followed a similar pattern to that of APP, with the 10nM 
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treatment, elicited the strongest response, but it was considered not significant.  The 
minimal rise would have been negligible to normal cell processing.   
 
The changes in protein levels as a response to the treatment can be 
compensated for by positive feedback, initiating a rise in transcription.  The increase 
of APP could have activated the transcription of BACE1 or other enzyme to 
compensate for lack of function.  The qPCR was aimed to determine the mRNA levels 
after the 24-hour treatment with the BACE1 inhibitor.  The mRNA levels did not 
increase for either APP or BACE1.  The hypothesis that an increase in APP protein 
levels would promote BACE1 transcription was rejected, as there was no 
compensation observed.  The BACE1 and APP mRNA levels, as a response to the 
treatments, were not significant.   
 
4.5  Conclusion 
 The production of BACE1 and APP was not up or down regulated in response 
to the inhibitor treatment.  As a response to BACE1 inhibition, an increase to APP was 
observed with Western blot analysis.  The densitometric analysis of gel bands showed 
an increase in APP but not BACE1.  This increase could have initiated a feedback 
system to upregulate BACE1 transcription to compensate but it was not observed 
using qPCR techniques.  The BACE1 inhibitor did not alter BACE1 levels after the 
treatment period in SY5Y cells. 
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Chapter 5 
 
Characterisation of Proteomic Effects on NT2 Cells After 
BACE1 Inhibitor treatment  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
Aims 
This chapter aimed to define the proteomic changes in human neuronal cell 
expression when treated with the BACE1 peptide.  The identified changes would be 
investigated with Western Blot analysis to confirm.   The BACE1 inhibitor can inhibit 
ɴŝŶŶĞƵƌŽŶĂůĐĞůůƐďƵƚƚŚŝƐĐŚĂƉƚĞƌĂŝŵƐƚŽŝĚĞŶƚŝĨǇĂŶǇĞĨĨĞĐƚƐŽŶƚŚĞƉƌŽƚĞŽŵĞ͘ 
 
Methods 
M17, SY5Y and NT2 cells were tested for BACE1 activity using a fluorescent 
activity assay.  The cell line with the highest BACE1 activity was used for the 
proteomic analysis.  Prior to the proteomics, all three cell lines were tested for cell 
viability after 24 hour treatment with the BACE1 inhibitor.  NT2 cells were treated 
and lysed prior to the 2-dimensional separation of proteins. The protein gel was 
stained and the gel spots analysed for density variants. The selected spots we excised 
and the proteins identified by mass spectrometry.  The spot variation were then 
confirmed by Western blot analysis. 
 
Results 
NT2 cells produced a significantly higher BACE1 activity than SY5Y and M17.  
All cell lines were treated with the BACE1 inhibitor for 24 hours and tested for 
viability. The inhibitor treatment did not cause any significant decrease in the amount 
of live cells.  The 2-dimensional separation of NT2 cell proteins produced a number 
of spot variants that were identified by mass spectrometry.  The proteins identified 
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were enzymes from the glycolytic pathway.  The upregulation of these enzymes was 
confirmed by Western blot analysis. 
 
Conclusion 
BACE1 activity of NT2, M17 and SY5Y cells was determined to find a candidate 
for the proteomic analysis.  The NT2 cells produced the highest amount of BACE1 
substrate cleavage and were treated with the BACE1 inhibitor in preparation for 2-
dimensional separation.  The proteomic analysis of gel spots identified a number of 
upregulated candidates in the pH 7-8 range.  These proteins, after identification by 
mass spectrometry, were recognised as part of the glycolytic pathway.  The 
upregulation suspected by increase in gel spot density, was confirmed by Western 
blot with TPI, PKI and ALDOA enzymes.    
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5.1  Introduction 
The use of continuous neuronal cell lines provides an in vitro representation 
of the proteomic changes that may be associated with an in vivo model.  The benefit 
of using these models for the investigation of a potential treatment is to characterise 
potential toxicity prior to testing in an in vivo model. The cells maintain majority of 
the in vivo characteristics making them ideal for monitoring proteomic pathways 
while in a functional eukaryotic environment. Continuous cell lines have the ability to 
multiply and be split into multiple new flasks where they can proliferate again, 
allowing them to be used as multidimensional treatment groups. For use in this 
chapter, the M17, NT2 and SY5Y cell lines are grown and split into multiple flasks 
allowing for multiple treatments under the same conditions.  Microscopically, they 
maintain the same physical shape while developing the dendrites of a dividing cell. 
  
The M17 neuroblastoma cell line is a sub-clone of SK-N-BE(2) that was 
acquired in 1972 from the bone marrow of a 2 year old Caucasian male with 
malignant neuroblastoma (ATCC, Manassas, USA). Similarly, the NT2 line was derived 
from the N-TERA2 clone D1 cells, which originated from a teratocarcinoma. The NT2 
cells are a pluripotent human embryonal carcinoma, which is a sub-clone of the N-
TERA parent line. The cells were extracted from a 22 year old patient experiencing 
primary embryonal carcinoma of the testes with the cells removed from the lung 
metastasis (ATCC, Manassas, USA).  NT2 cells are highly metastatic and have the 
ability to be differentiated into non-dividing neuronal cells.218  The SY5Y line 
originated in 1978 from SK-N-SH cells that were extracted from a bone marrow biopsy 
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of a patient with a metastatic tumour, and sub-cloned.219 All cell lines are continuous 
and originated as a clone from a previous parent line. They are all adherent, dividing 
neuronal cells that can be easily harvested for the use of treatment testing. 
 
In this chapter, the human neuronal NT2, SY5Y and M17 cell lines were used 
to compare for BACE1 activity and tested for potential treatment toxicity effects by 
measuring the live cell numbers.  Investigating the more specific intracellular 
changes, treated NT2 cell line were harvested for investigation of the whole 
proteome to identify possible anomalies and toxic effects.  
 
5.2  Materials and Methods 
5.2.1  BE(2)-M17 (M17) Neuroblastoma Cell Culture 
A vial containing cryopreserved M17 cells (Sigma Aldrich, Australia) (ATCC 
CRL-2267) was removed from liquid nitrogen storage and thawed in a water bath at 
37°C.  Cells were transferred to a Corning 75mm2 (Sigma-Aldrich, Australia) 
untreated flask containing media, HamsF12:EMEM (1:1), 2mM glutamine, 1% non-
essential amino acids and 15% FBS (v/v).  The flask was placed in an incubator at 
37°C with 5% CO2.  The media was discarded and replaced after two days of 
incubation.   
 
Passaging Cells 
Cells were seeded at 80% confluency by discarding the media and washing 
the cell monolayer twice with PBS, 137mM NaCl, 2.7mM KCl, 8.1mMNa2HPO4 and 
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1.47mM KH2PO4.  Cells were harvested with 3ml of 0.25% Trypsin-EDTA in PBS.  
Cells were removed from the flask after a 2-minute incubation time and gently 
agitated to remove.  The flask was checked for attached cells under an inverted 
microscope before quenching with 7ml of fresh media.  The cells were washed over 
the base of the flask three times then 1ml transferred to two new 75mm2 flasks 
containing fresh media. 
 
Storage of Cells 
Cells were grown during passage three and four on a 75mm2 flask to 90% 
confluence.  Before harvesting, the media was discarded and the monolayer 
washed twice with PBS.  The cells were harvested with 3ml of 0.25% 
trypsin/EDTA/PBS and quenched with 7ml of media.  Cell viability and number were 
calculated using a TC10 Automated Cell Counter (Bio-Rad Laboratories, Inc., USA).  
The cell solution was transferred to a 15ml tube and pelleted at 1000xg for 5 
minutes.  The media was removed and cells resuspended in cryomedia, 40% (v/v) FB 
S, 10% (v/v) dimethyl sulfoxide (DMSO) and 50% (v/v) SY5Y media, to 1x106 cell/ml 
and 1ml transferred into cryovials.  The vials were added to a Mr. Frosty (Nalgene, 
USA) container and placed in the -80°C freezer for 24hours.  The vials were then 
transferred to the liquid nitrogen storage dewar. 
 
5.2.2  N-TERA2 cl.D1 (NT2) Malignant Pluripotent Embryonal Carcinoma Cell 
Culture 
A vial containing cryopreserved NT2 cells (Sigma Aldrich, Australia)(ATCC 
CRL-1973) was removed from liquid nitrogen storage and thawed in a water bath at 
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37°C.  Cells were transferred to a Corning 75mm2 untreated flask containing media, 
HamsF12:DMEM (1:1), 1% non-essential amino acids and 10% FBS(v/v).  The flask 
was placed in an incubator at 37°C with 5% CO2.  The media was discarded and 
replaced after two days of incubation.   
 
Passaging Cells 
Cells were seeded at 80% confluence by discarding the media and washing 
the cell monolayer twice with PBS containing 137mM NaCl, 2.7mM KCl, 
8.1mMNa2HPO4 and 1.47mM KH2PO4.  Cells were harvested by adding 3ml of 0.25% 
Trypsin-EDTA in PBS.  The cells were removed from the flask after a 2 minute 
incubation time and gently agitated to remove.  The flask was checked for attached 
cells under an inverted microscope before quenching with 7ml of fresh media.  The 
cells were washed over the base of the flask three times then 1ml transferred to 
two new 75mm2 flasks containing fresh media. 
 
Storage of Cells 
Cells were grown from passage three and four on a 75mm2 flask to 90% 
confluence.  The media was discarded and the monolayer washed twice with PBS.  
The cells were harvested with 3ml of 0.25% trypsin/EDTA/PBS and quenched with 
7ml of media.  Cell viability and number were calculated using a TC10 Automated 
Cell Counter (Bio-Rad Laboratories, Inc., USA).  The cell solution was transferred to a 
15ml tube and pelleted at 1000xg for 5 minutes.  The media was removed and cells 
resuspended in NT2 cryomedia, 40% (v/v) FB S, 10% (v/v) DMSO and 50% (v/v) NT2 
media, to 1x106 cell/ml and 1ml transferred into cryovials.  The vials were added to 
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a Mr. Frosty (Nalgene, USA) container and placed in the -80°C freezer for 24 hours.  
The vials were then transferred to the liquid nitrogen storage dewar. 
 
5.2.3  SY5Y Neuroblastoma Cell Culture 
SY5Y cells were grown, passaged, treated and stored as explained in Chapter 
3. 
 
5.2.4  Cell Viability and Number Calculation 
ϮϬϬʅůŽĨĐĞůůƐ͕ĂĨƚĞƌƚƌǇƉƐŝŶŝƐĂƚŝŽŶĂŶĚƋƵĞŶĐŚŝŶŐ͕ǁĞƌĞƚƌĂŶƐĨĞƌƌĞĚƚŽa 
microcentrifuge tube and pelleted at 1,000xg for 5minutes to remove any traces of 
ƚŚĞƌĞŵĂŝŶŝŶŐƐĞƌƵŵ͘dŚĞŵĞĚŝĂǁĂƐƌĞŵŽǀĞĚĂŶĚƚŚĞƉĞůůĞƚǁĂƐŚĞĚǁŝƚŚϮϬϬʅůŽĨ
W^͘dŚĞĐĞůůǁĞƌĞƚŚĞŶƌĞƐƵƐƉĞŶĚĞĚŝŶϮϬϬʅůŽĨŵĞĚŝĂ;ǁŝƚŚŽƵƚƐĞƌƵŵͿǁŝƚŚϮϬʅů
transferred ƚŽĂĨƌĞƐŚŵŝĐƌŽĐĞŶƚƌŝĨƵŐĞƚƵďĞ͘ϮϬʅůŽĨƚƌǇƉĂŶďůƵĞĚǇĞƐŽůƵƚŝŽŶǁĂƐ
ĂĚĚĞĚƚŽƚŚĞϮϬʅůŽĨĐĞůůƐĂŶĚůŽĂĚĞĚŝŶƚŽƚŚĞdϭϬƐĂŵƉůĞĐŚĂŵďĞƌƐŽŶƚŚĞ
counting slide.  The slide was added to the TC10 Automated Cell Counter and the 
cell viability and counts analysed. 
 
5.2.5  BACE1 Activity Assay of Neuronal Cell Lysates 
The BACE1 activity was tested with fluorescent activity assay kit (Sigma 
Aldrich, Australia).  The kit contained a 7-methoxycoumarin-4-acetyl-0.5mg [Asn670, 
Lue671]-amyloid b/A4 precursor protein 770 fragment 667-676-(2,4-
dinitrophenyl)lys-arg-arg amide trifluoroacetate salt fluorescent substrate that was 
ĚŝƐƐŽůǀĞĚŝŶD^KƚŽĂϱϬϬʅDƐƚŽĐŬ͘&ŽƌƚŚĞĐŽŶƐƚƌƵĐƚŝŽŶŽĨƚŚĞĂƐƐĂǇ͕ƚŚĞƐƵďƐƚƌĂƚĞ
ƐƚŽĐŬǁĂƐ ĚŝůƵƚĞĚ ƚŽ ϱϬʅDǁŝƚŚ Ă Ɛupplied FAB.  The substrate solution required 
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dissolving of the 0.5mg APP in 0.05ml dimethyl sulfoxide which was divided into 1.2ml 
tubes in 50μl aliquots and stored as a stock solution at -20°C.  Cell lysate protein 
concentration for M17, SY5Y and NT2 were quantified by Qubit fluorometer.  Cell 
lysates were standardised to 7mg/ml then added to the reaction.  The tubes 
contained 50μM of BACE1 substrate (20μl) along with the cell lysate and FAB to make 
up 100μl.  All tubes and incubated with agitation for 2 hours at 37°C before being 
transferred to a Granier flat bottom, 96-well plate and read on a BMG Labtech 
Fluostar Omega fluorometer with excitation of 320nm and emission 405nm. 
 
5.2.6  2-Dimensional Separation of BACE1 Inhibitor Treated NT2 Cell Lysates 
Cells were grown to 80% confluency and removed from the flask using 3ml 
of 0.25% trypsin/EDTA/PBS and quenched with 7ml of media.  The cells were 
transferred to a six-well plate and allowed to adhere overnight.  Media was pre-
treated for 24 hours with the BACE1 peptide inhibitor (characterised in Chapter 2) 
to 1, 10 and 100nM.  The old media was replaced with the treatment media and the 
cells incubated for 24 hours.  The media was removed and the monolayer washed 
with PBS.  The cells were then harvested with 0.25% trypsin/EDTA/PBS and 
quenched with the respective media then transferred to microcentrifuge tube and 
pelleted at 1200xg for 5 minutes.  The cells were washed with PBS and stored in -
80°C until ready to use. 
 
Cell Lysis 
A ĐĞůůůǇƐŝƐďƵĨĨĞƌ͕ϰϱϱʅůŽŽŵΡϮƉƌŽƚĞŝŶSolubilizer 1 (Life Technologies, 
h^Ϳ͕ϭ͘ϱʅůŽĨϭDdƌŝƐĂƐĞ͕ϱʅůŽĨĂϭϬϬǆƉƌŽƚĞĂƐĞŝŶŚŝďŝƚŽƌĐŽĐŬƚĂŝů;ZŽĐŚĞ͕h^Ϳ͕
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ϱʅůŽĨϮDĚŝƚŚŝŽƚŚƌĞŝƚŽů;ddͿĂŶĚϵʅůĚ,2O, was composed and added to each of 
the aliquoted cell pellets for suspension.  All samples were mixed by vortexing then 
passed through a 18-21 gauge syringe 5-10 times to thoroughly homogenise the 
lysate and then stored on ice. The pH was confirmed to be within a range of 8.4-9.0 
and the samples incubated on a rotary shaker for 15 minutes at room temperature.  
dŚĞůǇƐĂƚĞǁĂƐĂůŬǇůĂƚĞĚǁŝƚŚϮ͘ϱʅůŽĨϵϵйE͕E-dimethylacrylamide (DMA) and 
incubated on a rotary shaker for 30 minutes at room temperature.  DMA was 
ƋƵĞŶĐŚĞĚǁŝƚŚϱʅůŽĨϮDddĂŶĚƚŚĞƵŶƐŽůƵďŝůŝƐĞĚĨƌĂŐŵĞŶƚŽĨůǇƐĂƚĞǁĂƐƉĞůůĞƚĞĚ
at 16,000xg for 20 minutes.  The supernatant was removed and transferred to a 
fresh tube and stored at -80°C.  The lysates were thawed and protein concentration 
determined via Qubit fluorometer following the manufacturer’s instructions.   
 
First Dimension 
Samples for isoelectric focussing contained treated lysate, standardised to 
ϭϬϬʅŐ͕ϭʅůŽĨϮDdd͕ϭʅůŽĨĂŵƉŚŽůǇƚĞƐ͕ϭʅůŽĨϭŵŐͬŵůďƌŽŵŽƉŚĞŶŽůďůƵĞĂŶĚ
ŽŽŵϮWƌŽƚĞŝŶ^ŽůƵďŝůŝǌĞƌϭƚŽϭϱϱʅůĂŶĚǁĞƌĞĂĚĚĞĚƚŽĂĚĞƐŝŐŶĂƚĞĚǁĞůůŽĨĂ
Zoom IPGRunner Cassette (Life Technologies, USA).  Next, the non-linear, pH 4-10 
Zoom strips were rehydrated by inserting them gel side up and positive end first in 
the corresponding well containing rehydration buffer.  The wells were sealed at 
both ends with provided tape and incubated overnight at room temperature.  After 
incubation, the tape was removed and, with the rehydrated strips remaining in the 
cassette, electrode wicks were adhered across the gel wells and dampened with 
ϲϬϬʅů,2O.  The cassette was added to the Zoom IPGRunner Core (Life 
Technologies, USA) and the outer chamber filled with dH2O.  Isoelectric focussing 
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was performed at 200V for 20 minutes, 450V for 15 minutes, 750V for 15 minutes 
and 2000V for 60 minutes.  The cassette, still containing the strips, was incubated 
overnight at -80°C.  
 
Second Dimension 
Prior to equilibration, the cassette was allowed to thaw to room 
temperature.   Strips were removed and placed into an equilibration tray containing 
2ml of NuPAGE LDS reducing buffer (Life Technologies, Australia), 1.8ml of 1x 
EƵW'>^^ĂŵƉůĞƵĨĨĞƌǁŝƚŚϮϬϬʅůƐĂŵƉůĞƌĞĚƵĐŝŶŐĂŐĞŶƚ͕ĂŶĚŝŶĐƵďĂƚĞĚĂƚ
room temperature for 15 minutes with shaking.  The buffer was discarded and 
ƌĞƉůĂĐĞĚǁŝƚŚϮŵůŽĨĂůŬǇůĂƚŝŶŐƐŽůƵƚŝŽŶ͕ϭǆEƵW'Ρ>^^ĂŵƉůĞƵĨĨĞƌǁŝƚŚϰϲŵŐ
Iodoacetamide, and incubated at room temperature for 15 minutes with shaking.  
The strips were removed, trimmed and positioned gel side out to the well of an IPG 
gel. To ŚŽůĚƚŚĞƐƚƌŝƉŝŶƚŚĞ/W'ŐĞůǁĞůů͕ϰϬϬʅůŽĨĂϬ͘ϱйĂŐĂƌŽƐĞ;ϲϬΣͿƐŽůƵƚŝŽŶŝŶ
1x NuPAGE running buffer (Life Technologies, Australia) was poured over the IPG 
strip and allowed to set without bubbles.  The gel cassettes were assembled into 
the X-Cell Surelock gel tank, with the upper and lower chambers filled with 1x 
EƵW'ƌƵŶŶŝŶŐďƵĨĨĞƌ͘ĞĨŽƌĞƌƵŶŶŝŶŐƚŚĞƐĞĐŽŶĚĚŝŵĞŶƐŝŽŶ͕ϱϬϬʅůŽĨEƵW'
antioxidant was added to the upper chamber.  The proteins were separated at 125V 
for approximately 90 minutes.  
 
5.2.7  Gel Digestion for Mass Spectrometry Preparation 
The gel was removed from the cassette and washed three times for five 
minutes each in dH2O.  The gel was then covered with SimplyBlue SafeStain (Life 
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Technologies, Australia) and incubated for one hour with gentle shaking. The gel 
was then washed with dH2O firstly for one hour, then secondly for two hours.  Gel 
spots were selected for analysis according to the changes in staining between 
different treatments.  The spots chosen for analysis were then cut out using a 
ŵŽĚŝĨŝĞĚƉŝƉĞƚƚĞƚŝƉĂŶĚĂĚĚĞĚƚŽĂŵŝĐƌŽĐĞŶƚƌŝĨƵŐĞƚƵďĞĐŽŶƚĂŝŶŝŶŐϮϬʅůŽĨDŝůůŝY
water and stored in -20°C until ready for mass spectrometry. The individual gel 
ƐƉŽƚƐǁĞƌĞĨŝƌƐƚůǇĚĞƐƚĂŝŶĞĚďǇǁĂƐŚŝŶŐƚǁŝĐĞĨŽƌϮϬŵŝŶƵƚĞƐƵƐŝŶŐϮϬϬʅůŽĨďƵĨĨĞƌ, 
50mM tetraethylammonium bromide (TEAB) with 100% acetonitrile (1:1), on a 
ƌŽƚĂƌǇŵŝǆĞƌ͘dŚĞĞǆĐŝƐĞĚŐĞůƉůƵŐƐǁĞƌĞƚŚĞŶĚĞŚǇĚƌĂƚĞĚǁŝƚŚϮϬϬʅůŽĨϭϬϬй
ĂĐĞƚŽŶŝƚƌŝůĞĨŽƌϮϬŵŝŶƵƚĞƐ͘dŚĞĚĞŚǇĚƌĂƚŝŽŶďƵĨĨĞƌǁĂƐƌĞƉůĂĐĞĚǁŝƚŚϮϬʅůŐĞů
digestion solution, 214nM trypsin with 25mM TEAB, and incubated overnight at 
ϯϳΣ͘dŚĞƐĂŵƉůĞƐǁĞƌĞƚŚĞŶƚƌĂŶƐĨĞƌƌĞĚƚŽĂĨƌĞƐŚƚƵďĞĂůŽŶŐǁŝƚŚϭʅůŽĨϮϱй
formic acid for mass spectrometry analysis, which was completed at the Bio21 
Institute, Melbourne.  Protein spots were identified by the amino acid sequences 
produced by the mass spectrometry and cross referenced with the Msile database.  
Proteins of interest were characterised according to both the isoelectric point and 
molecular weight, determined by molecular weight marker used in the second 
dimension.  
 
5.2.8  Western Blot Analysis to Confirm Mass Spectrometry Results 
SDS-PAGE 
Novex Tris-glycine, 10-well, 1mm mini-gels (Life Technologies, Australia) 
were brought to room temperature and washed with dH2O.  Treated cell pellets 
were lysed using CelLytic MT (Sigma-Aldrich, Australia) and protein concentration 
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ĚĞƚĞƌŵŝŶĞĚďǇƵƐŝŶŐƚŚĞYƵďŝƚĨůƵŽƌŽŵĞƚĞƌ͘^ĂŵƉůĞƐǁĞƌĞƉƌĞƉĂƌĞĚďǇŵŝǆŝŶŐϱʅů
Tris-ŐůǇĐŝŶĞ^^ƐĂŵƉůĞďƵĨĨĞƌ;>ŝĨĞdĞĐŚŶŽůŽŐŝĞƐ͕ƵƐƚƌĂůŝĂͿ͕ϭʅůEƵW'ZĞĚƵĐŝŶŐ
Agent (LiĨĞdĞĐŚŶŽůŽŐŝĞƐ͕ƵƐƚƌĂůŝĂͿĂŶĚƐĂŵƉůĞůǇƐĂƚĞƐĂŵƉůĞƚŽϭϬʅů͘dŚĞĐĞůů
ůǇƐĂƚĞƐǁĞƌĞƐƚĂŶĚĂƌĚŝƐĞĚƚŽϭϱŵŐƉĞƌǁĞůůĂŶĚĂĚũƵƐƚĞĚƚŽϱʅůǁŝƚŚĞǆƚƌĂĞů>ǇƚŝĐ
MT.  Prior to filling the wells, samples were mixed thoroughly and heated to 85°C 
for two minutes.  The gels were brought to room temperature and the samples 
added with a SeeBlue Pre-stained Standard in lane 1.  Gels were added to the X-Cell 
SureLock electrophoresis tank with Novex Tris-glycine SDS running buffer (Life 
Technologies, Australia) in the upper and lower chambers.  The electrophoresis was 
run over approximately 90 minutes at a constant 125V.   
 
Protein Transfer 
The gels were removed from the X-Cell SureLock electrophoresis tank and 
washed with dH2O.  Six blotting pads and two filter papers were immersed in 
transfer buffer solution, NuPAGE transfer buffer, NuPAGE antioxidant, methanol 
and dH2O, and all the bubbles removed.  Using a chisel, the gel cassettes were 
disassembled and the gel foot removed.  The transfer sandwich was constructed by 
first adding three blotting pads to the base of the transfer core, followed by one of 
the pieces of blotting paper, the freshly run gel and the nitrocellulose membrane, 
with all the bubbles removed with a Western blot roller.  On top of the membrane 
was another piece of blotting paper and the last three blotting pads.  The core was 
squeezed together, placed into the X-Cell SureLock tank and filled to the top with 
transfer buffer; the lower chamber filled with dH2O.  The proteins were transferred 
for two hours at a constant 25V.  The core was then removed and disassembled 
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with BACE1 and APP to be identified with the WesternBreeze chromogenic Western 
blot immunodetection kit.  The membrane was placed in a blocking buffer for 30 
minutes on a rotary shaker.  The excess blocking buffer was washed off twice for 
five minutes with dH2O and replaced with a primary antibody solution (aldolase, 
triosephosphate isomerase and pyruvate kinase monoclonal antibodies (Abcam, 
USA) were diluted 1:5000 in blocking buffer) for one hour.  The membrane was 
washed three times for five minutes with the antibody wash solution prior to a 30-
minute incubation with a secondary antibody (anti-mouse).  The membrane was 
washed another three times for five minutes with wash buffer then a further two 
times for two minutes each with dH2O.  The NBT/BCIP chromogen was added for 60 
minutes and then washed twice for two minutes with dH2O.  Until read with the 
Chemidoc, the membranes were stored in PBS at 4ȗ͘ 
 
 
5.3  Results 
5.3.1  BACE1 Activity Comparison for the NT2, SY5Y and M17 Neuronal Cell Lines 
Three neuronal cell lines with known BACE1 expression were tested for 
comparisons of enzymatic activity.  The NT2, SY5Y and M17 cell lines were grown to 
confluence in the same conditions but with specific growth media.  Protein 
concentrations were standardised prior to the assay to negate fluctuations in cell 
growth and get a true difference in enzymatic activity.  Success of the cell line was 
determined by a higher measurement of fluorescence, which was represented by the 
cleavage of a tagged substrate specific for BACE1.  The amount of substrate cleavage 
from the NT2 cell lysate was significantly higher than that of both SY5Y and M17 
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(Figure 5.1).  Therefore, the NT2 cell line was selected for use in the 2D analysis, as 
there was a significantly higher amount of BACE1 activity.   
 
Figure 5.1. BACE1 activity across the M17, SY5Y and NT2 neuronal cell lines.  This 
assay aims to quantify mean enzymatic activity of BACE1 from the M17, SY5Y and 
NT2 neuronal cell lines.  The cells were grown to confluence and lysed according to 
the protein concentration calculated for uniformity across all samples.  The activity 
of BACE1, determined by the cleavage of a fluorescently tagged substrate, is 
measured as mean fluorescent units (FU) + SEM (n=3).  Statistical significance was 
determined using the Student’s t-test (p < 0.05). 
* Denotes a significant difference between the BACE1 activity between the NT2 and 
M17 cells. 
**Denotes a significant difference between the BACE1 activity between the NT2 and 
SY5Y cells. 
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5.3.2  Cell Viability Test of BACE1-Inhibitor-Treated NT2, SY5Y and M17 Neuronal 
Cell Lines 
The SY5Y, NT2 and M17 cell lines were tested for viability after the BACE1 
inhibitor treatments.  The toxicity caused by treatments of BACE1 inhibitor would 
have an influence over the amount of viable cells removed from the flask.  The live, 
viable cells cannot absorb the trypan blue as the competent membrane is not 
permeable but if dead, there is no protection and become stained.  All of the cell lines 
did not undergo a significant reduction in the percentage of live cells after the 24-
hour BACE1 inhibitor treatments (Figures 5.2, 5.3 and 5.4).  All experimental samples 
had more than 85% viable cells, which prompted the treatments to be tested for any 
proteomic changes.  
Figure 5.2. Cell viability of the SY5Y cell line with treatments of the BACE1 inhibitor.  
This assay determines the potential cellular toxicity by the treatment, measuring 
dead to live SY5Y cell ratios. The live cells that maintain a complete cell membrane, 
will not absorb the trypan blue but the dead cells will retain the stain. The cell 
monolayer was incubated for 24 hours with standard growth media containing 1nM, 
10nM and 100nM of BACE1 inhibitor, respectively, with the negative control 
remaining untreated.  The number of live to dead cells is represented as mean 
percentage viability + SEM (n=3). Statistical significance was calculated using the 
Student’s t-test (p < 0.05) but no differences were measured. 
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Figure 5.3. Cell viability of the NT2 cell line with treatments of the BACE1 inhibitor.  
This assay determines the potential cellular toxicity by the treatment, measuring 
dead to live NT2 cell ratios. The live cells that maintain a complete cell membrane, 
will not absorb the trypan blue but the dead cells will retain the stain. The cell 
monolayer was incubated for 24 hours with standard growth media containing 1nM, 
10nM and 100nM of BACE1 inhibitor, respectively, with the negative control 
remaining untreated.  The number of live to dead cells is represented as mean 
percentage viability + SEM (n=3).  Statistical significance was calculated using the 
Student’s t-test (p < 0.05) but no differences were measured. 
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Figure 5.4. Cell viability of the M17 cell line with treatments of the BACE1 inhibitor.  
This assay determines the potential cellular toxicity by the treatment, measuring 
dead to live M17 cell ratios. The live cells that maintain a complete cell membrane, 
will not absorb the trypan blue but the dead cells will retain the stain. The cell 
monolayer was incubated for 24 hours with standard growth media containing 1nM, 
10nM and 100nM of BACE1 inhibitor, respectively, with the negative control 
remaining untreated.  The number of live to dead cells is represented as mean 
percentage viability + SEM (n=3). Statistical significance was calculated using the 
Student’s t-test (p < 0.05) but no differences were measured. 
 
5.3.3  Proteomic analysis of BACE1-inhibitor-treated NT2  Neuronal Cell Lines. 
The viability test aimed to determine cell competence after the treatment 
time frame. The percentage of viable cells was not significantly reduced after BACE1 
inhibitor treatment and no regression in confluence was observed.  Investigation of 
cellular competence from a proteomic perspective was undertaken using a 2-
dimensional separation of proteins according to isoelectric focussing and molecular 
mass.  The protein expression levels were displayed as spots on the gels with the 
changes in size relating to the up or down regulation effects as a response to the 
treatments.   
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The NT2 cell line was selected for the proteomic analysis as it contained the 
highest BACE1 activity from the fluorescent assay performed. The cells were grown 
to confluence and treated with the BACE1 inhibitor at 1nM, 10nM and 100nM 
concentrations, with the negative control only containing the required media.  As a 
result, there was a number of protein spot size variation from the untreated cells to 
the 100nM treatment. 
 
The non-linear pH separation of the isoelectric focussing showed a number of 
protein spot increases from the negative control to the 100nM treatment sample.  
Multiple spots exhibiting density variance on the negative and 100nM treatment gels 
were excised and analysed using mass spectrometry (Figures 5.5 to 5.8).  The 
resulting amino acid sequences were analysed for comparisons with known Homo 
sapiens proteins in the Msile database (Bio21, Melbourne University, Melbourne). 
 
A common theme emerged of six samples that showed an increase in density 
from the negative control to the to 100nM treatment sample (Table 5.1).  Five of the 
six spots were located within a pH 7-9 range, where a group of proteins showed an 
increase in density.  Three of these were selected for further investigation of protein 
expression changes as a response to BACE1 inhibitor treatments. 
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Figure 5.5.  2-Dimensional separation of proteins from untreated NT2 cell lysates.   
NT2 cells were treated for 24 hours with standard growth media, this sample 
represented the negative (baseline) control as there was no BACE1 inhibitor added. 
The cells were lysed and separated firstly by isoelectric focussing and then by SDS-
PAGE prior to mass spectrometry.  Gels were stained with SimplyBlue SafeStain to 
identify protein locations.  Proteins that exhibited changes in spot density and have 
been labelled accordingly. The molecular mass marker (Mr) is located on the left.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6.  2-Dimensional separation of proteins from NT2 cells treated with 1nM 
of BACE1 inhibitor.   NT2 cells were treated for 24 hours with standard growth media 
containing 1nM of BACE1 inhibitor. The cells were lysed and separated firstly by 
isoelectric focussing and then by SDS-PAGE prior to mass spectrometry.  Gels were 
stained with SimplyBlue SafeStain to identify protein locations.  Proteins that 
exhibited changes in spot density and have been labelled accordingly. The molecular 
mass marker (Mr) is located on the left.  
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Figure 5.7.  2-Dimensional separation of proteins from NT2 cells treated with 10nM 
of BACE1 inhibitor.   NT2 cells were treated for 24 hours with standard growth media 
containing 10nM of BACE1 inhibitor. The cells were lysed and separated firstly by 
isoelectric focussing and then by SDS-PAGE prior to mass spectrometry.  Gels were 
stained with SimplyBlue SafeStain to identify protein locations.  Proteins that 
exhibited changes in spot density and have been labelled accordingly. The molecular 
mass marker (Mr) is located on the left.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8.  2-Dimensional separation of proteins from NT2 cells treated with 
100nM of BACE1 inhibitor.  NT2 cells were treated for 24 hours with standard growth 
media containing 100nM of BACE1 inhibitor. The cells were lysed and separated 
firstly by isoelectric focussing and then by SDS-PAGE prior to mass spectrometry.  Gels 
were stained with SimplyBlue SafeStain to identify protein locations.  Proteins that 
exhibited changes in spot density and have been labelled accordingly. The molecular 
mass marker (Mr) is located on the left.  
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2D Protein Spot Species Accession Number 
Protein 
Mr 
Protein  
pI 
Protein 
Score 
(%) 
Pyruvate kinase Homo sapiens P14618 57,937 6.34 79 
Enolase Homo sapiens P06733 47,169 7.01 85 
Aldolase A Homo sapiens H3BPS8 39,420 8.3 85 
L-lactate dehydrogenase Homo sapiens P0038 36,898 8.4 70 
Malate dehydrogenase Homo sapiens P40925 36,426 8.1 68 
Triosephosphate 
isomerase 
Homo 
sapiens P60174 26,943 7.8 90 
 
Table 5.1.  2D gel spot protein identification by mass spectrometry.  Confluent NT2 
monolayers were incubated with standard growth media containing BACE1 inhibitor 
at 1nM, 10nM and 100nM concentrations with the negative control receiving no 
treatment. The cell lysate proteins were separated using the 2D technique with single 
spot variants identified by mass spectrometry. Six proteins were characterised by 
amino acid signatures and identified using the Msile database.  Molecular mass (Mr); 
isoelectric point (pI). 
 
 
5.3.4  Western Blot Analysis of Candidate Enzymes Identified from Mass 
Spectrometry of Protein Spots  
Resulting protein spot analysis from the mass spectrometry identified six 
proteins of interest.  Three of the proteins were selected for western blot analysis to 
confirm spot density variation. NT2 cells were treated following the same protocol as 
used for the 2-dimensional separation, with media containing 0nM, 1nM, 10nM and 
100nM of BACE1 inhibitor.  The cells were lysed and separated by SDS-PAGE and 
transferred to a nitrocellulose membrane.  The membrane was incubated with TPI, 
ALDOA and PKI monoclonal antibodies to identify the proteins of interest.   
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Enzyme specific antibodies indicated a significant increase in the amount of 
TPI with BACE1 inhibitor treatments by calculation of blot band density.  The samples 
containing 10nM and 100nM of inhibitor showed a significant increase in the amount 
of TPI produced, with the latter inhibitor concentration producing the most.  The 1nM 
treatment did not exhibit any significant increase in the amount of TPI but a gradual 
increase was produced with the amount of inhibitor added (Figure 5.9). 
 
The monoclonal antibodies specific for ALDOA showed the NT2 cells treated 
with media containing 1nM BACE1 showed a significant increase in band density.  The 
1nM treatment produced significantly more ALDOA than all other treatments.  The 
10nM and 100nM treatments also increased the amount of ALDOA significantly from 
that of the negative control but not as much as the 1nM sample (Figure 5.10). 
 
Similarly to ALDOA, the PKI gel band intensity increased significantly in 
response to the 1nM BACE1 inhibitor treatment.  The 1nM treatment produced 
significantly more PKI than all other treatments.  The 10nM and 100nM treatments 
also increased the amount of PKI significantly when compared to the negative control 
but not more than the 1nM sample (Figure 5.11). 
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Figure 5.9.  TPI protein expression levels 
of BACE1-inhibitor-treated NT2 neuronal cells. Western blot analysis of NT2 cell 
lysates (A) expression of the TPI protein when the growth media has BACE1 inhibitor 
added at 0nM, 1nM, 10nM and 100nM concentrations, respectively. Molecular mass 
protein marker (MrͿŝƐŝŶĚŝĐĂƚĞĚŽŶƚŚĞƌŝŐŚƚƐŝĚĞŽĨƚŚĞŐĞů͘dŚĞɴ-actin housekeeping 
protein is represented under the corresponding band.  Densitometric analysis (B) is 
measured in arbitrary units (AU) and is measured by mean relative band density when 
ĐŽŵƉĂƌĞĚǁŝƚŚƚŚĞɴ-actin housekeeping protein. Error bars are representative of the 
standard error (n=3). Statistical significance was calculated using the Student’s t-test 
(p < 0.05). 
*Represents a significant difference between TPI level in the 10nM sample and the 
negative control. 
**Represents a significant difference between TPI level in the 100nM sample and the 
negative control. 
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Figure 5.10. ALDOA protein expression levels of BACE1-inhibitor-treated NT2 
neuronal cells. Western blot analysis of NT2 cell lysates (A) expression of the ALDOA 
protein when the growth media has BACE1 inhibitor added at 0nM, 1nM, 10nM and 
100nM concentrations, respectively. Molecular mass protein marker (Mr) is indicated 
ŽŶƚŚĞƌŝŐŚƚƐŝĚĞŽĨƚŚĞŐĞů͘dŚĞɴ-actin housekeeping protein is represented under 
the corresponding band.  Densitometric analysis (B) is measured in arbitrary units 
;hͿĂŶĚŝŶŵĞĂƐƵƌĞĚďǇŵĞĂŶƌĞůĂƚŝǀĞďĂŶĚĚĞŶƐŝƚǇǁŚĞŶĐŽŵƉĂƌĞĚǁŝƚŚƚŚĞɴ-actin 
housekeeping protein. Error bars are representative of the standard error (n=3). 
Statistical significance was calculated using the Student’s t-test (p < 0.05). 
*Represents a significant difference between the ALDOA level in the 1nM sample and 
the negative control. 
**Represents a significant difference between the ALDOA level in the 10nM sample 
and the negative control. 
***Represents a significant difference between the ALDOA level in the 100nM 
sample and the negative control.
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Figure 5.11.  PKI protein expression levels of BACE1-inhibitor-treated NT2 neuronal 
cells. Western blot analysis of NT2 cell lysates (A) expression of the PKI protein when 
the growth media has BACE1 inhibitor added at 0nM, 1nM, 10nM and 100nM 
concentrations, respectively. Molecular mass protein marker (Mr) is indicated on the 
ƌŝŐŚƚ ƐŝĚĞ ŽĨ ƚŚĞ ŐĞů͘  dŚĞ ɴ-actin housekeeping protein is represented under the 
corresponding band.  Densitometric analysis (B) is measured in arbitrary units (AU) 
ĂŶĚ ŝŶŵĞĂƐƵƌĞĚďǇŵĞĂŶ ƌĞůĂƚŝǀĞďĂŶĚĚĞŶƐŝƚǇǁŚĞŶ ĐŽŵƉĂƌĞĚǁŝƚŚ ƚŚĞɴ-actin 
housekeeping protein. Error bars are representative of the standard error (n=3). 
Statistical significance was calculated using the Student’s t-test (p < 0.05). 
*Represents a significant difference between the PKI level in the 1nM sample and the 
negative control. 
**Represents a significant difference between the PKI level in the 10nM sample and 
the negative control. 
***Represents a significant difference between the PKI level in the 100nM sample 
and the negative control. 
 
 
5.4  Discussion 
BACE1 inhibitor specificity may not be limited to the amyloidogenic pathway, 
even as a high affinity binder to BACE1.  Non-specific binding and interaction with 
alternative proteins can cause adverse reactions leading to detrimental effects for 
patients already trying to fight AD.   Cell treatments of the BACE1 inhibitor have 
indicated effective inhibition of BACE1, causing detrimental consequences to the 
amyloidogenic pathway.  Investigation into the broader, cell wide effects to the 
whole proteome after BACE1 inhibitor treatment for 24 hours aims to determine 
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these variances.  
 
Selection of an adequate neuronal cell line was determined by analysis of 
BACE1 activity.  Three continuous human neuronal cell lines, including M17, SY5Y and 
NT2, were tested to determine which contained the most BACE1 activity. Using a 
fluorescent BACE1 activity assay, the untreated NT2 cell line showed significantly 
more BACE1 activity than the most significant reaction, once BACE1 was inhibited.  
All cell lines were tested for viability as an indication of a toxicity caused by the BACE1 
inhibitor. None of the cell lines experienced a significant drop in viability suggesting 
the nanomolar concentrations were not effecting normal proliferation and growth. 
 
Confluent NT2 cells were treated for 24 hours with BACE1 inhibitor to 
examine the change in the proteome.  The cell lysates were firstly separated by 
isoelectric focussing followed by SDS-PAGE to characterise the particular proteins of 
interest.  The variation in gel spots density created by the 2-dimensonal separation, 
indicated an up or down regulation of protein concentration.  A number of protein 
spots were picked from the gels for mass spectrometry identification.  Six of the 
proteins identified showed a common theme to an upregulation of glycolysis.  These 
proteins all exhibited an up-regulation response by means of a gel spot density.  The 
effect of the BACE1 inhibitor was influencing an up-regulation of glycolysis in NT2 
cells.  
 
The proteins identified were triosephosphate isomerase (TPI), pyruvate 
kinase (PKI), enolase (ENO), aldolase A (ALDOA), L-lactase dehydrogenase (LDH) and 
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malate dehydrogenase (MDH) (Krebs cycle), which are all enzymes used to modify 
sugars into creating ATP.  Confirming the increase was determined by using Western 
blot analysis and comparing gel band density with the use of monoclonal antibodies.  
Of the six enzymes, three were chosen according to mass spectrometry results and 
importance to the continuation of glycolysis. The Western blot gel band densities 
supported the mass spectrometry results by showing a significant increase in the 
amount of TPI, PKI and ALDOA as a response to the BACE1 inhibitor treatment. 
 
The site of glycolysis resides in the mitochondria, the site of oxidative 
phosphorylation.  The generation of ATP is determined by the reduction of O2 to H20 
for the generation of ATP, which is universal to all eukaryotic cells.  Mitochondrial 
dysfunction is a common indicator of AD that consequently undergoes a reduction in 
glucose utilisation causing a decrease in ATP production.220,221 The enzymes identified 
from the proteomic analysis heavily influence oxidative phosphorylation and more 
specifically gluconeogenesis.  TPI catalyses the aldose-ketone conversion of 
dihydroxyacetone phosphate (DHAP) to glyceraldehyde-3-phosphate (G3P) after 
ALDOA cleaves hexose sugars into two triose phosphates.  G3P provides valuable 
NADH, but reduction of TPI causes the mitochondria to retain DHAP, which if not 
modified to G3P, can cause downstream toxic effects.  DHAP non-enzymatically 
ďƌĞĂŬƐĚŽǁŶŝŶƚŽŵĞƚŚǇůŐůǇŽǆĂů͕ǁŚŝĐŚŝƐĂŚŝŐŚůǇƌĞĂĐƚŝǀĞɲ-oxo-aldehyde that can 
cause detrimental modifications to proteins and DNA to form advanced glycation end 
products.222 Repercussions of activating this pathway has been linked to diabetes, 
inflammation, renal failure, aging and neurodegeneration.223   
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The energy reduction associated with mitochondrial function effects 
numerous enzymes in glycolysis.  Enolase, identified in the 2D analysis as a spot 
variant, responsible for the dehydration of 2-phosphoglycerate to 
phosphoenolpyruvate, decreases in activity during times of oxidative stress relating 
to AD while showing an increased enzyme availability.224  The reduction in enolase 
activity causes a decrease in the amount of glycolysis occurring.224 Treatment of 
human neuronal cell with BACE1 inhibitor could be either aiding or causing oxidative 
stress as the increase in protein levels could be a response. 
 
ɴŚĂƐďĞĞŶƌĞƉŽƌƚĞĚƚŽĞĨĨĞĐƚŵŝƚŽĐŚŽŶĚƌŝĂůĨƵŶĐƚŝŽŶĂƐŝƚĐĂŶƉĂƐƐƚŚƌŽƵŐŚ
the outer membrane and aggregate.225 Furthermore, the localised accumulation of 
ɴ ƚŽ ŵŝƚŽĐhondria has the ability to cause dysfunction to cell morphology and 
increased ROS production.226,227 Testing the hypothesis that the BACE1 inhibitor 
ĐŽƵůĚƉŽƚĞŶƚŝĂůůǇ ŝŶĐƌĞĂƐĞŐůǇĐŽůǇƐŝƐǁŚŝůĞĂƚ ƚŚĞ ƐĂŵĞ ƚŝŵĞ ƌĞĚƵĐŝŶŐɴ ůŽĂĚŝŶŐ 
could serve as an new avenue to treat the disease, which is a result of the significant 
and novel findings of this project.   
 
5.5  Conclusion 
dĞƐƚŝŶŐƚŚĞϭŝŶŚŝďŝƚŽƌƉŽƚĞŶƚŝĂůĨŽƌƉƌĞǀĞŶƚŝŽŶŽĨɴƉƌŽĚƵĐƚŝŽŶŝƐŽŶůǇ
part of the treatment process. Proteomic studies of treatment effects aim to 
investigate the whole proteome for potential changes in protein expression.  The 
BACE1 inhibitor, oriŐŝŶĂůůǇ ŝŶǀĞƐƚŝŐĂƚĞĚƚŽƌĞĚƵĐĞɴ ůŽĂĚŝŶŐ͕ŚĂƐƌĞǀĞĂůĞĚĂŶŽǀĞů
function that could increase glycolysis.  While neuronal cells are under stress, 
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glycolysis is reduced, which creates a decrease in energy production for the cell.  
Western blot analysis of NT2 cells after treatment with BACE1 inhibitor showed an 
increase in the amount of glycolytic enzymes, which could serve as a positive effect 
during AD.
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Chapter 6 
 
General Discussion and Conclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.1  Introduction 
The BACE1 enzyme has been investigated as a target for Alzheimer’s disease 
prevention since its discovery in 1999.33,80-82  The development of Alzheimer’s disease 
is centred around amyloid plaque generation where the symptoms start to evolve.2,11 
Plaques are ŐĞŶĞƌĂƚĞĚďǇƚŚĞĂŐŐƌĞŐĂƚŝŽŶŽĨɴƐƵď-units that originate as part of 
WW͘^ĞƋƵĞŶƚŝĂůĐůĞĂǀĂŐĞŽĨWW͕ďǇɲ- ĂŶĚɶ-secretase enzymes, results in a non-
amyloid causing state and plaque generation does not commence.31 Substitute ɲ-
secretase for BACE1 and a change in cleavage length of APP occurs, shortening the 
N-terminal fragment.  The shorter C-terminal fragment becomes elongated where 
ƐĞĐŽŶĚĂƌǇĐůĞĂǀĂŐĞďǇɶ-secretase releases the 38–ϰϮĂŵŝŶŽĂĐŝĚĨƌĂŐŵĞŶƚ͕ɴ͘17 
 
 dŚĞ ĂŵǇůŽŝĚŽŐĞŶŝĐ ƉĂƚŚǁĂǇ͕ ƚŚĂƚ ƉƌŽĚƵĐĞƐ ɴ͕ ĐĂŶ ďĞ ƉƌĞǀĞŶƚĞĚ ďǇ ƚŚĞ
ŝŶŚŝďŝƚŝŽŶŽĨϭ͕ůĞĂǀŝŶŐɲ-secretase to process APP.  The enzyme-cleave-protein 
construction of this pathway makes it an ideal target for inhibition as no other 
enzymes cleave APP at this location, leaving BACE1 the only candidate required for 
intervention.  Previous attempts to provide a valid candidate have proved 
unsuccessful as the BBB environment restricts permeability and strictly protects 
against from external chemical damage.133,134 The BBB is composed of an endothelial 
layer of cells covered in smooth muscle, pericytes and astrocytes to prevent entry of 
potentially hazardous substances.136 A tight endothelial layer of cells restrict the 
molecular weight threshold to 450-500Da which prevents larger chemicals from 
freely passing through to the brain.136 Current research for the inhibition of BACE1 
has aimed to produce smaller, freely permeable chemicals and antibodies that can 
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cross the BBB but have since struggled in mid-late phase trials.159-162 The freely 
permeable, smaller chemicals have yet elucidate a viable candidate that can bind 
with high affinity an specificity to BACE1.  For this project, the overall aim is to identify 
and characterise a peptide based inhibitor that shows a strong binding affinity and 
selectivity to BACE1.    
 
This chapter aims to cover all the concepts investigated in this thesis specific to: 
1. The Identification of a 12-mer peptide binding candidate with a high 
affinity for BACE1.   
2. Characterisation of the peptides ability to bind and inhibit recombinant 
BACE1 in vitro.   
3. Investigation into the BACE1 inhibitor’s effectiveness in human neuronal 
ĐĞůůƐĨŽƌƚŚĞŽǀĞƌĂůůƌĞĚƵĐƚŝŽŶŽĨɴ. 
4. Characterisation of BACE1 inhibition effects on BACE1 and APP protein 
and transcription levels.  
5. Proteomic effects as a result of BACE1 inhibitor treatment and 
investigation into the effected candidates.   
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6.2  The Identification of a 12-Mer Peptide Binding Candidate with a 
High Affinity for BACE1.   
Using the phage display and biopanning techniques, a 12-mer peptide was 
identified by means of affinity selection.  The main requirements of candidate 
peptides are to exhibit a high binding affinity to BACE1 and to be naturally attracted 
with an active site inhibitor being preferable.  The identification of a natural binding 
candidate is imperative as many current inhibitors, in clinical trials, have not been 
able to locate BACE1 and bind accordingly.  The aims of this project are intended to 
confirm inhibitor ŝŶĨůƵĞŶĐĞŽǀĞƌɴproduction within a human neuronal cell culture 
as a precedence to success.  The highly variable cellular environment is where a 
natural affinity can be examined with normal cellular functioning. 
 
 The expansion of biopanning rounds, from three to five, added a further 
stringency to the binding affinity of the candidates.  The number of rounds were 
extended to reduce the number of candidates and encourage a sequence motif.  
Sequencing of phage DNA supported this method as the number of binding 
candidates reduced to just one from the 109 varied clones.  The peptide was produced 
synthetically and was used to test for direct target coating.  Phage titre results from 
the amplified eluates confirmed with the synthetic peptide mimic of the candidate 
showed significant binding to the target.  The synthetic candidate was tested 
independently, and not attached to the protein coat of the phage which indicated 
that it could still bind effectively to BACE1 even as a monomeric peptide. 
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6.3  Characterisation of the Peptides Ability to Bind and Inhibit 
Specifically Recombinant BACE1 In Vitro  
The synthetic peptide was able to bind significantly to recombinant BACE1 in 
a one-on-one environment.  The closely related homologs of BACE2, Cathepsin D and 
Renin have previously shown a tendency to bind to BACE1 inhibitors creating adverse 
reactions.91  Non-specific binding to Renin can interrupt the Renin-Angiotensin-
Aldosterone system which could cause dangerous fluctuations to systemic blood flow 
by keeping the vessels dilated while Cathepsin D plays an important role in cell 
signalling and apoptosis.183,184  The synthetic peptide showed significant binding to 
the BACE2 and Cathepsin D homologs which could have caused unwanted side effects 
when introduced to an in vivo model.  However, when re-tested in competition 
assays, this unwanted binding was minimised as the synthetic peptide selective 
bound to BACE1.  
 
Binding of the synthetic peptide to the BACE1 target was tested for the ability 
to prevent enzymatic activity.  Biologically active recombinant BACE1 was able to 
cleave an APP fragment mimic resulting as simulation of amyloidogenesis.  The 
synthetic peptide, which had already exhibited binding affinity to BACE1, was added 
to the reaction in nanomolar concentrations.  As a result the immobilised peptide 
was able to bind BACE1 and causing a significant reduction the amount of APP 
fragment cleavage at 23% for the 10nM treatment and 44% for 100nM.  The synthetic 
peptide exhibited a significant effect over the recombinant BACE1 activity reaction in 
vitro.   
161 
 
6.4  Investigation into the BACE1 Inhibitor’s Effectiveness in Human 
Neuronal Cells for the Overall Reduction of ɴ 
The BACE1 inhibitor, formally ‘synthetic peptide candidate’, was able to elicit 
a down regulation of APP cleavage by removing BACE1 from enzyme-protein 
reaction.  As an indication of specificity to BACE1, the inhibitor was used to treat a 
human SY5Y neuroblastoma cell line.  The ability to locate BACE1 and inhibit activity 
would require penetration of the cell membrane to transport endosomes, where the 
enzyme is located, while eluding lysosomes that cause automatic degradation.92,94,95 
 
The cell treatments were performed using the same effective nanomolar 
treatment concentrations as the recombinant inhibition assay.  To determine the 
possible toxicity of the peptide, the cells were monitored for changes in viability.  At 
the low, nanomolar concentrations used in in the reaction there was no significant 
decrease observed in the amount of live cells.  From a cellular level there was no toxic 
effects observed by the treatments.  
 
dŚĞŽǀĞƌĂůůŽƵƚĐŽŵĞŽĨĂŵǇůŽŝĚŽŐĞŶĞƐŝƐ ŝƐ ƚŚĞƉƌŽĚƵĐƚŝŽŶŽĨɴ͘50 The cell 
ƚƌĞĂƚŵĞŶƚƐǁĞƌĞƉĞƌĨŽƌŵĞĚƚŽƉƌĞǀĞŶƚƚŚĞĂŵŽƵŶƚŽĨŝŶƚƌĂĐĞůůƵůĂƌɴƉƌŽĚƵĐĞĚĂƐŝƚ
represents a downstream confirmation of BACE1 inhibition.  The measurement of 
ĐĞůůƵůĂƌɴǁĂƐƚŽďĞƉĞƌĨŽƌŵĞĚďǇ>/^ƚŚĂƚǁĂƐƵŶŝǀĞƌƐĂůƚŽďŽƚŚ ɴϰϬĂŶĚɴϰϮ
fragments.  Biopanning and phage display were used to identify specific binders to 
ɴϰϬĂŶĚɴϰϮ ĨŽƌƵƐĞĂƐ ĐĂƉƚƵƌĞŵŽůĞĐƵůĞǁŝƚŚ ƚŚĞ Ăŝŵ ƚŽĚĞǀĞůŽƉĂŶ ŝŶ-house 
assay.  The direct target coating method was used as it was successful in providing a 
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successful candidate for BACE1.  However, differences between target molecules, 
ϭďĞŝŶŐϱϲŬĂĂŶĚɴũƵƐƚϰ͘ϱŬĂ͕ĐĂƵƐĞĚĂƌĞĚƵĐƚŝŽŶŝŶĂŵƉůŝĨŝĞĚĞůƵĂƚĞůĞǀĞůƐ
and subsequently, ƚŚĞŶƵŵďĞƌŽĨƉŽƚĞŶƚŝĂůďŝŶĚĞƌƐ͘dŚĞɴϰϮƚĂƌŐĞƚŐĞŶĞƌĂƚĞĚĂŶ
eluate of acceptable levels and was continued for sequencing and M13 phage ELISA 
to confirm the binding occurring in the biopanning.  The initial assays showed strong 
binding was occurring but when compared with the negative controls that did not 
contain a target, similar results were recorded.   
 
Binding that occurred in the M13 ELISA was not to the target and so the 
ŵĞƚŚŽĚǁĂƐĐŚĂŶŐĞĚƚŽĂƐŽůƵƚŝŽŶƉŚĂƐĞƉĂŶŶŝŶŐǁŚĞƌĞƚŚĞɴϰϬĂŶĚɴϰϮƚĂƌŐĞƚƐ
were biotinylated and bound to streptavidin coated bead capture.  This method 
accommodated for the smaller targets by making them more accessible in solution 
as opposed to bound to a plate well and crowded by BSA.  The results reflected this 
change and the eluates were of an adequate level to continue.  The sequencing 
provided three candidates each and all were tested with an M13 phage ELISA.  All 
candidates exhibited strong binding to both targets.  However, the increase in binding 
was again, not to the targets as the negative control test exhibited the same amount 
of binding for all candidates.  An alternative method was adopted, that utilised a 
different M13 specific antibody, but the same non-specific binding was occurring.  As 
Ă ƌĞƐƵůƚ͕ ɴϰϬ ĂŶĚ ɴϰϮ ƐƉĞĐŝĨŝĐ >/^ ŬŝƚƐǁĞƌĞ ƵƐĞĚ ŝŶƐƚĞĂĚ͘  ůƚĞƌŶĂƚŝǀĞůǇ͕ ƚŚĞ
phage display and biopanning could be reassessed using a biosensor, where the 
target would be bound to the dextran matrix and the phage used as the analyte or an 
ĂŶƚŝďŽĚǇ ĚŝƐƉůĂǇ ĐŽƵůĚ ďĞ ƵƐĞĚ ƚŽ ŝĚĞŶƚŝĨǇ ĂŶ ɴ ƐƉĞĐŝĨŝĐ ďŝŶĚĞƌ ĨŽƌ ƚŚĞ ƵƐĞ as a 
therapeutic answer for plaque generation.  
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^zϱzĐĞůůƐǁĞƌĞƚƌĞĂƚĞĚǁŝƚŚƚŚĞϭŝŶŚŝďŝƚŽƌĨŽƌƚŚĞƋƵĂŶƚŝĨŝĐĂƚŝŽŶŽĨɴ͘
dŚĞϭŝŶŚŝďŝƚŽƌǁĂƐĂďůĞƚŽĞůŝĐŝƚĂƐŝŐŶŝĨŝĐĂŶƚƌĞĚƵĐƚŝŽŶŽĨɴŝŶƐƚĂŶĚĂƌĚ^zϱz
cells. The results indicated that the inhibitor, now in a cellular environment, could 
ďŝŶĚĂŶĚŝŶŚŝďŝƚƚŚĞƉƌŽĚƵĐƚŝŽŶŽĨɴϰϬďǇϮϱйĂŶĚɴϰϮďǇϮϮй͘dŚĞƌĞĚƵĐƚŝŽŶŝŶ
ďŽƚŚ ɴϰϬ ĂŶĚ ɴϰϮ ŝƐ Ă ĚŝƌĞĐƚ ƌĞĨůĞĐƚŝŽŶ ŽĨ ƚŚĞ ŝŶŚŝďŝƚŽƌƐ ďŝŶĚŝŶŐ ĂŶĚ ŝŶŚŝďŝƚŝŶŐ
BACE1.   
 
An AD affected brain will experience a rise in oxidative stress which can 
ŝŶĐƌĞĂƐĞƚŚĞĂŵŽƵŶƚŽĨɴ͘202 This method was simulated successfully in SY5Y cells 
by adding H2O2 without compromising on viable cell counts.201,203 To determine 
BACE1 inhibitor effectiveness the treatments were tested while the cells were under 
ƐƚƌĞƐƐ͘dŚĞƌĞƐƵůƚŝŶŐĂŵŽƵŶƚŽĨɴϰϬǁĂƐƌĞĚƵĐĞĚďǇϭϮйǁŚŝůĞɴϰϮǁĂƐƌĞĚƵĐĞĚ
ďǇϮϭй͘dŚĞƌĞĚƵĐƚŝŽŶŽĨɴϰϮǁĂƐĐŽŶƐŝƐƚĞŶƚĂĨƚĞƌƚŚĞ,2O2 induced oxidative stress 
which is important considering it is a catalyser of plaque formation.47,48 
 
6.5  Characterisation of BACE1 Inhibition Effects on BACE1 and APP 
Protein and Transcription levels.  
Considering reduction of BACE1 as a consequence of the inhibitor, positive 
feedback effects can occur as a consequence, transcribing more BACE1 to regulate 
the increase of APP.  BACE1 protein levels did not show any changes with the inhibitor 
treatment where APP exhibited a significant increase from the 10nM and 100nM 
ĐŽŶĐĞŶƚƌĂƚŝŽŶ͘tŚĞŶĐŽŶƐŝĚĞƌŝŶŐƚŚĞƐŝŐŶŝĨŝĐĂŶƚƌĞĚƵĐƚŝŽŶŝŶƚŚĞĂŵŽƵŶƚŽĨɴĂƐĂ
response to the treatments, BACE1 inhibition would have reduced APP cleavage 
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causing an increase in protein levels.   
 
The increase in cellular APP could have altered gene transcription as a 
negative feedback response to standardise protein levels.  This could have also 
occurred to up-regulate BACE1 levels to control of increase of APP.  The mRNA levels 
for both APP and BACE1 showed no variation when compared with the negative 
controls.  Further analysis of this reaction could be achieved with varying 
concentrations of inhibitor to determine if the APP levels consistently follow the fall 
that occurred after the 10nM treatment.  The incubation time with the BACE1 
inhibitor could be altered to determine whether the fall in APP levels occurred at a 
specific moment as cells were only treated for 24 hours. 
 
6.6  Proteomic effects as a result of BACE1 inhibitor treatment and 
investigation into the effected candidates   
ϭ ŝŶŚŝďŝƚŝŽŶ ŽŶůǇ ĚĞƚĞƌƐ ƚŚĞ ƉƌŽĚƵĐƚŝŽŶ ŽĨ ɴ ďƵƚ ƚŚĞ ƐŝĚĞ ĞĨĨĞĐƚƐ ŽĨ
treatment could cause unwanted and detrimental effect on the patient.  Proteomic 
analysis of the BACE1 inhibitor treated neuronal cells in vitro provided an insight into 
the possible repercussion of treatment.  Three human neuronal cell lines were used 
to analyse BACE1 activity to determine an experimental platform that could be 
influenced most by treatment.  SY5Y, M17 and NT2 human neuronal cells were tested 
using a BACE1 activity assay with the latter producing the most substrate cleavage.  
All cell lines were tested for cell viability to determine possible toxicity caused by the 
treatment but none was recorded.   
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 BACE1 inhibitor treated NT2 cells revealed a number of protein spot variants 
after the 2-dimensional separation.  The Western blots, investigating the levels of 
APP, showed that treatments by the BACE1 inhibitor could cause varied spot densities 
in the SDS PAGE. A group of increase spot variants in the pH7-8 range elicited a 
common theme after mass spectrometry analysis.  The spots identified were either 
parts the glycolytic pathway or the Krebs cycle. The TPI, ALDOA and PKI enzymes were 
chosen from the group for Western blot analysis to confirm the increase. 
 
The TPI and PKI Western blots showed a similar responses to treatment with 
a large increase in protein levels after the 1nM treatment.  The ALDOA sample 
showed a gradual increase with the 100nM addition of inhibitor exhibiting the largest 
response.  The three enzymes selected from the mass spectrometry results all 
exhibited an increase in protein concentration after treatment with the BACE1 
inhibitor.  This suggests that BACE1 inhibitor treatment could serve as a stimulus for 
the glycolytic pathway.  
 
After the onset of AD there is a decrease in the amount of ATP produced by 
glycolysis.220,221  Possible causes could relate ƚŽɴĚĞƉŽƐŝƚŝŽŶǁŚŝĐŚĐĂƵƐĞƐŽǆŝĚĂƚŝǀĞ
stress on mitochondria as it can pass through the membrane and aggregate.225 The 
treatment of the BACE1 inhibitor could possibly ƌĞĚƵĐĞŝŶƚƌĂĐĞůůƵůĂƌɴĂŶĚƐƚŝŵƵůĂƚĞ
glycolysis in an AD affected brain.  
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6.7  Conclusion 
Using the biopanning and phage display techniques, a high affinity peptide 
binder was selected for BACE1.  Using the direct binding assay technique, a synthetic 
mimic of the peptide isolated from the biopanning exhibited a significant binding 
affinity to BACE1. 
 
The peptide candidate needed to be specific and when tested against the 
closely related BACE2, Renin and Cathepsin D, selectively binding was for BACE1.  The 
adverse reactions of binding to those closely related proteins could have been 
detrimental to the cell.  
 
When tested against the simulated amyloidogenic pathway by activity assay, 
the peptide candidate showed it could both: bind to recombinant BACE1 and deter 
the cleavage of a substrate in vitro.  Following into a human neuronal cell model the 
ŶŽǁ ͚ϭ ŝŶŚŝďŝƚŽƌ͛ ĐŽƵůĚ ƌĞĚƵĐĞ ƚŚĞ ĂŵŽƵŶƚ ŽĨ ɴ ůŽĂĚŝŶŐ ĞǀĞŶ ǁŝƚŚ ĐĞůůƐ
exhibiting oxidative stress.  Treatment of BACE1 inhibitor to the SY5Y cell model did 
not promote visible toxicity as the viability experiments showed no decrease in the 
number of live cells.  
 
dŚĞϭ ŝŶŚŝďŝƚŽƌ ĐĂƵƐĞĚ ĂĚĞĐƌĞĂƐĞ ŝŶ ĐĞůůƵůĂƌ ɴ ďƵƚ ĚŝĚŶŽƚ ƐŚŽǁ ĂŶ
influence over BACE1 protein levels in the Western blot analysis.  An increase of APP 
was observed but BACE1 processing was reduced as response to the BACE1 inhibitor 
treatment.  A possible feedback response to the inhibition was not observed as there 
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was no change in BACE1 and APP transcription. 
 
Proteomic analysis, investigating the possible side effects of BACE1 inhibitor 
treatment, highlighted a rise in glycolysis with a number of associated enzymes being 
upregulated.  TPI, PKI and ALDOA, identified from the mass spectrometry, confirmed 
the protein spot variation by producing an increase in enzyme expression. 
 
6.8  Future Perspectives 
The search for a viable BACE1 inhibitor is yet to provide an effective candidate 
to pass stage III clinical trials.  The identification of this BACE1 inhibitor has shown 
many positive attributes in vitro͘dŚĞĂďŝůŝƚǇƚŽŝŶŚŝďŝƚɴůŽĂĚŝŶŐŽŶŚƵŵĂŶŶĞƵƌŽŶĂů
cells suggests that an in vivo model could provide a better understanding of the 
possible benefits of treatment.  The in vivo model would specifically seek to define 
brain penetration by the peptide.  A rejected inhibitor would require refining to 
accommodate for this.  
 
dŚĞ ϭ ŝŶŚŝďŝƚŽƌ ƐŚŽǁĞĚ Ă ƐŝŐŶŝĨŝĐĂŶƚ ĚĞĐƌĞĂƐĞ ŝŶ ƚŚĞ ĂŵŽƵŶƚ ŽĨ ɴ
produced by the SY5Y cells after treatment with a concentration of 100nM over 24 
hours. The 1nM, 10nM and 100nM treatments were used throughout the project as 
they provided significant results.  The extension of this to try and define the LD50 and 
EC50, would need to investigate a wider range of concentrations.  The 24 hour 
timeframe was used universally across all the treatments for continuity but an 
extension of this could identify at what time the inhibitor is most effective.  
168 
 
To further investigate the 12-mer peptide isolated from the biopanning, 
alanine scanning and truncated peptide analysis aim to break down the peptide to 
define the most effective residues.  Refining the peptide could reduce the amount of 
ineffective amino acids permeability to large peptic structures can prevent the 
treatment from penetrating the brain.  
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